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General introduction
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General introduction
Serious infections in the critically ill are increasing in incidence and associated 
with significant morbidity and mortality [1-6]. A fast and accurate diagnosis is 
crucial in order to reduce adverse sequelae [7]. In critically ill patients the clas-
sical signs of infection are not always present or may overlap with the symptoms 
of other pathological conditions (e.g. cell death after trauma or necrotizing 
pancreatitis). Furthermore, microbiological cultures may be difficult to obtain 
or can be falsely negative. All these factors make the correct diagnosis and treat-
ment of infection in the critically ill patient challenging [7]. Therefore, there is a 
clear need for a fast and accurate biomarker for infection. Section I of this thesis 
will focus on the prediction of serious infections i.e. bloodstream infections. A 
substantial part of infections diagnosed in the critically ill are caused by invasive 
fungal infections and the incidence of invasive fungal infections is increasing 
[8,9]. Section II of this thesis will focus on the antifungal treatment of invasive 
Candida infections in the critically ill.
Section I– Prediction of infection in the critically ill
Because of low sensitivity and low specificity of sepsis for serious infection, the 
definition of sepsis has been revisited several times during the last decades to 
increase predictive values of infection. To assist the diagnosis of infection in 
clinical practice its symptoms have been grouped into the systemic inflamma-
tory response syndrome (SIRS) [10,11]. The SIRS criteria include the following 
conditions: body temperature >38 °C or <36 °C; WBC (>12,000/ µL), leukopenia 
(<4,000/µL), or > 10% bands; heart rate >90 beats/min; and respiratory rate 
>20 breaths/ min or mechanical ventilation [11]. In 1992 sepsis was described 
as the presence of two SIRS criteria together with a probable or proven infection 
[11]. The SIRS criteria have prognostic value, as mortality rates increase with 
increasing numbers of SIRS criteria and are higher in patients with infection [4]. 
Of all critically ill patients with fever only around 50% will suffer from an infec-
tion [12,13]. Fever, tachycardia and tachypnea are common clinical findings in 
critically ill patients with non-infectious causes of SIRS [11, 14] (Figure 1). The 
presence of systemic inflammation indicates the possibility of an infection, but 
none of the SIRS criteria is specific enough to confirm the diagnosis [7]. In 2001 
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the definition of sepsis was revisited, to optimize the prediction of infection, 
and included a longer list of signs of sepsis, including hemodynamic alterations, 
signs of organ dysfunction and the presence of inflammatory markers [15]. In 
2016 these long used definitions of sepsis and septic shock were revised again, 
because the SIRS- based definition was too non-specific, and considerable 
advances have been made into the understanding of the pathophysiology, the 
management, and the epidemiology of sepsis [16] (Table 1). The definition of 
sepsis has been revised several times, and the use of the sepsis syndrome as a 
surrogate for proven infection as an outcome parameter may be too sensitive 
and nonspecific. Therefore, we have chosen to study the prediction of serious 
infections (i.e. bacteraemia) in this thesis, which is a more robustly defined 
culture proven infection.
Diagnosing serious infections in critically ill patients is not always 
straightforward [7]. Critically ill patients often have ongoing disease problems, 
which can induce signs of inflammation without the presence of infection [7]. 
Furthermore, most critically ill patients are on antibiotics, which can result 
in false negative microbial cultures. Therefore, the need for more specific and 
accurate biomarkers is necessary to discriminate infection from non-infectious 
causes of SIRS in the critically ill patient.
Figure 1. Different causes of the systemic inflammatory response syndrome.
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Table 1.
-  Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.
-  Organ dysfunction can be identified as an acute change in total sequential organ failure assessment (SOFA) 
score ≥2 points consequent to the infection.
-  Patients with suspected infection who are likely to have a prolonged ICU stay or to die in the hospital can be 
promptly identified at the bedside with qSOFA (quick SOFA), i.e., alteration in mental status, systolic blood 
pressure ≤100 mm Hg, or respiratory rate ≥22/min.
-  Patients with septic shock can be identified with a clinical construct of sepsis with persisting hypotension 
requiring vasopressors to maintain MAP ≥65 mm Hg and having a serum lactate level >2 mmol/L (18 mg/dL) 
despite adequate volume resuscitation.
SOFA score
During the last years many biomarkers have been investigated as poten-
tial predictors of infection. To discuss all investigated biomarkers in this intro-
duction would be impossible and therefore we will focus on the most promising 
and most frequently used biomarkers nowadays. C-reactive protein (CRP) is 
an acute phase protein produced by the liver, which will be released just a few 
hours after inflammation is caused by variable conditions [17]. Another potential 
biomarker, which has been suggested to be more reliable than CRP, is procalci-
tonin (PCT) [18]. Procalcitonin is a peptide precursor of the hormone calcitonin, 
which rises in a response to inflammation especially caused by infection [19]. 
Both markers are frequently determined and widely available, but the predictive 
values vary and both markers are also elevated in non-infectious conditions of 
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inflammation [18, 20-25]. Like all other biomarkers they have in common that 
the predictive values are only moderate and they are more useful to rule out 
disease than to pinpoint infection [7]. This latter property of PCT could be useful 
to exclude the need for culturing blood in critically ill patients with fever. PCT 
has a high negative predictive value for the presence of microbiologically proven 
infection, so that a normal PCT level (PCT <0.25 ug/L) could be used to rule out 
the presence of bacteraemia in different clinical settings [26].
Sepsis is the result of a very complex host immune response to infection 
and therefore it will be unlikely that a single maker will ever be useful to detect 
infection [7, 15]. An option would be to combine different biomarkers, whether 
or not with clinical data, into a scoring system [27-29]. Another option would be 
the use of proteomics or genomics for the prediction of infection [30]. At last, but 
behind the scope of this thesis, new techniques that allow for the simultaneous 
detection of e.g. DNA, RNA and cell wall components in body fluids (e.g. blood, 
sputum, broncho-alveolar lavage) are looking promising, but to what extend they 
will be able to improve patient outcome remains to be seen [31]. Classical blood 
cultures need at least 12 hours to become positive and only after another day or 
more full identification with an antibiogram will be available. Furthermore, in 
many critically ill patients with sepsis blood cultures remain negative [32]. PCR 
technology is able to detect DNA traces of common bacterial and fungal infec-
tions in just a few hours [31]. Giving the complexity of proteomics, genomics 
and PCR techniques and the costs involved in this new area of research, it will 
be more likely that a new and more reliable scoring system for the prediction of 
infection will be developed in the next years. Important considerations for the 
development of such a scoring system are to determine which clinical param-
eters and which biomarkers should be included, using standardized assays, clear 
identification of cut-offs, and more homogeneous groups, in order to make the 
comparison of different scoring systems easier.
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Questions to be answered in this thesis:
1. Are immature granulocytes useful for the prediction of infection and it’s 
sequelae in critically ill patients? Should this marker replace other com-
monly used markers or should it be used together with the other markers? 
To answer this question, Chapter 2 of this thesis will present the results of a 
retrospective study analysing the predictive value of Immature Granulocytes 
compared with the white blood cell count and C-reactive protein for micro-
bial infection in critically ill patients. The study was performed in 46 patients 
critically ill patients.
2. Is the Intensive Care Infection Score an useful score for the prediction of in-
fection in critically ill patients? In Chapter 3 of this thesis we tried to answer 
this question by presenting the results of a prospective multi-center study 
on the predictive value of a new scoring system, the Intensive Care Infection 
Score (ICIS), for microbial infection in critically ill patients. The ICIS score 
was compared with the most frequently used biomarkers nowadays. The 
study included 301 patients.
3. Should we use procalcitonin as a marker for the prediction of bacteraemia or 
should we use it as a marker to exclude bacteraemia? In Chapter 4 of this 
thesis we tried to answer this question by presenting the results of a systemic 
review and meta-analysis on the diagnostic accuracy of procalcitonin for 
bacteraemia. The study included 58 articles, representing 16,514 patients.
4. Can procalcitonin be used to guide decision making on blood sampling for 
cultures in critically ill patients? In Chapter 5 of this thesis we tried to an-
swer this question by evaluating the usefulness of procalcitonin as a decision 
tool to sample (or not) blood for culture in critically ill patients. The ProBIC 
study is a prospective, multicentre, cluster-randomized, cross-over trial and 
included 564 patients.
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Section II – Candida infection in the critically ill
The incidence of serious infections in the critically ill continuous to increase 
[1-6]. Over the last decades the share of invasive fungal infections and in par-
ticular Candida spp. among the ICU patient with infection increased as well 
[8,9]. Invasive fungal infections are associated with prolonged hospital stay and 
increased mortality [8,9]. Early treatment with an appropriate antifungal drug 
is mandatory since mortality of candidemia is directly correlated with delayed 
antifungal therapy [33.34].
In the Netherlands critically ill patients receive selective decontamina-
tion of the digestive tract (SDD) when the expected duration of mechanical 
ventilation is more than 48 hours. SDD involves the administration of the 
non-absorbable antimicrobial agents tobramycin, amphotericin-B and colistin. 
Patients also receive cefotaxim 1 gram intravenously four times a day for a three-
day period. As part of this protocol, inventory cultures are taken of the throat, 
tracheal aspirates, and rectum on admission. To monitor the effect of SDD 
treatment, surveillance cultures (from throat, tracheal aspirates, and rectum) 
are performed routinely done thrice weekly as well. When the SDD cultures 
from the tracheal aspirate are repetitively positive for fungal growth (i.e. colo-
nization), the SDD protocol recommends to start amphotericin-B deoxycholate 
(ABDC) inhalation therapy via a nebulizer (Table 2). Treatment with ABDC can 
then be stopped after two consecutive cultures of the respiratory tract are nega-
tive or after detubation of the patient [35]. The use of ABDC to treat respiratory 
colonization with Candida spp. is still a subject of debate. First, Candida spp. 
are frequently cultured from non-sterile body sites in critically ill patients, but 
the clinical significance hereof is not easily defined [36-40]. When Candida spp. 
are repetitively cultured from the respiratory tract it mostly reflects harmless 
colonization, for which the start of antifungal treatment is a subject of debate, 
but in some rare cases it could also reflect an invasive pulmonary fungal in-
fection or may be a source of a subsequent candidemia [36-40]. Second, the 
safety and efficacy of ABDC treatment is not well established, and its use as an 
aerosol can interfere with pulmonary surfactant, a molecule produced by type 
II alveolar cells and essential for efficient exchange of gases and for maintaining 
the structural integrity of alveoli [41-44].
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In case a patient is suspected of having an infection, additional cultures 
(besides the routinely performed SDD cultures) can be taken from the possible 
source of infection, which includes the use of bloodcultures. A suspicion of 
infection can be raised by the presence of one or more of the following signs 
and symptoms of infection: fever or hypothermia; hypotension; localized signs 
and symptoms of inflammation; or radiological signs of an infection. When the 
cultures from sterile body sites become positive for fungal growth, treatment 
with an appropriate antifungal agent is necessary. In Table 3 the definitions 
of invasive fungal infections are given. Guidelines recommend to start with an 
echinocandin for the treatment of proven invasive fungal infections caused by 
Candida spp. in critically ill patients [45]. There are three echinocandins in clini-
cal use which can be chosen for therapy (Table 2). All three echinocandins are 
Table 2. Description of the different types of antifungal agents.
Polyene antimycotics
Polyene antimycotics are obtained from some species of Streptomyces bacteria. The polyenes bind to ergosterol in 
the fungal cell membrane and cause leakage of K+ and Na+ ions, which contributes to fungal cell death. Examples 
of polyene antimycotics are: amphotericin-B deoxycholate and nystatin. They can be administered intravenously 
or via inhalation.
Azoles
Azoles are antifungal drugs that inhibit the fungal enzyme 14α-demethylase which produces ergosterol (an important 
component of the plasma fungal membrane). The azoles in clinical use for systemic therapy are: fluconazole, 
voriconazole, isavuconazole, posaconazole and itraconazole. They can be given intravenously or via the oral route.
Echinocandins
Echinocandins are a relatively novel class of antifungal agents with activity against a broad spectrum of Candida 
spp., including C. Glabrata and C. Krusei, against which fluconazole has less or no activity. They inhibit the 
synthesis of glucan in the cell wall, via non-competitive inhibition of the enzyme 1,3-β glucan synthase. At this 
moment there are three echinocandins in clinical use: caspofungin, anidulafungin and micafungin. They can be 
administered intravenously only.
Table 3. Definitions of invasive fungal infections.
Candidemia
Defined as at least one positive blood culture for Candida spp. drawn from a peripheral vein or a central venous 
catheter.
Intra-abdominal candidiasis
Intra-abdominal specimens (obtained surgically, through a sterile puncture or a drain that is in place for <24 h) 
positive for Candida spp., irrespective of the fungal concentration and associated bacterial growth. Or a positive 
culture with Candida spp. obtained from a normally sterile site, such as peritoneal fluid.
Invasive pulmonary candidiasis
Positive cultures with Candida spp. obtained from a normally sterile site, such as pleural fluid, in the context of 
pleural exsudate/empyema. Or the presence of yeast cells in a lung biopsy.
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considered equally effective but studies that compared these different echino-
candins directly in critically ill patients with a proven invasive candida infection 
are scarce [46]. However, differences between the in vitro antifungal activity, 
the pharmacokinetic and toxicity profiles exist, but the clinical relevance is 
probably small[47]. The treatment duration is based on recommendation made 
by guidelines, which take several factors in account, such as the duration of posi-
tive cultures, the certainty of good drainage and clinical improvement, including 
absence of fever for >24 hours and haemodynamic stability, and recovery from 
neutropenia [45,48,49]. The recommended minimum length of treatment for 
a bloodstream infection caused by candida (candidemia) is 14 days after the 
first negative culture [45,48]. Removal of intravenous catheters which are a 
possible or likely source of the candidemia as well as drainage of suspected pus 
collections are important therapeutic interventions in the treatment of invasive 
candida infection as well.
During antifungal treatment it is possible to step-down to an azole in pa-
tients who have improved clinically after initial treatment with an echinocandin 
and in whom azole susceptible Candida spp. have been documented [45,48]. 
The timing of the step-down is subject of debate, guidelines suggest to step-
down after at least 10 days of initial treatment with echinocandin, while others 
suggest that this could be done earlier [45,48,50].
Questions to be answered in this thesis:
1. Is amphotericin-B inhalation therapy a safe and effective treatment for 
Candida spp. colonization of the respiratory tract? In Chapter 6 of this 
thesis we tried to answer this question by evaluating the safety and efficacy of 
amphotericin-B deoxycholate inhalation as a treatment for respiratory colo-
nisation with Candida spp. in critically ill patient. This retrospective study 
was performed in 113 patients.
2. Can we step-down to fluconazole safely after initial treatment with an echino-
candin for invasive and susceptible C. albicans in the critically ill? To answer 
this question we studied the safety and efficacy of step-down therapy from 
an echinocandin to an azole in critically ill patients with invasive Candida 
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albicans infections in Chapter 7 of this thesis. This retrospective study was 
performed in 56 patients.
3. Is micafungin safe and effective for the treatment of invasive candidiasis in 
critically ill patients? In Chapter 8 of this thesis we tried to answer this ques-
tion by comparing the safety and efficacy of micafungin with anidulafungin 
for the treatment of invasive Candida spp. infections in critically ill patients. 
This retrospective study was performed in 63 patients.
Aim and outline of the thesis
The main content of this thesis is divided into two sections. In section I we 
studied the predictive values of different biomarkers for serious infections 
i.e. bloodstream infections. The first goal was to find a biomarker that could 
discriminate between non-infectious causes of inflammation and microbial 
infection. The second goal was to determine if one of those biomarkers could 
predict the invasiveness (bacteraemia) and severity (septic shock, mortality) of 
microbial infection. The third goal was to determine optimal cut-off values for 
the prediction of microbial infection.
In the section II we describe the safety and efficacy of different antifungal 
treatment strategies in critically ill patients. The goal was to evaluate the safety 
and efficacy of currently used antifungal agents and strategies. The second goal 
was, when possible, to give recommendations for possible changes in the cur-
rent antifungal treatment strategies. These two sections are followed by a com-
mentary that summarizes and discusses the main findings.
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Abstract
Background
We evaluated the predictive value of immature granulocyte (IG) percentage in 
comparison with white blood cell counts (WBC) and C-reactive protein (CRP), 
for infection, its invasiveness and severity in critically ill patients.
Methods 
In 46 consecutive patients, blood samples were collected at the day (0) of a clini-
cal suspicion of microbial infection and at day 1 and 3 thereafter. We defined 
infections, bloodstream infection (BSI) and septic shock within 7 days after 
enrolment.
Results 
Of the 46 patients, 31 had infection, of whom 15 developed BSI and 13 septic 
shock. CRP and IG percentage increased with increasing invasiveness and 
severity of infection, from day 0 onwards. Receiver operating characteristic 
analysis (ROC) to predict infection showed an area under the curve (AUC) of 
0.66 (P=0.10) for WBC versus 0.74 (P=0.01) for CRP and 0.73 (P=0.02) for 
IG percentage on day 0. Comparing WBC and CRP to WBC and IG percentage 
results in comparable prediction of microbial infection. Comparing WBC and 
CRP with WBC, CRP and IG percentage suggests an additional early value of IG 
percentage, when not elevated, in ruling out infection. No marker carried any 
prognostic significance.
Conclusion 
IG percentage is a useful marker, as CRP, to predict infection, its invasiveness 
and severity, in critically ill patients. However, the IG percentage adds to WBC 
and CRP in the early exclusion of infection, and can be obtained routinely with-
out extra blood sampling or costs.
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Introduction
Only about 50% of clinically suspected infections in the intensive care unit (ICU) 
can be confirmed by imaging techniques and microbiological cultures[1,2]. Leuco-
cytosis with neutrophilia and increasing bands in the peripheral blood (indicating 
a left shift in the differentiation) are classical hallmarks of infection but their di-
agnostic accuracy vary, particularly in the critically ill, so that the search for better 
markers, including C-reactive protein (CRP), is ongoing[2-4]. Notwithstanding, 
international guidelines recommend to use a band count greater than 10% as a 
criterion for systemic inflammatory response syndrome and sepsis[3].
The quantification of immature granulocytes (IG) in the white blood cell 
count (WBC) differential count is routinely done by visual microscopy, which is 
labour intensive and time consuming but still considered helpful, particularly in 
leukopenic patients[5]. Nowadays, the differential count of WBC can be automated 
in modern cell counting machines. This allows simple, fast and inexpensive quan-
tification of the IG promyeloytes, myelocytes and metamyelocytes, as a marker 
of bone marrow activity, without the need for taking extra blood samples[1,6-9]. 
The total number of IG is expressed both as absolute cell count and as a percent-
age of WBC, i.e. the IG percentage, as supplied by the Sysmex XE-2100[4,10,11]. 
The latter has been studied as a predictor of neonatal sepsis and bloodstream 
infection[12,13]. The IG percentage may also be elevated in adult (non-critically 
ill) patients with (bloodstream) infection[8,11,14] or, less well defined, sepsis, 
particularly when severe[6,9]. There is one study in 70 adult critically ill surgi-
cal patients, who may have multiple reasons for developing a left shift in WBC, 
showing that an increased IG percentage helped to predict infection, superior to 
CRP[4]. Another study on the critically ill suggested the IG percentage to better 
help predict sepsis with a suspected or proven infection than CRP[1], which is 
less helpful in predicting proven infection. The value of IG percentage in addition 
to conventional infection markers (such as CRP) remained unclear in many of 
the foregoing studies, as well as its relation to invasiveness (bloodstream versus 
local infection) and severity of infection, e.g. development of hemodynamic and 
coagulation derangements and attributable mortality[2,4,6,9].
We therefore studied the predictive value of the IG percentage, in com-
parison to WBC count and CRP, in patients with a clinically suspected infection 
in the ICU. The hypothesis was that the IG percentage is of additive value in 
predicting microbial infection, its invasiveness and severity.
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Patients and methods
Patients
Informed consent was waived of for this study because the study parameters 
were collected during routine assessment, without extra blood sampling, of criti-
cally ill patients with a suspicion of infection. Data were treated anonymously, 
so that according to Dutch law no consent is required. The study was performed 
in a consecutive 5 months period. We included all consecutive patients admitted 
into the ICU with a clinical suspicion of infection on the day of admission on 
the basis of body temperature >38 °C or <36 °C measured rectally while in the 
ICU, a WBC count >10,000/µL or <4,000/µL or CRP >9 mg/L. Patients with 
neutropenia (WBC count <0.5/µL) or immunodeficiency (HIV, solid cancer, 
hematologic malignancy, solid- organ or bone marrow transplantation, or long 
term or high dose steroid treatment) were excluded.
Clinical protocol 
Patients were taken care of by intensivists unaware of the study results. The 
clinical suspicion of infection led to appropriate imaging and culturing at the 
discretion of attending intensivists, starting at day 0 of the study. A routine chest 
radiograph was obtained at day 0 and other imaging examinations were ordered 
when considered appropriate. Cultures were taken from different sources (blood, 
tracheal aspirate, urine, draining fluids), in order to confirm infection and were 
reported by the medical microbiological laboratory. Infection was defined and 
managed by the attending intensivist on the basis of clinical, imaging and mi-
crobiological data in close collaboration with infectious disease specialists and 
according to published criteria[15], within 7 days after enrolment. We routinely 
use selective decontamination of the digestive tract (SDD) for patients longer 
than 48 h on mechanical ventilation and 72 h in the ICU. This involves adminis-
tration of an oral paste and of a suspension via the nasogastric tube, containing 
the non-absorbable antibiotics tobramycin, amphotericin-B and colistin.
Study protocol and data collection 
At day 0 of study enrolment when the patient was suspected for having an 
infection, baseline demographic data and clinical variables, including age, sex, 
pre- morbidity, prior use of antibiotics, including SDD, steroids, immune status 
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(active malignancy or other causes of an immunocompromised state), reasons 
of admission, use of mechanical ventilation, use of renal replacement therapy 
were recorded. The acute physiology and chronic health evaluation II (APACHE 
II) was calculated on admission. On day 0, 1 and 3 clinical data were recorded, 
such as temperature, heart rate and respiratory parameters taken from the ven-
tilator. The primary site of infection, blood culture results, presence of sepsis 
or septic shock and use of norepinephrine during a 7 day observational period 
after enrolment were recorded. Blood samples for the analysis of WBC, CRP 
and IG percentage were routinely obtained at days 0, 1 and 3. Blood samples 
were collected from an arterial catheter, routinely in place in our ICU patients. 
The WBC was measured using a Sysmex XE-5000 analyzer (Toa Medical In-
struments, Kobe, Japan), CRP (using an Immunoturbidimetric assay, Modular 
Analytics <P> Roche diagnostics, Mannheim, Germany).The IG percentage was 
calculated with a specific type of automatic cell analyzer the Sysmex XE-2100 
Hematology analyzer (Toa Medical Instruments, Kobe, Japan). The method is 
described in detail elsewhere[16]. In brief, the IG measurement, which includes 
promyelocytes, myelocytes, and metamyelocytes but not bands or blasts, is per-
formed in the differential channel. A lysing reagent causes disruption of mature 
WBC membranes, leaving bare nuclei, while immature myeloid cells with low cell 
membrane lipid content remain intact. The increased permeability of leukocytes 
allows a polymethine dye to enter the cells with high affinity for nucleic acid. 
Subsequently, the cells are analyzed by nucleic acid fluorescence and side scatter. 
The IG percentage is the percentage of IG of total WBC count. Detection of IG by 
the Sysmex XE-2100 as compared to flow cytometry and previously automated 
and manual counting showed high correlation and predictive values, suggesting 
excellent performance[10,12,17-20]. The upper limit of normal in blood samples 
from healthy volunteers is 0.4% (mean of 0.22%)[19]. Patients were followed up 
until day 28 after enrolment and length of ICU stay was recorded.
Definitions 
The systemic inflammatory response syndrome (SIRS) was defined as two or 
more of the following conditions: (a) body temperature >38 °C or <36 °C; (b) 
WBC (>10,000/ µL), leukopenia (<4,000/µL), or >10% bands; (c) heart rate >90 
beats/min; and (d) respiratory rate >20 breaths/ min or mechanical ventilation. 
Sepsis was defined when meeting two or more of the SIRS criteria, together with a 
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confirmed microbial infection within 7 days after suspicion of infection was raised. 
Bloodstream infection (BSI) was defined as having a positive blood culture with a 
recognized pathogen except skin contaminants[15]. Shock was defined as an acute 
circulatory failure characterized by persistent systolic arterial pressure <90 mm 
Hg or mean arterial pressure (MAP) <70 mm Hg for at least one hour despite 
adequate fluid resuscitation or requirement of vasopressor support to maintain 
MAP. In the presence of sepsis, shock was considered septic shock.
Statistical analysis 
Continuous variables were expressed as the mean with standard deviation (SD) 
or, when the assumption of normality was violated (Kolmogorov- Smirnov test 
P<0.05), as median values and interquartile ranges. More than 2 groups were 
compared with help of the Kruskal-Wallis test for non-normally distributed 
data; otherwise the Student’s t test was used. For categorical data, the Fisher 
exact test was used. Areas under the receiver operating characteristics curves 
(AUCROC) curves were calculated to evaluate predictive values. The additive 
value of IG percentage above WBC and CRP for the prediction of infection was 
assessed with Harrell’s c- statistics (c- index which is identical to ROC) and the 
net reclassification improvement (NRI) by using R v 2.14 with the package for 
multivariate imputation by chained equations (MICE, R Foundation for Statisti-
cal Computing, Vienna, Austria) for SPSS version 20.0.0[21]. The NRI attempts 
to quantify how many individuals are correctly reclassified when adding a new 
marker, the IG percentage, to the old markers WBC and CRP. Since clearly 
defined classification thresholds were not available, the continuous variant of 
NRI was used. All tests were two-sided and a P<0.05 was considered statistically 
significant. Exact P values >0.001 are given.
Results
Patients and infections 
Table 1 describes the characteristics of the 46 consecutive patients enrolled 
in the study of whom 31 had a clinical suspicion of infection confirmed. Most 
patients were admitted to the ICU after elective surgery; only 2 patients were 
admitted because of suspected infection. Patients were enrolled at a median of 4 
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(5) days after ICU admission. Patients with an infection more often had a history 
of diabetes mellitus than patients without infection. The APACHE II score was 
higher and the use of renal replacement therapy was more frequent in patients 
with infection. Since all patients met SIRS criteria, the patients with infection 
had sepsis and 13 developed septic shock, 2 (2.5) days after enrolment. Table 2 
shows that BSI was diagnosed at median day 4 after enrolment in 15 patients. 
A total of 10 species of microorganism were detected from microbial cultures. 
Mortality rates did not differ between infection groups (Table 1).
Table 1. Patient characteristics.
Infection No infection P
n=31 n=15
Age (years) 18 (58) 9 (60) 0.54
Gender male) 59 (32) 53 (21) 0.90
APACHE II (day1) 16 (6) 11 (8) 0.002
Premorbidity
Cardiac 6 (19) 3 (20) 0.96
Pulmonary 7 (23) 1 (7) 0.12
Renal 4 (13) 2 (13) 0.97
Neurological 5 (16) 2 (13) 0.81
DM 4 (13) 0 (0) 0.04
Intestinal 20 (65) 10 (67) 0.89
Cancer 12 (39) 8 (53) 0.36
Immune 1 (3) 1 (7) 0.60
Other 4 (13) 2 (13) 0.97
Reasons of ICU admission 0.74
Postoperative 23 (77) 10 (66)
Trauma 4 (13) 3 (20)
Hepatic dysfunction 1 (3) 1 (8)
Neurological 1 (3) 1 (7)
Suspected infection 2 (7) 0 
Septic shock 13 (42) 0 0.002
CVVH 6 (19) 0 0.01
Mechanical ventilation 23 (74) 10 (67) 0.61
Norepinephrine 24 (77) 2 (13) 0.001
Antibiotics 31 (100) 8 (53) 0.001
Length of stay ICU (days) 18 (51) 6 (3) 0.001
28-day mortality 15 (48) 4 (27) 0.16
Numbers (percentage) or median (interquartile range), where appropriate. Abbreviations: APACHE = Acute 
Physiology and Chronic Health Evaluation II; DM = diabetes mellitus; CVVH = continuous venovenous hae-
mofiltration; ICU = intensive care unit.
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Markers
Table 3 shows that CRP and IG percentage increased with increasing invasive-
ness of microbial infection on day 0, 1 and 3. In patients with infection who 
developed septic shock the IG percentage at day 3 was higher than in patients 
with infection only (Table 4). No marker carried any prognostic significance.
Predictive values
The AUROC for the prediction of infection on day 0 was 0.66 (P=0.10) for WBC 
versus 0.74 (P=0.01) for CRP and 0.73 (P=0.02) for IG percentage. The AUROC 
to predict BSI on day 0 was 0.53 (P=0.74) for WBC versus 0.76 (P=0.005) for 
CRP and 0.79 (P=0.002) for IG percentage. Only day 3 AUROC’s for WBC 
(0.74, P=0.014) and IG percentage (0.82, P=0.001) helped to predict septic 
shock (ROC curves can be found in the online supplement). Table 5 summarizes 
predictive values.
We combined variables and judged their additive values. Comparing 
model 1 (WBC and CRP) to model 2 (WBC and IG percentage) results in compa-
rable AUROC for the prediction of microbial infection (Table 6). The predictive 
Table 2. Infection characteristics.
n Days between enrolment and diagnosis
Source (may be more than one)
Bacteremia 15 4 (2)
Pneumonia 15 2.5 (2.5)
Peritonitis 3 2 (2.5)
Soft tissue 3 2 (2.5)
Miscellaneous 5 1.5 (2)
Associated microorganism
Staphylococcus aureus 15 (19)
Pseudomonas spp. 14 (18)
Klebsiella pneumoniae 11 (14)
Enterococcus spp. 11 (14)
Candida spp. 10 (13)
Escherichia coli 10 (13)
Proteus mirabilis 3 (4)
Streptococcus pneumoniae 2 (3)
Stenotrophomonas spp. 1 (2)
Morganella morganii 1 (2)
Numbers (percentage) or median (interquartile range), where appropriate.
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value for absence of infection improves for each day when IG percentage is added 
(model 3) to WBC and CRP (model 1) (Figure 1). For day 3, the IG percentage 
improved the NRI for both having an infection and not having an infection. When 
combining IG percentage with the WBC and CRP, the sensitivity of the model 3 
was 80% at 90% specificity and the specificity was 75% at 90% sensitivity.
Table 3. Infection markers in patients with infection and bloodstream infection (BSI), patients with infection 
but no BSI or patients without infection.
Day Infection and BSI
n=15
Infection, no BSI
n=16
No infection
n=15
P
WBC, 109/L 0 9.6 (11.0) 12.6 (7.1) 8.9 (6.1) 0.19
1 11.8 (4.8) 13.4 (7.9) 9.2 (5.5) 0.02
3 11.3 (9.2) 11.9 (7.7) 7.1 (2.9) 0.02
CRP, mg/L 0 239 (247) 111 (67) 80 (65) 0.008
1 306 (152) 170 (168) 96 (114) < 0.001
3 245 (140) 106 (176) 89 (84) 0.006
IG percentage 0 1.3 (1.7) 0.4 (0.7) 0.2 (0.2) 0.003
1 1.1 (2.4) 0.6 (0.8) 0.4 (0.6) 0.006
3 1.8 (2.7) 1.1 (1.5) 0.3 (1.1) 0.009
Data are given as median (interquartile range). WBC = white blood cell count, CRP = C-reactive protein, IG = 
immature granulocytes.
Table 4. Infection markers in patients with or without septic shock.
Day Shock
n=13
No shock
n=18
P
WBC, 109/ L 0 11.3 (4.8) 10.6 (6.4) 0.96
1 12.5 (5.1) 12.9 (5.4) 0.71
3 14.0 (6.1) 10.4 (5.2) 0.07
CRP, mg/ L 0 192 (120) 159 (119) 0.56
1 243 (118) 211 (114) 0.45
3 212 (111) 160 (95) 0.35
IG percentage 0 2.7 (5.0) 1.0 (1.4) 0.27
1 3.3 (5.9) 1.5 (2.9) 0.24
3 3.5 (2.7) 1.3 (1.1) 0.01
Mean (standard deviation). WBC = white blood cell count, CRP = C-reactive protein, IG = immature granu-
locytes.
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Discussion
This study suggests that the IG percentage is an easily obtainable and useful 
adjunctive marker to predict microbial infection, its invasiveness and severity in 
the critically ill patient.
The elevation of IG percentage in patients with infection is confirmed in 
earlier studies, in (non-)critically ill adults and neonates[1,7,11,12,14]. One of 
those studies concluded that the IG percentage better predicted infection than 
the total WBC count, in agreement with our study, but similarly as the absolute 
neutrophil count[11]. ROCs performed in our study showed AUROCs between 
0.66-0.73 for the WBC and 0.73-0.78 for IG percentage, indicating that the 
Table 5. Individual predictive indices for infection for day 0 markers.
Cut-off value
WBC CRP IG percentage
>12.6 109/L >99 mg/L >0.4 %
 Sensitivity 45 77 58
 Specificity 93 71 80
 PPV 93 85 86
 NPV 45 59 48
WBC = white blood cell count, CRP = C-reactive protein, IG = immature granulocytes, PPV = positive predic-
tive value, NPV = negative predictive value.
Table 6. Net reclassification improvement (NRI). 
Day 0 Day 1 Day 3
c- index (model 1) 0.75 0.82 0.81
c- index (model 2) 0.75 0.80 0.85
P 0.79 0.49 0.25
NRI infection, P - 0.03, P = 0.59 - 0.22, P = 0.20 0.10, P = 0.59
NRI no infection, P - 0.09, P = 0.80 0.06, P = 0.80 0.20, P = 0.44
NRI overall, P 0.07, P = 0.92 - 0.16, P = 0.60 0.30, P = 0.35
c- index (model 1) 0.75 0.82 0.81
c- index (model 3) 0.80 0.87 0.88
P 0.01 0.01 0.001
NRI infection, P - 0.03, P = 0.86 - 0.03, P = 0.86 0.23, P = 0.21
NRI no infection, P 0.60, P = 0.02 0.60, P = 0.02 0.47, P = 0.07
NRI overall, P 0.57, P = 0.07 0.57, P = 0.07 0.69, P = 0.03
The concordance (c) statistic (identical to ROC and p for their comparison is given for model
1 (WBC and CRP), model 2 (WBC and IG percentage) and model 3 (WBC, CRP and IG percentage) at day 0, 1 
and 3. The NRI and associated P are calculated for infection, no infection and overall reclassification.
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IG percentage is indeed a better predictor of infection. Other studies suggest 
that IG percentage can be used as indicator for the invasiveness and severity of 
microbial infection[1,7,8,11,14], also in line with our study. The AUROC for IG 
percentage to predict infection, BSI and septic shock, and thus the invasiveness 
and severity of infection is similar or higher than reported in other studies in 
non-critically ill patients[11,12,14]. Of the two studies performed in the critically 
ill, the IG percentage was used to predict otherwise loosely defined sepsis, rather 
than proven infection[1]. Our results largely agree with those obtained in criti-
cally ill surgical patients including the absent relation with mortality[4], which 
may not agree with other studies showing IG to predict mortality[7].
Studies tried to combine IG percentage with WBC, absolute neutrophil 
count or other markers to increase the accurate prediction of microbial infec-
Figure 1. Reclassification plot of infection (+) and no infection (0) when IG percentage is
added to WBC and CRP at day 0. It is shown that the addition particularly lowered the
probability of no infection.
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tion[1,4,5,7,8,11,14]. The IG percentage combined with the WBC was as predic-
tive as WBC combined with CRP, so that the IG percentage can replace CRP, 
even in the critically ill, as suggested by our study. In fact, the predictive values 
of IG percentage and CRP as single markers were similar. Adding IG percentage 
to WBC and CRP gave a better prediction of microbial infection (AUC 0.80-0.88) 
than using the IG percentage as a single marker, and its addition was helpful at 
day 0 to exclude infection and at day 3 to predict or exclude infection. Hence, the 
IG percentage can still be useful when CRP measurements are available.
Furthermore, the IG percentage can be rapidly and accurately gener-
ated with each full blood count at no extra cost, as opposed to the use of other 
available markers for infection including CRP. The automatic measurement of 
IG is more precise and less labor intensive than the manual differential count, 
resulting in improved quality and even cost reduction in the clinical chemistry 
laboratory[9,12,17,20]. Because the measurement can be performed on the same 
machines incorporated for the daily routine measurements of the WBC count, 
no additional blood sampling is needed either.
A limitation of this study is the relatively small population enrolled in this 
study, so that results should be regarded as preliminary. There is a significant 
difference in disease severity between infected and non-infected patients, so that 
we cannot rule out whether the same alterations in IG percentage could be seen 
when both groups were comparably sick. The use of SDD may not interference 
with the predictive value of infection markers as concluded by Hoeboer et al[2]. 
The current study did not compare IG percentage with other novel biomarkers 
such as procalcitonin (PCT). However a PCT measurements requires extra blood 
sampling and additional costs in contrast to the IG percentage which can be 
obtained routinely without extra blood sampling nor costs. An advantage is the 
use of the relatively novel NRI indicating the additive value of IG percentage in 
addition to WBC and CRP for the prediction of infection. This was not performed 
in previous studies.
In conclusion, the IG percentage is a useful marker, as CRP, to predict 
infection, its invasiveness and severity, in the critically ill patient. However, the 
IG percentage adds to WBC and CRP in early exclusion of infection, and can 
be collected routinely without extra blood sampling or costs. The value of IG 
percentage in guiding infection management and improving patient outcomes 
deserves further study.
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Abstract
Introduction
The prediction of infection and its severity remains difficult in the critically ill. 
A novel, simple biomarker derived from five blood-cell derived parameters that 
characterize the innate immune response in routine blood samples, the inten-
sive care infection score (ICIS), could be helpful in this respect. We therefore 
compared the predictive value of the ICIS with that of the white blood cell count 
(WBC), C-reactive protein (CRP) and procalcitonin (PCT) for infection and its 
severity in critically ill patients.
Methods 
We performed a multi-center, cluster randomized, crossover study in critically 
ill patients between January 2013 and September 2014. Patients with a sus-
pected infection for which blood cultures were taken by the attending intensivist 
were included. Blood was taken at the same time for WBC, ICIS, CRP and PCT 
measurements in the control study periods. Results of imaging and cultures 
were collected. Patients were divided into groups of increasing likelihood of 
infection and invasiveness: Group 1 without infection or with possible infection 
irrespective of cultures, Group 2 with probable or microbiologically proven local 
infection without blood stream infection (BSI) and Group 3 with BSI irrespec-
tive of local infection. Septic shock was assessed.
Results
In total, 301 patients were enrolled. CRP, PCT and ICIS were higher in Group 
2 and 3 than 1. The AUROC for the prediction of infection was 0.70 for CRP, 
0.71 for PCT and 0.73 for ICIS (P<0.001). For the prediction of septic shock the 
AUROC was 0.73 for CRP, 0.85 for PCT and 0.76 for ICIS. These AUROC’s did 
not differ from each other.
Conclusion
The data suggest that the ICIS is potentially useful for the prediction of infec-
tion and its severity in critically ill patients, non-inferiorly to CRP and PCT. In 
contrast to CRP and PCT, the ICIS can be determined routinely without extra 
blood sampling and lower costs, yielding results within 15 minutes.
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Introduction
In approximately 50% of critically ill patients with suspected infection an infec-
tion is probable or can be proven [1,2]. This could lead potentially to overtreat-
ment with empiric antibiotics [1,2]. Moreover, infection diagnostics are often 
delayed since it takes 48 h at minimum for cultures to become positive and 
thereby to prove a clinically suspected infection. Hence, there is a continuing 
need for fast and accurate biomarkers of infection, that may help to predict in-
fection, its invasiveness and severity and may guide empiric antibiotic treatment 
in the future [3]. We belief that prediction of infection is more helpful in patient 
management than prediction of sepsis, since the majority of critically ill patients 
have two or more criteria of the systemic inflammatory response syndrome 
(SIRS) as criteria for sepsis, irrespective of infection.
Commonly applied biomarkers include C-reactive protein (CRP) and 
procalcitonin (PCT), but predictive values vary among studies [3-11]. A new 
biomarker is the Intensive Care Infection Score (ICIS) which is composed of five 
blood cell-derived parameters characterizing the early innate immune response 
and routinely obtainable in blood samples sent to the laboratory for cell counts. 
The ICIS score has been retrospectively evaluated in two pilot studies on 70 
and 172 patients, respectively, suggesting potential predictive value for infection 
[12,13].
We therefore performed a prospective study on the predictive value of 
ICIS for probable or proven infection in critically ill patients with suspected 
infection, and compared its performance with that of the white blood cell count 
(WBC), CRP and PCT levels. We hypothesized that in the critically ill patient 
with suspected infection the diagnostic accuracy of the simply obtainable ICIS is 
at least equivalent in this respect to WBC, CRP and PCT, without requiring extra 
blood sampling.
Methods
Study design and patients
The ICIS study is an add-on non-interventional study on patients which had 
been enrolled into a prospective, cluster-randomized, cross-over trial, involving 
both intensive care units (ICU) of the Erasmus Medical Center Rotterdam and 
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both ICU’s of the Maasstad hospital Rotterdam. The ICU’s were stratified and 
randomized by treatment regimen into a control group (standard of care) and 
an intervention group. In the intervention arm, blood culturing for a suspected 
infection was guided by PCT measurements. The acronym PCT-guided blood 
culturing in the intensive care, ProBIC, was used for this study and results will 
be reported later. The trial was conducted between January 2013 and September 
2014. The ICU of the Erasmus Medical Center is a tertiary care mixed medical-
surgical ICU with approximately 2000 admissions per year. The ICU of the 
Maasstad hospital is a secondary care mixed medical-surgical ICU with 1200 
admissions per year. The trial was conducted in accordance with the ethical 
principles decreed by the Declaration of Helsinki and in compliance with Inter-
national Conference on Harmonization Good Clinical Practice Guidelines. The 
institutional review board (IRB) or the independent medical ethical committee 
at each of the investigational centers (Medisch Ethische commissie Maasstad 
ziekenhuis, Rotterdam, Nederland and Medisch Ethische commissie Erasmus 
Medisch Centrum, Rotterdam, Nederland) reviewed and approved the protocol, 
amendments and informed consent document. The medical ethical committee 
of the Erasmus Medical Center finally approved the study (MEC 2011-505). The 
trial is registered at ClinicalTrial.gov (protocol ID NCT01847079) on 24 April 
2013. All patients or their proxy provided written informed consent prior to study 
inclusion, at ICU admission. Inclusion criteria were age above 18 and below 80 
years and the clinical suspicion of infection for which the attending intensivist 
established a medical need for a blood culturing. Suspicion of infection included 
but was not limited to increased body temperature above 38.3 °C (tympanic 
temperature), chills, progressive leukocytosis, increased CRP, increasing con-
solidations on chest radiography or other imaging of potential infection sources. 
For each patient it was possible to be included more than once, but we analyzed 
for the current study only the first time that blood for culture was taken. Patients 
were excluded if they were pregnant, had neutropenia (defined as leukocyte count 
less than 0.5x109/L), used immunosuppressive or immunostimulatory therapy, 
or had a predetermined illness with an expected death within 24 hours. Patients 
were not included if blood cultures were performed as part of a standard protocol 
(such as patients with veno-venous or veno-arterial extra corporeal membrane 
oxygenation) or were performed to check the effectiveness of treatment (such 
as in endocarditis), unless the blood culture was done because of suspicion of 
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infection. The ICU’s switched the allocated regimen every three months, so that 
there were six three-months episodes of standard care in which 774 patients were 
eligible for inclusion and 473 patient were excluded (≤ 18 years 5; neutropenia 
(<0.5x104/ L) 63; uncontrolled malignancy 35; immunosuppressive medication 
256; suspect dead < 24 hours 22; no informed consent 92). Data for the ICIS 
study were thus collected in 301 patients in the control arm (six, three months 
episodes) of the ProBIC study.
Study protocol, data collection and assays
Baseline demographic data and clinical variables were recorded at the day of 
inclusion, and included age, sex, comorbidity, reasons of admission, use of 
antibiotics including selective decontamination of the digestive tract (SDD), 
antifungal treatment, steroids, immunosuppressive medication, immune status 
and recent surgery. The treatment received during ICU stay was also recorded 
and included mechanical ventilation, renal replacement therapy, total paren-
teral nutrition, arterial and central venous catheters and the use of vasopressor 
or inotropic medication. The acute physiology and chronic health evaluation II 
(APACHE II) and the sequential organ failure assessment (SOFA) score were 
recorded at admission. The length of ICU and hospital stays and vital outcomes 
were recorded, up to 90 days after inclusion. At the same time that blood for 
culture was taken for each, blood samples for determinations of WBC, CRP, PCT 
and ICIS (Day 0) were taken. Blood for similar measurements (except for PCT) 
was taken in the morning of the two following days (Day 1 and 2). Treating physi-
cians and investigators were blinded for the PCT and ICIS measurement results. 
Also the outcome adjudicators that decided presence/ absence of infection were 
blinded to biomarker results. Two sets of blood cultures were taken and directly 
send to the department of medical microbiology. The set taken for blood culture 
consists of one aerobic and one anaerobic bottle (BD BactecTM, New Yersey, 
USA) that contain resin to enhance recovery of organisms. The samples were 
incubated for a seven-day period in an automatic analyzer (BD BACTECTM, New 
Jersey, USA) that automatically demonstrates the time to positive blood culture 
in case of positive bacterial or fungal growth. Gram strains were performed, 
and the organisms were cultured on agar plates after growth identification was 
performed, using the VITEK® 2  (Biomerieux, Marcy l’Etoile, France). Blood 
for the WBC and ICIS measurement was obtained in a K3EDTA tube. Both the 
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WBC and ICIS parameters were measured on a modified fluorescence flow he-
matology analyzer with fully automated gating (Sysmex, Kobe, Japan) [14]. The 
ICIS was measured promptly after collection but within a maximum of 24 hours. 
The ICIS score is composed of five blood-cell derived parameters that character-
ize the innate immune response [15-19]. The five parameters include the mean 
fluorescence intensity of mature (segmented) neutrophils, the difference in 
hemoglobin concentration between newly formed and mature red blood cells, 
the total segmented neutrophil count, the antibody secreting lymphocytes and 
the accurate immature granulocytes count, as previously described [12]. Each 
parameter is available from a standard routine method and can be measured 
within 1 minute without sample preparation on a modified fluorescence flow 
hematology analyzer with fully automated gating (Symex, Kobe, Japan) [12]. 
The methodology is based on routine hematology fluorescence flow cytometry 
using different fluorescence reagents for mainly nucleic acids, as well as specifi-
cally designed blood cell membrane surfactant reagents generating information 
about cell shape and the formation of bioactive lipids from cell membranes [12]. 
Side and forward scatter light are used to determine intracellular structure and 
size of blood cells [12]. By adding all weighting values for all five parameter 
components the maximum possible ICIS score is 20. Serum CRP (turbidimetric 
assay) and PCT (electrochemiluminescence BRAHMS immunoassay) measure-
ments were routinely performed using an Cobas 8000 platform (Roche, Almere, 
Netherlands). Blood for PCT measurement was sampled in a z serum clot activa-
tor tube.
Definitions
After completion of the study, the investigators decided whether an infection 
was present from Day 0-2, on the basis of the available imaging and culture 
results. The outcome adjudicators were blinded for all biomarkers. Source 
and likelihood of infection were based on criteria defined at the International 
Sepsis Forum Consensus Conference [20]. For judging results of cultures, a 48 
h window prior and after taking blood cultures was taken. The causative micro-
organisms were recorded. Blood stream infection (BSI) was defined as a positive 
blood culture with a recognized pathogen except skin contaminants [20,21]. In 
case of skin contaminants, BSI was considered if at least 2 blood cultures drawn 
on separate locations were positive [20,21]. Patients were divided into groups 
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of increasing likelihood of infection and invasiveness of associated micro-
organisms, suggestive of increasing severity: Group 1 without infection or with 
possible infection irrespective of cultures, Group 2 with probable (irrespective 
of cultures) or proven local infection (with positive cultures of a causative mi-
croorganism) without BSI and Group 3 with BSI irrespective of local infection. 
SIRS was defined as two or more of the following criteria: (I) body temperature 
>38 °C or <36 °C; (II) WBC (>10,000/µL), leukopenia (<4,000/µL), or >10% 
bands; (III) heart rate >90 beats/min; and (IV) respiratory rate >20 breaths/ 
min or mechanical ventilation, for values at Day 0. When SIRS and a probable/
proven infection (Group 2 or 3) were present, patients were classified as having 
sepsis. Shock was defined as an acute circulatory failure characterized by persis-
tent systolic arterial pressure <90 mm Hg or mean arterial pressure (MAP) <70 
mm Hg for at least one hour despite adequate fluid resuscitation or requirement 
of vasopressor support to maintain MAP, at Day 0. In the presence of sepsis, 
shock was considered septic shock.
Statistical analysis
This was performed using SPSS version 23 (SPSS inc., Chicago Ill., USA) and 
using R package. Data are expressed are expressed as median (interquartile 
range) or as number of patients (percentage) where appropriate. Most data were 
distributed non-normally (Kolmogorov-Smirnov test P<0.05). Group (>2) dif-
ferences were evaluated using the Kruskal-Wallis test or X2 test, for continuous 
and categorical data, respectively. The Mann-Whitney U test and Fisher exact 
test were used to compare two groups. To evaluate predictive values we calcu-
lated the areas under the receiver operating characteristic curves (AUROC) for 
Day 0 values. For the predictive values of sepsis and septic shock we used the 
values of Day 0. We consider an AUROC >0.70 as clinically relevant [22]. The 
optimum cut-off value was calculated on the basis of the highest sensitivity and 
specificity combined (Youden index). Positive and negative predictive values 
were calculated. To correct for multiple testing we set the level of statistical 
evidence at P≤0.01. Exact P values >0.001 are given.
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Results
Patient characteristics
Table 1 describes the baseline characteristics of the 301 patients enrolled: 149 
(Group 1) patients had no infection and 152 (Group 2+3) patients had a prob-
able or proven infection. Patients with a probable or proven infection were 
older and more often had a history of cancer, cardiac disease or gastro-intestinal 
problems. Mechanical ventilation or renal replacement therapy was more often 
used in patients with a probable or proven infection. All patients with a probable 
or proven infection were on antibiotics. No difference was seen in 28- or 90-day 
mortality and in the length of ICU or hospital stay .
Source of infection and microbial species
The abdomen and lungs were the most frequent source of infection (Table 2). 
Gram-positive pathogens were mostly cultured, followed by Gram-negatives, 
fungi and viruses (Table 2).
Biomarkers
Table 2 shows the infection markers according to invasiveness of infection. Most 
patients had SIRS on Day 0, so that the patients with infection in Group 2 and 3 
had mostly sepsis. CRP, PCT and ICIS were increased at Day 0-2 in patients with 
infection as compared to those without infection. In contrast to PCT, there was 
no difference in CRP and ICIS between Groups 3 and 2. The CRP, PCT and ICIS 
where increased in patients with septic shock (Table 3).
Predictive values
The AUROC for the prediction of infection (Group 2+3 vs Group 1) on Day 0 was 
similar for CRP, PCT and ICIS (Table 4, Fig. 1). At a cut-off ≥7, the positive pre-
dictive value of ICIS was >80% and at a cut-off ≤1 the negative predictive value 
of ICIS was >80%. Otherwise, the AUC for ICIS did not differ from that of any 
other biomarkers, including PCT, expect for that of WBC (P<0.001). PCT had 
the highest AUROC for the prediction of septic shock (AUROC 0.85, P<0.001), 
but not different from that of ICIS (AUROC 0.76, P<0.001), whereas CRP had 
an AUROC of 0.73 (P<0.001) and WBC of 0.53 (P=0.68) (Fig. 2).
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Table 1. Baseline demographic and clinical characteristics.
Group 1 Group 2+3 P
(n=149) (n=152)
Age (years) 57 (24) 62 (19) 0.01
Gender (male) 100 (67) 105 (69) 0.72
APACHE II score 22 (10) 22 (8) 0.92
APACHE IV score 63 (38) 60 (34) 0.49
SOFA score 7 (7) 8 (6) 0.06
Comorbidity
Neurologic 39 (26) 41 (27) 0.88
Cardiac 40 (27) 58 (38) 0.04
Pulmonary 28 (19) 38 (25) 0.25
Gastrointestinal 39 (26) 55 (36) 0.05
Renal 15 (10) 24 (16) 0.14
DM II 22 (15) 33 (22) 0.13
Cancer 22 (15) 46 (30) 0.002
Autoimmune 7 (5) 8 (5) 0.97
Reasons of ICU admission <0.001
Suspected infection 23 (15) 69 (45)
Respiratory failure 24 (16) 33 (22)
Renal failure 0 (0) 1 (1)
Liver failure 5 (3) 3 (2)
Neurology 31 (21) 8 (5)
CPR 9 (6) 5 (3)
Shock 10 (7) 3 (2)
Trauma 13 (9) 5 (3)
Postoperative 34 (23) 25 (17)
Treatment on ICU
Antibiotics 140 (94) 152 (100) 0.02
Norepinephrine 109 (73) 128 (84) 0.03
Dobutamine 18 (12) 17 (11) 0.80
TPN 39 (26) 50 (33) 0.20
Mechanical ventilation 133 (89) 125 (82) 0.06
Renal replacement therapy 15 (10) 52 (34) <0.001
Length of ICU stay (days) 9 (17) 11 (17) 0.49
Length of hospital stay (days) 22 (34) 26 (36) 0.13
Mortality day 28 42 (28) 58 (38) 0.09
Mortality day 90 98 (36) 68 (45) 0.13
Numbers (percentage) or median (interquartile range), where appropriate. Abbreviations: APACHE II = 
Acute Physiology and Chronic Health Evaluation II; CPR = cardiopulmonary resuscitation; DM II = diabetes 
mellitus type II; ECMO= extra corporeal membrame oxygenation; SOFA = sequential organ failure assess-
ment score; TPN = total parenteral nutrition.
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Table 2. Infection characteristics.
Group 1  Group 2 Group 3 P
(n=149)  (n=91) (n=61)
Source of infection 0.01
Pulmonary - 44 (48) 15 (25)
Abdominal - 30 (33) 29 (47)
Urogenital - 8 (9) 2 (3)
Neurologic - 2 (2) 2 (3)
Soft tissue/ bones - 7 (8) 10 (17)
Blood and catheter - 0 3 (5)
Gram strain 0.01
Gram negative - 30 (33) 16 (26)
Gram positive - 27 (30) 36 (59)
Type of microorganism 0.15
Staphylococci - 15 (16) 17 (28)
Streptococci - 12 (13) 19 (31)
Enterobacteriaceae - 26 (29) 15 (25)
Pseudomonas - 4 (4) 1 (2)
Fungi - 12 (13) 6 (10)
Viral - 5 (5) 3 (5)
Biomarkers
SIRS 146 (98) 90 (99) 58 (95) 0.94
Septic shock - 12 (13) 9 (15) 0.78
Temperature (°C) 38.1 (1.5) 38.3 (1.7) 38.0 (1.5) 0.94
Heart rate (beats/ min) 105 (29) 109 (37) 112 (39) 0.15
Respiratory rate (breaths/ min) 28 (13) 29 (17) 29 (17) 0.61
WBC day 0 (109/L) 12.4 (7.8) 14.4 (12.9) 13.9 (12.2) 0.63
WBC day 1 (109/L) 11.7 (8.1) 13.9 (13.1) 13.4 (11.3) 0.47
WBC day 2 (109/L) 12.1 (7.2) 14.4 (9.8) 14.8 (15.0) 0.19
CRP day 0 (mg/L) 84 (109) 163 (156) 167 (161) <0.001
CRP day 1 (mg/L) 88 (131) 156 (156) 197 (154) <0.001
CRP day 2 (mg/L) 82 (141) 131 (136) 180 (172) <0.001
PCT day 0 (µg/L) 0.65 (2.30) 2.71 (9.88) 4.13 (38.0) <0.001
ICIS day 0 3 (3) 6 (5) 6 (5) <0.001
ICIS day 1 3 (3) 6 (4) 6 (4) <0.001
ICIS day 2 4 (4) 6 (4) 6 (4) <0.001
Numbers (percentage) or median (interquartile range), where appropriate. Group 1: no infection; Group 2: 
local infection without blood stream infection; Group3: blood stream infection. Abbreviations: CRP = C- reac-
tive protein; ICIS = intensive care infection score; PCT = procalcitonin; SIRS, systemic inflammatory response 
syndrome; WBC = white blood cells.
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Discussion
This study evaluated the predictive values of ICIS, to discriminate between non-
infectious systemic inflammation and infection (mostly sepsis) in critically ill 
patients with a suspicion of infection. The data suggest that ICIS is an useful 
marker to predict probable or proven infection and its severity and is non-
inferior in this respect to CRP and PCT.
In the current study the frequency of probable or proven infection was 
56% of patients when an infection was suspected, which is comparable with the 
reported frequency of 51-58% in a large studies on the epidemiology of sepsis in 
Table 3. Septic shock.
No (n=280) Yes (n=21) P
Temperature (°C) 38.2 (1.5) 38.2 (1.6) 0.75
Heart rate (beats/ min) 108 (33) 119 (59) 0.04
Respiratory rate (breaths/ min) 28 (15) 29 (13) 0.85
WBC day 0 (109/L) 12.8 (9.5) 12.5 (17.6) 0.68
WBC day 1 (109/L) 12.4 (9.5) 14.1 (20.4) 0.60
WBC day 2 (109/L) 12.5 (9.4) 14.6 (14.4) 0.41
CRP day 0 (mg/L) 107 (144) 234 (182) <0.001
CRP day 1 (mg/L) 124 (147) 327 (160) <0.001
CRP day 2 (mg/L) 107 (144) 244 (205) <0.001
PCT day 0 (µg/L) 1.15 (6.1) 32.2 (94.0) <0.001
ICIS day 0 4 (5) 9 (6) <0.001
ICIS day 1 4 (4) 8 (7) <0.001
ICIS day 2 5 (5) 7 (6) 0.03
Median (interquartile range). Abbreviations: CRP = C- reactive protein; ICIS = intensive care infection score; 
PCT = procalcitonin; WBC = white blood cells.
Table 4. Receiver operating characteristic curve analysis to determine the optimum cut-off value of the dif-
ferent biomarkers at Day 0 for the prediction of infection (Group 2 + 3).
Biomarkers
Parameters
AUC (95% CI) P Cut-off Sensitivity Specificity PPV NPV
WBC (109/L) 0.53 (0.46, 0.60) 0.38 12.9 0.54 0.54 0.55 0.54
CRP (mg/L) 0.70 (0.64, 0.76) <0.001 111 0.65 0.64 0.65 0.64
PCT (µg/L) 0.71 (0.66, 0.77) <0.001 1.41 0.65 0.66 0.66 0.65
ICIS 0.73 (0.67, 0.79) <0.001 5 0.66 0.71 0.70 0.67
Abbreviations: CI = confidence interval; CRP = C- reactive protein; ICIS = intensive care infection score; PCT 
= procalcitonin; PPV = positive predictive value; NPV = negative predictive value; WBC = white blood cells. 
The AUC for ICIS differed from that of WBC (P<0.001).
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the ICU [23]. The lung and abdomen were the most common origin of sepsis, 
followed by infections of soft tissues, as described before [24]. A large recently 
performed study showed that Gram-negative bacteria were isolated in 62% of 
patients with sepsis who had positive cultures, Gram-positive bacteria in 47%, 
and fungi in 19% [23]. The results are in contrast with our study, which suggests 
that Gram-positive isolates are most likely to cause infection. The difference 
can be explained by the fact that we use SDD in our ICU’s, which is known to 
eliminate Gram-negative bacteria and fungi from the digestive tract [25]. Blood 
cultures are typically positive in approximately one third of the patients with 
sepsis, in line with the incidence of 20% in this study [24]. The overall ICU and 
hospital mortality rates were 28 and 37%, respectively. The results are compa-
Figure 1. Area under the receiver operating characteristic (AUROC) curve of the four biomarkers for the pre-
diction of infection during suspected infection episode I: for white blood cell count (WBC) 0.53, for C-reactive 
protein (CRP 0.70), for procalcitonin (PCT) 0.71 and for intensive care infection score (ICIS) 0.73.
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rable with the reported rates in a European multi-center study of critically ill 
patients with sepsis [26].
In the current study the predictive values of WBC and CRP for infection 
and sepsis are comparable with previous studies which reported a low AUROC 
of 0.55-0.66 for WBC (sensitivity 65-91%; specificity 35-54%) and an interme-
diate AUROC of 0.64-0.77 for CRP (sensitivity 82-100%; specificity 40-64%) 
[4,5,10,11]. Large reviews reported an AUROC of 0.78-0.81 for PCT (sensitivity 
42-100%; specificity 48-100%), comparable to our study [7,9]. The reported pre-
dictive value of ICIS in this study is lower compared with two previous studies, 
which reported an AUROC of 0.79 (sensitivity 70%; specificity 79%) and 0.85 
(sensitivity 80%; specificity 75%), respectively [12,13]. Both studies investigated 
a relatively small number of patients or investigated postoperative critically ill 
patients only [12,13]. They were pilot studies to define the cut-off values of ICIS 
Figure 2. Area under the receiver operating characteristic (AUROC) curve of the four biomarkers for the pre-
diction of septic shock during episode I: for white blood cell count (WBC) 0.53, for C-reactive protein (CRP) 
0.73, for procalcitonin (PCT) 0.85 and for intensive care infection score (ICIS) 0.76.
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as a marker of infection in critically ill patients and recommended determina-
tion of the suitability and effectiveness of this score in a prospective trial [12,13].
Using ICIS has several advantages over using CRP or PCT. First, no extra 
blood needs to be taken since the ICIS can be measured from the same K3EDTA 
tube which is used for the WBC measurement, thereby allowing routine daily 
measurements. Second, lower costs are involved because the ICIS measurement 
is performed on the same machine used for a WBC measurement. The major 
limitation is that in our study the predictive values of biomarkers including ICIS 
was not very high. Nevertheless, a high ICIS increases the likelihood of infec-
tion when suspected and a low ICIS decreases it. This may help the clinician in 
ordering extra test or start empiric antibiotics. The predictive value of ICIS for 
infection and septic shock is comparable with that of immature granulocytes 
percentage in a relatively small study in critically ill patients [27]. Both the im-
mature granulocytes percentage and ICIS can be obtained routinely without ex-
tra blood sampling nor costs, though the current study focused on the diagnostic 
accuracy of ICIS and not its feasibility or cost-effectiveness. For future use the 
ICIS is expected to prove more robust.
In conclusion, the present study suggest that ICIS is a novel and po-
tentially useful predictor of infection and sepsis in critically ill patients with 
a suspected infection. The ICIS score can be collected routinely without extra 
blood sampling and lower costs, yielding results within 15 minutes.
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Abstract
Objective 
The diagnostic use of procalcitonin for bacterial infections remains a matter of 
debate. So far most studies used ambiguous outcome measures such as sepsis 
instead of infection. We performed a systematic review and meta-analysis to 
investigate the diagnostic accuracy of procalcitonin for bacteraemia, a proven 
bloodstream infection.
Methods 
We searched all major databases from inception to June 2014 for original, 
English written, research articles that studied the diagnostic accuracy between 
procalcitonin and positive blood cultures in adult patients. We calculated the 
area under the summary receiver-operating characteristic curves (SROC) and 
pooled sensitivities and specificities. To minimise potential heterogeneity we 
performed subgroup analyses.
Results 
In total 58 of 1,567 eligible studies were included in the meta-analysis and 
provided a total of 16,514 patients of whom 3,420 suffered from bacteraemia. 
In the overall analysis the SROC was 0.79. The optimal and most widely used 
procalcitonin cut-off value was 0.5 ng/mL with a corresponding sensitivity of 
76% and specificity of 69%. In subgroup analyses the lowest SROC was found in 
immunocompromised/neutropenic patients (0.71), the highest SROC was found 
in intensive care patients (0.88), sensitivities ranging 66-89% and specificities 
55-78%.
Conclusions 
In spite of study heterogeneity, procalcitonin had a fair diagnostic accuracy for 
bacteraemia in adult patients suspected of infection or sepsis. In particular low 
procalcitonin levels can be used to rule out the presence of bacteraemia. Further 
research on the safety and efficacy of procalcitonin as a single diagnostic tool to 
withhold taking blood cultures is needed.
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Introduction 
Infection and the subsequent sepsis syndrome are associated with morbidity 
and mortality [1,2]. The fear of undertreatment leads to the routine collection of 
specimen for microbiological culture and initiation of empiric antibiotic therapy 
[3]. On the other hand, antibiotic overuse increases microbial selection and 
resistance and can cause adverse drug reactions [4]. To assist the diagnosis of 
infection in clinical practice its symptoms have been grouped into the systemic 
inflammatory response syndrome (SIRS [5]. A clinically suspected or proven 
infection in the presence of SIRS is termed sepsis [5]. In recent years authors 
have studied the use of biomarkers, like procalcitonin, to improve the diagnosis 
of the sepsis syndrome rather than of proven infection [6-9]. The use of the 
sepsis syndrome as a surrogate for proven infection as an outcome parameter 
may be too sensitive and nonspecific. This could partially explain the contradict-
ing results in previous studies [6-9,10] and meta-analyses on the diagnostic use 
of procalcitonin for sepsis [11-18].
The definition of proven local infection remains matter of debate and 
we therefore study the more robustly defined proven bloodstream infections, 
i.e. bacteraemia. Bacteraemia can be identified in about 30% of septic patients 
and necessitates further diagnostic evaluation [19]. However, culture results 
take several days and can be falsely negative in patients on antibiotic treatment 
[20-22]. Recent studies demonstrated that procalcitonin can accurately predict 
bacteraemia in patients with community-acquired pneumonia [23], acute fe-
ver [24], and in elderly patients suspected of infection [25]. Procalcitonin can 
also accurately discriminate between true bacteraemia and coagulase negative 
staphylococci-contaminated blood cultures [26]. Another study demonstrated 
that bacteraemia is unlikely when procalcitonin levels are low [27]. Some meta-
analyses focused on the diagnostic value of procalcitonin for microbiologically 
confirmed local infection [28-39] or bacteraemia [40]. However, the number of 
included studies was small, specific patient subgroups were analysed or studies 
concerning sepsis were included as well [28-40].
We therefore performed a systematic review and meta-analysis to inves-
tigate the diagnostic accuracy of procalcitonin for bacteraemia. Our hypothesis 
is that in adult patients suspected for infection or sepsis procalcitonin is a useful 
biomarker of bacteraemia.
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Methods
Search strategy and study selection 
We used the Preferred Reporting Items for Systematic Reviews and Meta-Analy-
ses (PRISMA) statement for reporting this systematic review and meta-analysis 
[41]. A flowchart of the literature search can be found in Figure 1. All prospective 
and retrospective, original, observational (case-control, cross sectional, cohort 
and longitudinal) studies published in English from inception until June 2014 
were considered eligible for inclusion. Studies were screened by title and ab-
stract and definite inclusion was decided upon after full text review.
We included studies on adult hospitalised patients suspected of infection 
or sepsis, in which bacteraemia with a known pathogen was confirmed by blood 
culture and measurement of procalcitonin levels was performed within 24 hours 
of inclusion. Studies had to give a detailed description of patient groups and 
demographic variables. The comparison of procalcitonin levels had to be be-
tween hospitalised patients with and without bacteraemia, regardless of clinical 
symptoms. To be included for analysis studies had to report the diagnostic accu-
racy estimates of procalcitonin for bacteraemia; knowingly area under the curve 
(AUC), sensitivity, specificity and corresponding P-values. The corresponding 
authors of eligible studies that did not provide sufficient data for meta-analysis 
were contacted to retrieve additional data. We excluded case-control studies 
were controls were healthy subjects, reviews, meta-analyses, case reports, edi-
torials, commentaries, letters, meeting abstracts, poster presentations, animal 
studies and research performed in children (<18 years old). Two investigators 
(SHH and PJG) independently evaluated all eligible studies for inclusion and 
extracted the data. In case of disagreement a third investigator (ABJG) was 
consulted.
Quality assessment 
We used the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool 
[42], scores range from 0 to 14, to assess the methodological quality of included 
studies.
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Statistical methods
To avoid double inclusion of the same patient group we only included one sensi-
tivity and specificity from each article, unless results clearly came from different 
patient groups. We used the bivariate random-effects regression model for pool-
ing the sensitivity and specificity estimates, as recommended by the Cochrane 
Diagnostic Test Accuracy Working Group [43]. The bivariate model takes into 
account the potential trade-off between sensitivity and specificity by explicitly 
Figure 1. Flow chart of literature search. PCT = procalcitonin.
Search databases: PubMed, Medline, Embase, ISI Web of Knowledge, the Cochrane Library, Scopus, BioMed 
Central, and Science Direct.
Search strategy: (procalcitonin OR PCT) AND (bacterial infection OR bacteraemia OR bloodstream infection).
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incorporating this negative correlation in the analysis [44,45]. Cut-off values 
differed among the included studies, the cut-off value closest to 0.5 ng/mL was 
used for the analysis if multiple cut-off values were given. The 0.5 ng/ml cut-off 
was chosen based on recommendations of the manufacturer, current literature 
[46-49] and was the cut-off used most often in the included studies (Table 1). 
Summary receiver-operating characteristics curves (SROC) were drawn using 
the bivariate model. The closer the curve is to the upper left-hand corner of the 
SROC curve plot, the better the overall accuracy of the test. An area under the 
SROC curve between 0.90-1.0 is considered as excellent diagnostic accuracy, 
0.80-0.90 as good, 0.70-0.80 as fair, 0.60-0.70 as poor and 0.50-0.60 as fail 
[50]. We expected substantial heterogeneity in the of the overall analysis and in 
order to obtain more homogenous results subgroup analysis were performed. 
First, we calculated the diagnostic accuracy in specific patient subgroups based 
on their underlying disease. We calculated the diagnostic accuracy in studies 
comparing bacteraemia vs. non-bacteraemia in patients with SIRS and compar-
ing bacteraemia vs. non-bacteraemia in patients with SIRS developing localised 
infections. When a specific subgroup for the controls could not be identified we 
categorised the study in the category non-bacteraemia. We studied the diagnostic 
accuracy of procalcitonin for bacteraemia in immunocompromised/neutropenic 
and immunocompetent patients separately. We categorised all studies accord-
ing to department of inclusion. Finally, we also studied retrospective studies 
separately from prospective studies. We tested for a threshold effect by adding a 
covariate for threshold to the bivariate model.
We used IBM statistics 21.0 (IBM SPSS, Chicago, IL, USA) and R 3.1.1 
(Vienna, Austria XX) to analyse the data. The R package mada was used to per-
form the pooling of sensitivity and specificity and generating of SROC-curves. 
Pooled sensitivity and specificity estimates were generated, with their 95% con-
fidence interval (CI). To assess heterogeneity among studies I2 and X2/cochrane 
Q statistics were performed. We used the Deeks funnel plot asymmetry test to 
evaluate potential publication bias [51]. P<0.10 for the slope coefficient is con-
sidered as significant asymmetry, which indicates potential publication bias. All 
other tests were two-sided and a P<0.05 was considered statistically significant; 
exact P-values >0.001 are given.
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Table 2. Excluded studies.
Reason of exclusion Excluded study  
Not providing PCT Pettila 2002 [6]
Not studying bacteraemia Adamzik 2010 [106] Pizzolato 2014 [119]
Barati 2008 [107] Quiroga 2014 [120]
Bele 2011[108] Reynolds 2012 [121]
Bugden 2004 [109] Rowther 2009 [122]
Delevaux 2002 [110] Sakr 2008 [123]
Fluri 2012 [111] Stankovic 2010 [124]
Freund 2012 [112] Steichen 2009 [125]
Hettwer 2010 [113] Uusitalo 2011 [126]
Jereb 2009 [114] Viallon 2008 [127]
van Langevelde 2000 [115] Wang 2014 [1]
Magrini 2013 [116] Wunderink 2012 [128]
Oberhoffer 2000 [117] Yan 2014 [129]
Patil 2012 [118] Zhu 2014 [130]
Studying candidaemia Charles 2006 [131] Martini 2010 [133] 
Charles 2009 [132]
No comparison to non-bacteraemia Charles 2008 [134] Mueller 2004 [136]
Knudsen 2010 [135] Shomali 2013 [137]
Not providing sensitivity or specificity Ahn 2010 [138] Lee 2014 [139]
No AUC values of PCT for bacteraemia Al Shuaibi 2013 [140] Lehmann 2010 [154]
Aouifi 2000 [141] Lodes 2012 [155]
Bloos 2012 [142] Mauro 2012 [156]
Boussekey 2005 [143] Park 2012 [56]
Cuculi 2008 [144] Peters 2006 [157]
Endo 2012 [145] Previsdomini 2012 [158]
Feld 2008 [146] Sandri 2008 [159]
Foushee 2012 [147] Scott 2003 [160]
Gille johnson 2012 [148] Su 2012 [161]
Groeneveld 2008 [149] Svaldi 2001 [162]
Guven 2002 [150] Ugarte 1999 [163]
Juutilainen 2011 [151] von Lilienfeld 2009 [164]
Kim 2010 [152] Yilmaz 2011 [165]
Kruif de 2008 [153]
Longitudinal studies not providing PCT on inclusion Lavrentieva 2012 [166]
Healthy controls Gaini 2008 [167] Kocazeybek [168] 
The diagnostic accuracy of procalcitonin for bacteraemia | 69
Results
Literature search
The literature search resulted in a total of 1,567 articles of which 1,443 studies 
were excluded because of: written language other than English (n=118), age <18 
years (n=759), in vitro/animal studies (n=57) or lack of original data (reviews, 
meta-analysis, case reports, editorials, commentaries and letters, meeting 
Figure 2. Summary receiver-operating characteristic (SROC) curve plot of procalcitonin for the diagnosis 
of bacteraemia, including all studies (n=58). Individual studies are shown as open circles. Summary point is 
shown as a closed square, representing sensitivity estimates pooled by using bivariate random-effects regres-
sion model. The area under the SROC curve (dashed line) is 0.79, pooled sensitivity 76% and specificity 69%. 
The 95% confidence region displays the 95% confidence interval of the pooled sensitivity and specificity. The 
95% prediction region is the region for a forecast of the true sensitivity and specificity in a future study.
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Table 3. Raw QUADAS scores.
QUADAS item
Reference
1 2 3 4 5 6 7 8 9 10 11 12 13 14  QUADAS
SCORE
Aalto 2004 [58] y y y y y y y y y y u y n y 12
Albrich 2011 [59] y y y y y y y y y y n y n y 12
Bell 2003 [60] y y y n y y y y y y y y u n 11
Bogar 2006 [61] y y y y y y y y y n y y n y 12
Bossink 1999 [62] y y y y y y y y y n y y n y 12
Caterino 2004 [63] y y y y y y y y y y n y y y 13
Charles 2008 [64] y n y y y y y y y y y y y y 13
Chen 2011 [65] y y y y y y y y y y y y u u 12
Cheval 2000 [66] y n y y y y y y n y y y u u 10
Chirouze 2002 [67] n y y y y y y y y y u y y y 12
Dwolatzky 2005 [68] y n y y y y y y y y y y y y 13
Engel 1999 [69] y y y y y y y y n y u y y n 11
Gac 2011 [70] y n y y y y y y n u y y y y 11
Gaini 2007 [71] y y y y y y y y y y n y y y 13
Giamarellos 2001 [72] y y y y n n y y y y n y y y 11
Giamarellou 2004 [73] y n y y y y y y n y y y y n 11
Guinard-Barbier 2001 [53] y y y y y y y y y u y y y y 13
Ha 2013 [74] y n y y y y y y y y y y y n 12
Hoeboer 2012 [75] y y y y y y y y y n y y n y 12
Hoenigl 2013 [54] y y y y y y y y y u y y y y 13
Hoenigl 2014 [76] y y y y y y y y y y y y n n 12
Jeong 2012 [77] y n y y y y y y y y y y y n 12
Jimeno 2004 [78] y y y n n y y y y y n y y y 11
Kallio 2000 [79] y n y y y y y y n y y y y y 12
Karlsson 2010 [80] y y y y y y y y y y y y y y 14
Kim D 2011 [81] y n y y y y y n n u u y u n 7
Kim M 2011 [24] y n y y y y y u u u u y u u 7
Koivula 2011 [82] y n y y y y y y y n n y y y 11
Lai 2010 [25] y y y y y y y y y y y y y n 13
Lee 2013 [83] y y y y y y y y y y y y n y 13
Liaudat 2001 [84] y u y y y y y y y y n y y y 12
Loonen 2014 [85] y y y y y y y y y y y y y y 14
Mencacci 2012 [86] y y y y y y y y y y y y y n 13
Menendez 2012 [55] y y y y y y y y y y y y n n 12
Muller 2010 [23] y y y y y y y y y y y y n y 13
Munoz 2004 [87] y y y n y y y y y y y y u u 11
Nakamura 2009 [88] y n y y y y y n n y y y y n 10
Nieuwkoop van 2010 [89] y y y y y y y y y y y y n y 13
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abstract, poster presentations, n=509). We performed a full text review of the 
124 articles considered eligible for inclusion, which resulted in the exclusion of 
another 66 studies whom did not provide AUC values/ sensitivity/ specificity 
(n=29), did not study bacteraemia (n=26), did not compare to non-bacteraemia 
(n=4), studied candidemia (n=3), used healthy controls (n=2), did not provide 
Table 3. Raw QUADAS scores. (continued)
QUADAS item
Reference
1 2 3 4 5 6 7 8 9 10 11 12 13 14  QUADAS
SCORE
Pereira 2013 [90] y y y y y y y y y u y y y n 12
Persson 2004 [91] y n y y y y y y y n y y y n 11
Prat 2008 [92] y u y y y y y y u n u y u u 8
Ratzinger 2014 [93] y y y y y y y y y y y y u y 13
Riedel 2011 [27] y y y y y y y y y y y y y y 14
Rintala 2001 [94] y n y y y y y y y y y y u n 11
Robinson 2011 [95] y y y y y y y y y n y y y n 12
Romualdo 2014 [96] y y y y y y y y y y y y n y 13
Schuetz 2007 [26] y y y y y y y y n y y y y n 12
Schuetz 2008 [97] y y y y y y y y y y y y y n 13
Shi 2013 [98] y y y y y y y y y n y y y n 12
Shomali 2012 [99] y y y y y y y y y y y y y n 13
Su 2011 [100] y y y y y y y y y y n y y n 12
Suarez-Santamaria 2010 [101] y y y y y y y y y y y y y n 13
Theodorou 2012 [57] y y y y y y y y y y y y n y 13
Tromp 2012 [102] y y y y y y y y y y y y n y 13
Tsalik 2012 [103] y y y y y y y y y u u y y y 12
Vanska 2012 [104] y y y y y y y y y u u y u u 10
Von Lillienfeld-Toal 2004 [105] y y y y y y y y n y y y y n 12
Wang 2013 [10] y n y y y y y y y y y y y n 12
The quality assessment of studies of diagnostic accuracy checklist. Item 1: Was the spectrum of patients rep-
resentative of the patients who will receive the test in practice?; 2: Were selection criteria clearly described?; 
3: Is the reference standard likely to correctly classify the target condition?; 4: Is the time period between 
reference standard and index test short enough to be reasonably sure that the target condition did not change 
between the two tests?; 5:Did the whole study population or a random selection of the sample, receive verifica-
tion using a reference standard for diagnosis?; 6: Did patients receive the same reference standard regardless 
of the index test result?; 7: Was the reference standard independent of the index test?; 8: Was the execution 
of the index test described in sufficient detail to permit replication of the test?; 9: Was the execution of the 
reference standard described in sufficient detail to permit its replication?; 10: Were the index test results inter-
preted without the knowledge of the results of the reference standard?; 11: Were the reference standard results 
interpreted without knowledge of the index test results?; 12: Were the same clinical data available when test 
results were interpreted as would be available when the test is used in practice?; 13: Were uninterpretable / in-
termediate test results reported?; 14: Were withdrawals from the study explained? Each item can be answered 
with yes (Y), no (N) or unknown (U).
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the procalcitonin level for bacteraemia (n=1), or used a longitudinal study design 
and analysis (n=1). The remaining 58 articles were used in the meta-analysis. 
Table 2 depicts the 66 studies excluded after full text review.
Study characteristics and quality assessment
Table 1 provides some details of the included studies. In total, 16,514 patients 
of whom 3,420 suffered from bacteraemia were included. There was a slight 
tendency towards male preponderance. The average age ranged from 33 to 77 
years. Eight studies had a retrospective and 50 a prospective study design. All 
58 studies provided AUC values, but only 49 studies provided sensitivity and 
specificity. The cut-off values varied between 0.10 and 17 ng/mL. All samples 
for blood culture and procalcitonin measurement were collected on inclusion or 
Table 4. Accuracy estimates.
Analysis AUC 
Pooled 
sensitivity 
Pooled 
specificity Heterogeneity (%)
(95% CI) (95% CI) I2 X2/ Q p
Overall (N=3,420 ) 0.79 76 (72-80) 69 (64-72) 86% 1397 <0.001
Control group
Non-bacteraemia (N=1,884 ) 0.78 72 (66-78) 74 (69-76) 88% 1070 <0.001
SIRS (N=931) 0.78 76 (60-87) 66 (44-82) 83% 114 <0.001
Local infection and/or sepsis (N=605) 0.84 84 (80-87) 55 (47-63) 71% 162 <0.001
Immunocompromised/ 
neutropenic
Yes (N=320) 0.71 66 (54-76) 78 (71-83) 76% 120 <0.001
No (N=3,100) 0.79 79 (75-83) 65 (60-65) 81% 926 <0.001
Department
ICU (N=399) 0.88 89 (79-94) 68 (57-77) 77% 54 <0.001
Mixed (N=1,009) 0.77 76 (65-85) 66 (57-76) 31% 501 <0.001
Ward (N=587) 0.76 71 (63-78) 71 (64-77) 90% 433 <0.001
ED (N=1,425) 0.78 76 (69-82) 68 (61-75) 77% 285 <0.001
Study type
Prospective (N=2,507) 0.79 76 (71-80) 69 (64-73) 86% 721 <0.001
Retrospective (N=913) 0.79 78 (66-86) 68 (56-78) 79% 636 <0.001
X2/Q = X2/cochrane Q, CI = confidence interval; ED = emergency department; ICU = intensive care unit; 
mixed = ICU/ ED/ ward together; SIRS = systemic inflammatory response syndrome.
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within 24 hours at the emergency department, ward and/or intensive care unit. 
The median QUADAS score was 12 (range 7-14) the per item QUADAS scores are 
presented in Table 3. Problematic QUADAS items were: the description of selec-
tion criteria and description of the execution of the reference standard, whether 
the index test results were interpreted without knowledge of the results of the 
reference standard and vice versa, reporting of uninterpretable/intermediate 
test results and the explanation of withdrawals.
The diagnostic accuracy of procalcitonin for bacteraemia
In the overall analysis the area under the SROC was 0.79 (Figure 2 and Table 
4). The optimal and most widely used procalcitonin cut-off value was 0.5 ng/mL 
(Table 5) and corresponded with a 76% sensitivity and 69% specificity (Table 4). 
In Figure 3, the sensitivity and specificity per study are given. The lowest SROC 
was found in immunocompromised/neutropenic patients (0.71), the highest 
Table 6. 2x2 tables with corresponding sensitivity, specificity, PPV and NPV.
Ward Emergency Department Intensive Care Unit
BSI+ BSI- BSI+ BSI- BSI+ BSI-
PCT+ 7 26 33 6 29 35 11 28 39
PCT- 3 64 67 2 63 65 1 60 61
10 90 100 8 92 100 12 88 100
Prevalence 10% 8% 12%
Sensitivity 71% 76% 89%
Specificity 71% 68% 68%
PPV 21% 17% 28%
NPV 95% 97% 98%
BSI = blood stream infection; NPV = negative predictive value; PCT = procalcitonin; PPV = positive predictive 
value, += positive test, -= negative test.
Table 5. Accuracy estimates for different cut-off values.
Analysis AUC 
Pooled sensitivity Pooled specificity Heterogeneity (%)
(95% CI) (95% CI) I2 X2/ Q p
Cut-off 0.1 0.73 91 (82-96) 35 (22-51) 88% 385 <0.001
Cut-off 0.5 0.77 74 (66-81) 68 (61-75) 75% 478 <0.001
Cut-off 1.0 0.76 67 (52-78) 74 (67-80) 85% 154 <0.001
Cut-off 2.0 0.63 50 (31-69) 83 (64-94) 92% 313 <0.001
 X2/Q = X2/cochrane Q, CI = confidence interval.
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SROC (0.88) in ICU patients. The lowest sensitivity was found in immunocom-
promised/neutropenic patients (66), the highest in ICU patients (89). The low-
est specificity was found in patients with localised infections (55) and the high-
est in immunocompromised/neutropenic patients (78). Table 6 shows the 2x2 
tables with low positive predictive values (17-28%) and high negative predictive 
values (95-98%) for different hospital settings at the 0.5 ng/mL procalcitonin 
cut-off. There was significant heterogeneity in the overall analysis and in most 
subgroups (Table 4). However, there was no indication of a threshold-effect.
Figure 4. Evaluation of publication bias. The Deeks funnel plot assymetry test was non-significant (P=0.13). 
Individual studies are shown as open circles and the interrupted line represents the regression line. ESS = 
effective sample size.
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Evaluation of publication bias
Figure 4 displays the Deeks funnel plot asymmetry test of this meta-analysis. 
The Deeks test was not statistically significant (P=0.13) indicating that there is 
no direct evidence for publication bias.
Discussion
This study evaluates the diagnostic accuracy of procalcitonin for bacteraemia 
in different subgroups of adult hospitalised patients suspected of infection or 
sepsis. Overall, at a cut-off level of 0.5 ng/mL, procalcitonin had a fair diag-
nostic accuracy for bacteraemia with an SROC of 0.79. The pooled AUC values 
of procalcitonin for the diagnosis bacteraemia in subgroups ranged from 0.71-
0.88, with sensitivities ranging from 66% in immunocompromised/neutropenic 
patients to 89% in ICU patients and specificities ranging from 55% in bacterae-
mia vs. local infections to 78% in immunocompromised/neutropenic patients. 
Based on these results low procalcitonin levels in particular can be used to rule 
out the presence of bacteraemia.
Two previous meta-analyses on the diagnostic accuracy of procalcito-
nin for sepsis had contradicting conclusions while having comparable results 
[12,18]. Tang et al. concluded that there was no clear use for procalcitonin in di-
agnosing sepsis (area under the SROC of 0.78, sensitivity of 71% and specificity 
of 70%) [12]. However, their inclusion may be biased by specifically excluding 
sepsis originating from certain types of common infection sites [12]. In contrast, 
Wacker et al. concluded that procalcitonin was useful for the diagnosis of sepsis 
(area under the SROC 0.85, sensitivity 77%, specificity 79%) [18]. They included 
studies on adult and paediatric patients comparing sepsis to SIRS. Sepsis, how-
ever, was defined as clinically suspected or microbiologically proven infection 
[18]. Two other meta-analyses studying the diagnostic use of procalcitonin for 
bacterial infection found an area under the SROC curve ranging from 0.82-0.89, 
sensitivity 83-88%, specificity 81-83% [28,34]. Both analyses had comparable 
results but again contradicting conclusions. Simon et al. compared CRP and 
procalcitonin in a meta-analysis on the diagnostic accuracy in either proven or 
suspected bacterial infection, favouring PCT to be used in clinical practice [28]. 
In contrast, Lee et al. contented that PCT should not be used as single diagnostic 
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tool for infection [34]. However their conclusion was based on only four stud-
ies on the diagnostic accuracy of procalcitonin for bacterial infection in elderly 
patients [34]. As far as we know there is only one previous meta-analysis on 
the diagnostic accuracy of procalcitonin for bacteraemia with an area under the 
SROC of 0.84, sensitivity 76%, specificity 70% [40]. This study concluded that 
widespread use of procalcitonin is not recommended because of the moderate 
diagnostic accuracy of PCT to predict bacteraemia [40]. This conclusion was 
based on 17 included studies of which not all contained bacteraemia as primary 
endpoint. Even though previous meta-analyses showed similar results their 
conclusion differ, possibly due to differences in interpretation of clinically useful 
AUC values. In contrast to our study, the above-mentioned meta-analyses only 
used a small selection of the available literature or used sepsis syndrome and not 
microbiologically documented infection as their endpoint. Our study shows that 
procalcitonin can be used in the diagnostic process of bacteraemia regardless of 
its clinical symptoms. As shown in Table 6 low procalcitonin levels can be used 
to rule out the presence of bacteraemia in different clinical settings.
This meta-analysis has several limitations. There is some evidence for 
a concentration-response relation between procalcitonin levels and probability 
of infection and disease severity [52]. The definition of our primary outcome 
measure, bacteraemia, does not acknowledge such a concentration-response 
relation. Only a minority of the studies in this meta-analysis formally excluded 
patients treated with antibiotics prior to inclusion [23,24,53-57]. We cannot be 
certain that false negative results, due to possible antibiotic treatment prior to 
inclusion, led to underestimation of the effect. Even though the effect size is only 
fair (area under the SROC 0.79) its direction is positive in almost all studies, in 
spite of heterogeneity. High I-squares are to be expected because of the variation 
in cut-offs used in the different included studies and sensitivity and specificity 
both depend on cut-offs. To homogenise the results we attempted to use the 
sensitivities and specificities corresponding with the cut-off value closest to 0.5 
ng/mL if multiple cut-off values were given. Other potential factors that could 
have contributed to heterogeneity are variety in inclusion criteria, underlying 
diseases, co-morbidities, clinical course and treatment prior to inclusion, variety 
in the control groups used for comparison against bacteraemia, department of 
sample collection, and differences in test performance of the various procalcito-
nin assays. In order to reduce the influence of these factors on heterogeneity we 
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performed analyses in the supposedly more homogeneous patient subgroups. 
As to be expected, substantial heterogeneity remained in most subgroups. A 
Funnel plot analysis based on the standard error of the lnDOR can be mislead-
ing, therefore we evaluated potential publication bias using the recommended 
effective sample size-based funnel plots and associated regression tests of asym-
metry according to Deeks [51].
Conclusions
In conclusion, this systematic review and meta-analysis shows that procalcito-
nin has a fair diagnostic accuracy for bacteraemia in adult, hospitalised patients 
suspected of infection or sepsis. In particular low procalcitonin levels can be 
used to rule out the presence of bacteraemia. Further research on the safety 
and efficacy of using procalcitonin as a single diagnostic tool to withhold taking 
blood cultures remains to be proven.
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Abstract
Objectives 
Bacteraemia increases morbidity and mortality of critically ill patients; a fast 
and accurate diagnosis is therefore crucial. A low plasma procalcitonin (PCT) 
may virtually and rapidly rule out bacteraemia and its use could lead to a cost 
reduction by saving blood cultures. We therefore aimed to study the safety and 
efficacy of PCT in guiding blood culture taking in critically ill patients with sus-
pected infection.
Design
Multi-center, cluster-randomized, cross-over trial in critically ill patients be-
tween January 2013 and September 2014. Patients suspected of infection by 
the attending intensivist in whom taking blood for culture was indicated were 
included. Patients in the participating intensive care units, stratified and ran-
domized by regimen, were divided in a control group (standard of care) and a 
PCT-guided group.
Intervention
In both groups blood was drawn at the same moment for a PCT measurement 
and blood cultures. In the PCT-guided group, the attending intensivist sent 
blood cultures to the department of medical microbiology based on the result 
of the PCT measurement. Blood cultures were not sent if the PCT was below 
0.25 ng/ml, unless otherwise indicated. In the control group, PCT results were 
available prior to analysis only.
Setting
Critically ill patients in the intensive care unit.
Subjects 
The study included 564 patients who were suspected for having infection.
Measurements and main results
Two hundred eighty-eight patients were included in the control group and 
276 patients in the PCT-guided group. No differences were seen in baseline 
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characteristics. The occurrence of bacteraemia was similar for both groups. The 
negative predictive value of PCT <0.25 ng/mL for bacteraemia was 96%. In the 
PCT-guided group 18 sets of blood cultures were saved in 17 patients. The inten-
tion to treat analysis showed a hazard ratio of 0.85 (95% CI, 0.62-1.17) and 0.89 
(95% CI, 0.67-1.17) for 28- day and 90-day mortality respectively. The results 
were deemed non-inferior since the upper limit of the 95% CI was below the 
margin of 1.20. Using the PCT strategy can save €1.14 per suspected infection 
episode.
Conclusion
Applying PCT to guide blood cultures in critically ill patients with suspected 
infection seems to be safe and (cost-)effective.
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Introduction
Critical illness predisposes to bacteraemia thereby increasing morbidity and 
mortality [1,2], particularly when diagnosis and administration of antibiotics 
are delayed [3,4]. Indeed, culturing costs time, and only 15-25% of blood cul-
tures taken in critically ill patients suspected of infection prove positive, sugges-
tive of a waste of resources [5]. The use of biomarkers, including procalcitonin 
(PCT), has been studied to improve a fast and accurate diagnosis of sepsis and 
bacteraemia with varying results [4,6-8]. However, we recently performed a 
meta-analysis of studies suggesting that a normal PCT has 96% negative predic-
tive value for bacteremia [9]. Based on nine studies, the area under the receiver 
operating characteristic curve of PCT for bacteraemia in critically ill patients 
was 0.88 [6,9-17]. The studies included, however, were relatively small [10-12, 
15-17] and not primarily designed to rule out or detect bacteraemia [6,10,12-14]. 
Nevertheless, a rapidly available and normal PCT might allow early prediction of 
negative blood cultures when blood sampling is clinically indicated for suspicion 
of infection and thereby avoid unnecessary blood culturing.
In the hypothesis that a normal PCT can be used to predict absence of 
bacteraemia in critically ill patients, we aimed to study the usefulness of a rapidly 
determined PCT, in saving blood cultures in critically ill patients in whom taking 
blood for culture is clinically indicated because of a suspicion of infection. We 
hypothesized that such a strategy can be safely applied in critically ill patients 
without increasing morbidity and mortality and is (cost-) effective.
Methods
Patients and study design
We performed a prospective, single-blinded, cluster-randomized, cross-over 
trial, involving the intensive care unit (ICU) of the Erasmus Medical Center Rot-
terdam and the Maasstad hospital Rotterdam. We conducted this trial between 
January 2013 and September 2014. The ICU of the Erasmus Medical Center 
is a tertiary care mixed medical-surgery ICU with 2000 admissions per year. 
The ICU of the Maasstad Hospital is a secondary care mixed medical-surgical 
ICU with 1200 annual admissions. The trial was conducted in accordance with 
the ethical principles decreed by the Declaration of Helsinki and in compliance 
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with International Conference on Harmonization Good Clinical Practice Guide-
lines. The final protocol, amendments and informed consent document were 
reviewed and approved by the institutional review board (IRB) or the indepen-
dent medical ethical committee at each of the investigational centers. This study 
was finally approved by the medical ethical committee of the Erasmus Medical 
Center (MEC 2011-505) and registered with ClinicalTrial.gov (protocol ID NCT 
01847079). All patients or their proxy provided written informed consent prior 
to study inclusion, as a presumed consent at ICU admission.
Patients on the intensive care unit above the age of 18 years in whom 
a suspicion of infection was raised and taking blood for culture was clinically 
indicated by the attending intensivist were enrolled in the study. Suspicion of 
infection could be increasing body temperature above 38.3° C (tympanic 
temperature), chills, progressive leukocytosis or increased C-reactive protein 
(CRP), increasing consolidations on chest radiography or other imaging of 
potential infection sources. Patients could be included more than once; every 
time that blood for culture is taken counts as a suspicion of infection episode 
(SIE). Patients were excluded if they had one of the following exclusion criteria: 
pregnancy, neutropenia (defined as leukocyte count less than 0.5x109/L) and 
preterminal illness with an expected death within 24 hours. Patients were not 
included if blood cultures were performed as part of a standard protocol (such 
as patients with veno-venous or veno-arterial extracorporeal membrane oxy-
genation) or were performed to check the effectiveness of treatment (such as in 
endocarditis), unless the blood culture was done because of a SIE. A flow chart 
of the included patients is given in Additional file 1, Figure 1.
Patients were otherwise taken care of by board certified intensivists, ac-
cording to local and national guidelines. In case of a microbial infection source 
control was performed when possible and antibiotic treatment was given in 
close collaboration with a medical microbiologist.
Study protocol. The participating ICU’s (2 per medical center) were 
stratified and randomized by treatment regimen into a control group (standard 
of care) and a PCT-guided group. Randomization was performed per cluster al-
location, being an assigned ICU. All patients included into this trial followed the 
regimen which was allocated to the ICU for that period. The participating units 
switched the allocated regimen every three months. We used a wash-out period 
between the cross-over period, to minimize the risk for a patient to follow two 
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different regimens. The wash-out period was set for 1 month, in which >99% of 
the patients in the previous period has left the ICU. None of the patients included 
into this study followed two regimens. The participating ICU’s were matched for 
a 1:1 ratio of allocation (Additional file 2, Figure 2).
In both the control and PCT-guided group blood was taken at the same 
moment for the PCT measurement and blood cultures. In the control group, 2 
sets of blood cultures were sent directly to the department of medical micro-
biology. The PCT measurement in the control group was determined by the 
department of clinical chemistry, however the results of the measurement were 
blinded for the investigators and only available prior to analysis. In the PCT-
Additional file 1: Figure 1. Flowchart of patients who met the inclusion and exclusion criteria
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guided group the PCT measurement was determined as a stat determination, 
rendering results within 1 hour.
Blood samples for the PCT measurement were immediately centrifuged 
at 3000rpm for 10 minutes at room temperature (HETTICH Rotina 420R, Tut-
tlingen, Germany). The PCT measurement was performed on the automated 
Kryptor platform (BRAHMS AG, Hennigsdorf, Germany), using the Roche 
Elecsys BRAHMS PCT assay. Upon receiving results, the attending intensivists 
determined whether to send the blood cultures to the department of medical 
microbiology or not. We used a cut-off of 0.25 ng/ml in the PCT-guided group. 
Values below this cut-off were regarded as normal, and thus not worth cultur-
ing (and blood cultures taken were destroyed). It was possible for the attending 
intensivists to overrule the PCT-guided strategy and still send in blood cultures 
at normal PCT. Values higher than the cut-off of 0.25 ng/ml were regarded as a 
possible infection, and in these patients blood cultures were sent to the depart-
ment of medical microbiology for further analysis. Each set of  blood cultures 
Additional file 2: Figure 2. Flowchart of the cluster allocation (BC = blood culture; ICU = intensive care 
unit; PCT = procalcitonin).
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consists of one aerobic and one anaerobic bottle (BD Bactec™, New Jersey, 
USA) containing resin to enhance recovery of organisms. The blood cultures 
were incubated for 7 days in an automatic analyser (BD BACTEC™, New Jersey, 
USA) that automatically demonstrates the time to positive blood culture in case 
of positive bacterial or fungal growth. Gram strains were performed, and the 
organisms were cultured on agar plates and after growth identification was per-
formed, using the VITEK® 2  (Biomerieux, Marcy l’Etoile, France). Polymerase 
chain reaction (PCR) technique was carried out using a LightCycler480 PCR-
system (Roche Diagnostics, Almere, The Netherlands) to detect viral growth in 
blood samples. Bacteraemia was defined as having a positive blood culture with 
a recognized pathogen except skin contaminants [18,19]. In case of skin con-
taminants, bacteraemia was only considered if at least 2 blood cultures drawn 
on separate occasions were positive for the same microorganism [18,19]. We 
otherwise determined inflammatory parameters such as CRP and white blood 
cell counts.
Data collection
At the day of inclusion, baseline demographic data and clinical variables, includ-
ing age, sex, pre-morbidity, reasons of admission, use of antibiotics including 
SDD, antifungal treatment, steroids, immunosuppressive medication, immune 
status (active malignancy or other causes of an immunocompromised state), 
recent surgery, mechanical ventilation, renal replacement therapy, total par-
enteral nutrition, central venous catheters and vital parameters were recorded. 
The acute physiology and chronic health evaluation IV (APACHE IV) and the 
sequential organ failure assessment (SOFA) score were recorded at admission. 
Patients were followed until day 28 and 90 after inclusion and length of ICU stay 
and vital outcomes were recorded.
Statistical analysis
The primary outcome measurement of this study is safety, expressed as mortal-
ity at day 28 and 90. We calculated that 550 patients were needed to determine 
non-inferiority in a parallel group design with a power of 90%, an one sided 
alpha error of 5% and a non-inferiority limit of 10% [20]. The sample size cal-
culation was based on an assumed risk of death of 20% in both the control and 
intervention group [21-24]. A hierarchical poisson regression model, using the 
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logarithm of the survival time as an offset variable, was used to estimate the 
relative risk of mortality and associated 95% confidence intervals (CI) between 
control and PCT-guided groups. The ward and ward-period interaction were 
used as random effects to account for systematic effects of ward and period 
on the outcome [25]. The results were deemed non-inferior when the 95% CI 
was below 1.20 since our design was more complicated than a parallel group 
design and had precluded a power analysis based on poisson regression. We 
performed an intention-to-treat analysis (all PCT-guided vs control patients), 
per protocol analysis (PCT-guided patients without blood cultures vs controls), 
and an as-treated analysis (PCT-guided patients without blood cultures vs PCT-
guided patients with blood cultures and controls). All analyses were performed 
using R version 3.2.1 and the hierarchical poisson models were fitted using the 
lme4 package. We provide an overview with the involved costs and savings 
when using a PCT-guided strategy. Data are expressed as median (interquartile 
range) or as number of patients (percentage) where appropriate. Indeed, data 
were distributed non-normally (Kolmogorov-Smirnov test P<0.05). The Mann-
Whitney U test and Fisher exact test were used to compare two groups. All tests 
were 2 sided, and P<0.05 was considered statistically significant. Exact P values 
> 0. 001 are given.
Results
Descriptives
In total, 1.448 patients were possibly eligible for inclusion, of whom 564 were 
included and remained for analysis (Figure 1). The control group consisted of 
288 patients and the PCT-guided group of 276 patients (Table 1). No difference 
was observed between the groups, except for more neurologic premorbidity in 
the control group (Table 1).
Suspected infection episodes (SIE)
Table 2 shows that the control group represented 554 SIE against 576 SIE in 
the PCT-guided group, with a somewhat higher CRP in the latter. In the con-
trol group there were 118 episodes of bacteraemia in 58 patients, against 156 
episodes in 63 patients in the PCT-guided group (Table 3). In only 6 episodes 
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Table 1. Baseline demographic and clinical characteristics.
Control group PCT-guided group P
(n=288) (n=276)
Age (years) 59 (21) 61 (22) 0.36
Gender (male) 200 (69) 177 (64) 0.21
APACHE IV score 62 (36) 67 (45) 0.27
SOFA score 8 (6) 8 (6) 0.79
Premorbidity
Neurologic 75 (26) 47 (17) 0.02
Cardiac 95 (33) 91 (33) 0.99
Pulmonary 66 (23) 50 (18) 0.11
Gastro intestinal 89 (31) 91 (33) 0.60
Renal 37 (13) 28 (10) 0.26
DM II 55 (19) 47 (17) 0.45
Cancer 63 (22) 77 (28) 0.08
Auto immune 14 (5) 14 (5) 0.93
Steroids 46 (16) 50 (18) 0.57
Immune suppression 20 (7) 22 (8) 0.64
Reasons of ICU admission 0.70
Suspected sepsis 86 (30) 83 (30)
Respiratory failure 54 (19) 61 (22)
Renal failure 1 (1) 2 (1)
Liver failure 0 2 (1)
Neurology 35 (12) 26 (9)
CPR 14 (5) 14 (5)
Shock 12 (4) 7 (3)
Trauma 17 (6) 14 (5)
Postoperative 55 (19) 58 (21)
Miscellaneous 14 (5) 9 (3)
Treatment in ICU
Mechanical ventilation 245 (85) 246 (89) 0.15
Renal Replacement Therapy 63 (22) 69 (25) 0.44
ECMO 9 (3) 3 (1) 0.09
CVC 210 (73) 179 (65) 0.04
Norepinephrine 225 (78) 232 (84) 0.07
Antibiotics 279 (97) 270 (98) 0.32
Total parenteral nutrition 86 (30) 99 (36) 0.13
Numbers (percentage) or median (interquartile range), where appropriate. Abbreviations: APACHE IV = 
Acute Physiology and Chronic Health Evaluation II; CPR = cardiopulmonary resuscitation; CVC = central 
venous catheter; DM II = diabetes mellitus type II; ECMO = extra corporeal membrane oxygenation; SOFA = 
sequential organ failure assessment score.
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of bacteraemia the PCT value was below 0.25 ng/mL (3x Enterococcus faecalis, 
1x Enterococcus faecium, 1x Staphylococcus aureus and 1x Staphylococcus epi-
dermidis). The genus of the micro-organism cultures in the other 268 episodes 
were: 99x staphylococci, 39x streptococci, 88x enterobacteriaceae, 7x bacteroi-
des, 5x bacillus, 2x burkholderia, 6x pseudomonas, 24x fungi and 4x viral.
Predictive values
A low <0.25 ng/mL PCT occurred in 121 and 76 SIE in the control and PCT-
guided group, respectively (Table 3). The sensitivity of a low PCT for predicting 
bacteraemia was 98% with a specificity of 20%, negative predictive value 96% 
and positive predictive value 29%.
Primary outcome
No difference was seen in 28-day or 90-day mortality between the groups (Table 
4). In the PCT-guided group, a PCT <0.25 ng/mL occurred in 37 patients. Ap-
plying the study protocol saved 18 sets of blood cultures in 17 patients with a low 
PCT. These 17 patients had a 28 and 90-day mortality rate of 29% and 35% re-
spectively, whereas the other 20 patients with low PCT and blood cultures taken 
had a mortality rate of 19% and 29%, respectively. The intention to treat analysis 
showed a hazard ratio of 0.85 (95% CI, 0.62-1.17) and 0.89 (95% CI, 0.67-1.17) 
for 28- day and 90-day mortality, respectively, favoring the PCT-guided group. 
The per protocol analysis showed a hazard ratio of 0.89 (95% CI, 0.67-1.17) and 
0.89 (95% CI, 0.67-1.17) for 28- day and 90-day mortality, respectively. The 
as-treated analysis showed a hazard ratio of 0.89 (95% CI, 0.67-1.17) and 0.89 
(95% CI, 0.67-1.17) for 28-day and 90-day mortality, respectively. The results 
Table 2. Infection markers of all 1130 suspected infection episodes.
Control group PCT-guided group P
(n=554) (n=576)
Temperature (°C) 38.1 (1.6) 38.0 (1.6) 0.14
Heart rate (beats/ min) 109 (32) 111 (32) 0.11
Respiratory rate (breaths/ min) 30 (16) 28 (18) 0.97
WBC (109/ L) 12.6 (9.7) 12.5 (9.9) 0.40
CRP (mg/L) 111 (147) 148 (178) <0.001
PCT (µg/ L) 1.1 (5.2) 1.4 (6.1) 0.18
Median (interquartile range). Abbreviations: CRP = C- reactive protein; PCT = procalcitonin; WBC = white 
blood cell count.
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Table 3. Procalcitonin measurements and blood culture results for the different SIE.
SIE I
Control 
group
(n=288)
PCT- 
group
(n=276)
SIE II
Control 
group
(n=149)
PCT- 
group
(n=127)
SIE III and IV
Control 
group
(n=117)
PCT-
group
(n=173)
Number (percentage) of blood cultures taken 288 (100) 259 (94) 149 (100) 126 (99) 117 (100) 173 (100)
Positive blood cultures 71 (25) 70 (25) 43 (29) 37 (29) 37 (32) 62 (36)
PCT < 0.25 ng/mL and BC negative 47 (16) 15 (5) 24 (16) 15 (12) 25 (21) 17 (10)
PCT < 0.25 ng/mL and BC contamination 8 (3) 4 (1) 6 (4) 2 (2) 7 (6) 3 (2)
PCT < 0.25 ng/mL and BC positive 2 (1) 1 (1) 1 (1) 1 (1) 1 (1) 0 
PCT ≥ 0.25 ng/mL and BC negative 170 (59) 174 (63) 82 (55) 74 (58) 55 (47) 94 (54) 
PCT ≥ 0.25 ng/mL and BC contamination 4 (1) 3 (1) 1 (1) 0 7 (6) 1 (1)
PCT ≥ 0.25 ng/mL and BC positive 57 (20) 62 (22) 35 (23) 34 (27) 22 (19) 58 (33)
On antibiotics
PCT < 0.25 ng/mL and BC negative 43 (91) 30 (94) 24 (100) 16 (100) 25 (100) 17 (100)
PCT < 0.25 ng/mL and BC contamination 8 (100) 4 (100) 6 (100) 2 (100) 7 (100) 3 (100)
PCT < 0.25 ng/mL and BC positive 2 (100) 1 (100) 1 (100) 1 (100) 1 (100) 0 
PCT ≥ 0.25 ng/mL and BC negative 167 (98) 171 (98) 81 (99) 74 (100) 55 (100) 94 (100) 
PCT ≥ 0.25 ng/mL and BC contamination 4 (100) 3 (100) 1 (100) 0 7 (100) 1 (100)
PCT ≥ 0.25 ng/mL and BC positive 57 (100) 62 (100) 35 (100) 34 (1000 22 (100) 58 (100)
Abbreviations: BC = blood culture; PCT = procalcitonin.
Table 4. Primary outcome measures for SIE I.
Control group PCT-guided group P
(n=288) (n=276)
Length of ICU stay (days) 10 (17) 12 (20) 0.21
Length of hospital stay (days) 23 (35) 31 (39) 0.005
Mortality day 28 92 (32) 80 (29) 0.36
Mortality day 90 115 (40) 105 (38) 0.53
PCT<0.25 and no BC sent in (n=0) (n=17)
Mortality day 28 - 5 (29) -
Mortality day 90 - 6 (35) -
PCT<0.25 and BC sent in (n=57) (n=20)
Mortality day 28 11 (19) 4 (19) 0.57
Mortality day 90 15 (26) 6 (29) 0.65
PCT>0.25 and BC sent in (n=231) (n=239)
Mortality day 28 81 (35) 71 (30) 0.20
Mortality day 90 100 (43) 93 (39) 0.27
Abbreviations: BC = blood culture; PCT = procalcitonin.
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were deemed non-inferior since the upper limit of the 95% CI was below the 
margin of 1.20. The length of ICU stay was comparable between groups, but the 
length of hospital stay was longer in the PCT-guided group (Table 4).
Secondary outcome
If in practice a low PCT would always be followed by withholding blood cultures 
it would save €1,284.40 (Table 5) per 1,130 SIE, or €1.14 per SIE .
Discussion
This study evaluated the predictive value of PCT for bacteraemia and the safety 
and cost-effectiveness of a normal PCT to withhold blood cultures in critically ill 
patients with a SIE. Based on the high negative predictive value and the regres-
sion analyses, which did not exceed a 20% group difference for mortality, a low 
PCT can be safely used to rule out bacteraemia. This could lead to a modest cost 
reduction when blood culturing is withheld or postponed.
This study suggests that a PCT-guided algorithm for performing blood 
cultures can be safely applied. Mortality rates in this study are comparable with 
the observed 28- day mortality rates of 20-38% found in a large systematic review 
and meta-analysis on PCT-guided antibiotic therapy in critically ill patients with 
bacteraemia [22]. The overall ICU mortality rate was 27% (30% control group vs 
24% PCT-guided group) and the overall in hospital mortality rate was 35% (38% 
control group and 33% PCT-guided group) which agrees with an international 
study of the prevalence and outcomes of infection in ICU’s [5]. There is no obvi-
ous explanation for a longer hospital length of stay in the PCT-guided group.
Table 5. Potential cost analysis in 1130 suspected infection episodes.
If we applied the study protocol to all included patients and would have not taken a blood culture in all patients 
with procalcitonin (PCT) <0.25 ng/mL, 197 cultures would have been saved, while a blood culture costs €35.20. 
The extra costs involved are those of PCT for €5.00 per determination.
Extra costs PCT measurement
1130 x €5.00 €5.650,00
Saved cultures
197 x €35.20 €6.934,40 -
Total - €1.284,40
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The observed occurence of bacteraemia in this study varies between 20-
23% which is comparable with a recently performed meta-analysis on the diag-
nostic accuracy of PCT for bacteraemia with a described occurence of 21% [9]. In 
the current study we have chosen to use a cut-off value of 0.25 ng/mL for PCT. 
The 0.25 ng/ml cut-off was chosen based on two previous studies which looked 
at the predictive value of PCT for bacteraemia in patients on the emergency de-
partment [26, 27]. Both studies suggested that a PCT value ≤0.25 ng/ml can be 
used to rule out bacteraemia and suggested that using this cut-off could possibly 
be useful to save blood cultures in large volumes [26, 27]. With the used cut-off of 
0.25 ng/ml we found a sensitivity of 98% and a specificity of 20% for the predic-
tion of bacteraemia. Other studies performed on the diagnostic accuracy of PCT 
for bacteraemia in the critically ill used a cut-off value of 0.5 ng/ml [6, 10-17]. By 
using a cut-off of 0.5 ng/ml we found a sensitivity of 86% and specificity of 32% 
for the prediction of bacteraemia. The results are comparable with the other 
performed studies on the diagnostic accuracy of PCT for bacteraemia [6, 10-17]. 
The corresponding negative and positive predictive value at a cut-off value of 
0.25 ng/ml are 96% and 29%, respectively, and are comparable with the ob-
served negative predictive value of 98% and positive predictive value of 28% in a 
large meta-analysis [9]. With the used cut-off, PCT classified 143 SIE’s correctly 
for not having bacteraemia (true negative) and classified 6 SIE’s false for not 
having bacteraemia (false negative). In all cases, the cultured micro-organisms 
were susceptible for antibiotics and all patients were treated with vancomycin or 
flucloxacillin in case of the cultured Staphylococcus epidermidis. In all patients 
arterial and central venous catheters were replaced. The question remains if we 
would have missed cases of severe bacteraemia by using the PCT strategy and 
destruction of all blood cultures at low PCT and whether this would have harmed 
patients. Many experts favor deferring antimicrobial therapy for a bacteraemia 
caused by Enterococcus species in the setting of a single positive blood culture, 
since catheter removal alone may be sufficient enough to cure the infection in 
case the intravascular catheter is the likely source of bacteraemia [8,28,29]. In 
the 4 cases of enterococcal bacteraemia in this study only a single blood culture 
was positive and the 4 cases could be regarded as low grade infection in which 
removal of indwelling catheters could have been sufficient treatment. The other 
2 cases should be regarded as true bacteraemia which would have been falsely 
classified as having no bacteraemia if cultures had been destroyed. In the case 
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of the Staphylococcus epidermidis, 3 sets of blood cultures were even positive. 
We may speculate that in the PCT-group with low PCT and discarded blood 
cultures, similar, low pathogenic microorganisms as in controls were involved. 
We may also speculate that PCT had risen in a second SIE, with positive blood 
cultures. Otherwise, clinical judgement should always predominate over PCT 
determinations.
A total of 1130 blood cultures were taken in this study of which 197 (17%) 
could have been saved by using PCT as a pre-test. The observed incidence of 
17% is much lower compared with two other studies which predicted a possible 
reduction of 37-40% of blood cultures [26,27]. These studies were primarily de-
signed to evaluate the predictive value of PCT for bacteraemia in patients in the 
emergency department and not to study the usefulness of PCT to guide efficient 
use of blood cultures. Both studies used a cut-off of 0.25 ng/mL and described 
sensitivities of 96% and 94%, respectively, which are comparable with our study 
[26,27]. The observed difference could be explained by the fact that both studies 
were performed on the emergency department or primary care unit, including 
patients with a clinical suspicion of urinary tract infection or pneumonia. In 
contrast to our study which was performed in critically ill patients, in which 
a suspected infection can be proven in only 50% or less. Despite the lower in-
cidence of 17% in blood culture reduction, applying a PCT-guided strategy on 
the ICU can still be cost-effective, as our study suggests, moreover using this 
strategy results in lower volumes of blood taken from patients (10 mL for a PCT 
measurement versus 40 ml for a blood culture) and thereby a possible reduction 
of the risk of anemia caused by repetitive laboratory measurements [30].
This study has several limitations. First of all, in only 17 (46%) patients 
with low PCT levels, blood cultures were saved in the PCT-guided group. When 
the protocol was strictly followed, blood cultures could be saved in 76 SIE’s, 
for which a classic intention to treat analysis could be performed. However, we 
used a hierarchical approach as described by Christiansen and Morris, having 
several advantages such as removal of regression to the mean bias and the use 
of smaller sample sizes in the analysis [25]. Second, for the primary sample size 
calculation of this study we used a non-inferiority limit of 10%. Since our study 
design was more complicated than a parallel group design and had precluded a 
power analysis based on poisson regression, we decided to use a non-inferiority 
limit of 20% for final analysis of the study. A non-inferiority limit is usually 
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set at 10-20%, however, choosing an non-inferiority limit remains difficult and 
debatable [31].
Conclusion
In conclusion, this prospective multicenter randomized trial showed that using 
a PCT-guided strategy to obtain blood cultures in critically ill patients with a 
suspicion of infection seems to be safe and (cost-)effective.
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Abstract
Purpose
To assess the safety and efficacy of amphotericin-B deoxycholate (ABDC) inha-
lation for the treatment of respiratory Candida spp. colonization in critically ill 
patients.
Methods 
All non-neutropenic patients admitted into the intensive care unit (ICU) of a 
university hospital from December 2010 - 2011, who had positive Candida spp. 
cultures of the respiratory tract for more than 1 day and required mechanical 
ventilation >48 h were retrospectively included. The decision to start ABDC 
inhalation had been made by attending intensivists on clinical grounds in the 
context of selective decontamination of the digestive tract. Infection character-
istics and patient courses were assessed.
Results 
Hundred and thirteen consecutive patients were studied. Fifty-one of them 
received ABDC inhalation and their characteristics at baseline and day 1 of 
respiratory colonization did not differ from those of colonized patients not re-
ceiving treatment (n=62). The ABDC-treated group had a similar Candida spp. 
load but did not decolonize more rapidly as compared to untreated patients. The 
clinical pulmonary infection and lung injury scores did not decrease as in the 
untreated group. In a Cox proportional hazard model, the duration of mechani-
cal ventilation was increased (P<0.003) by ABDC treatment independently of 
other potential determinants and Candida spp. colonization. No differences 
in ventilator-associated pneumonia or in overall mortality (up to day 90) were 
observed.
Conclusion 
Treatment of respiratory Candida spp. colonization in non-neutropenic criti-
cally ill patients by inhaled ABDC may not affect respiratory colonization but 
may increase duration of mechanical ventilation, because of direct toxicity of 
the drug on the lung.
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Introduction
In critically ill patients, Candida spp. are frequently cultured from non-sterile 
body sites. However, the clinical significance hereof is not easy to define. When 
Candida spp. are isolated from the respiratory tract, discriminating between 
relatively harmless colonization or invasive infection is still surrounded by con-
troversy and leads to therapeutic dilemmas [1-8]. On the one hand, respiratory 
isolation of Candida spp. could reflect the patient’s state of immunoparalysis and 
the elimination of normal flora through previous antibiotic treatment but may 
otherwise be relatively harmless. On the other hand, it could reflect a risk factor 
for invasive Candida spp. infections, even in non-neutropenic patients, such 
as candidemia or pulmonary candidiasis, a rare and difficult to diagnose deep 
infection in the critically ill [2,3]. Respiratory Candida spp. colonization has 
also been suggested to be a risk factor for (multidrug-resistant) Gram-negative 
airway infection, i.e. ventilator-associated pneumonia (VAP) or tracheobron-
chitis, to prolong ventilator dependency and to increase mortality, even in the 
absence of direct pulmonary pathogenicity [6,9-11].
One way to examine the clinical role of Candida spp. colonization of 
the respiratory tract is to examine the effect of treatment aimed at eradicating 
the fungus. The criteria to start antifungal drugs continue to be debated [1,4]. 
Nevertheless, one study suggests that systemic antifungal treatment may help to 
prevent Pseudomonas spp.-associated VAP in the critically ill patient colonized 
by Candida spp. in the respiratory tract [11]. Also, in neutropenic hematology 
patients at risk for invasive fungal infections inhalation therapy with liposomal 
amphotericin B has been proven to prevent invasive pulmonary aspergillosis 
[12,13]. ABDC inhalation is also used to prevent pulmonary aspergillosis in 
many lung transplant units but the safety and efficacy of this approach has never 
been validated in a large randomized placebo-controlled trial.
Selective decontamination of the digestive tract (SDD) is a strategy used 
in many Dutch intensive care units (ICU’s) and consists of oral administration 
of non-absorbable antibiotics. When Candida spp. respiratory colonization is 
documented during routine surveillance cultures of the respiratory tract and the 
patient is at risk for deep infection, intensivists often start with amphotericin-
B deoxycholate (ABDC) inhalation therapy via a nebulizer. This treatment is 
started as part of many SDD protocols used in large trials [14,15]. However, its 
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safety and efficacy are not well established, in the absence of randomized tri-
als [16]. In rats, aerolized ABDC decreases activity of surfactant suggesting a 
possibility to harm [17-19]. In humans, however, (liposomal) amphotericin-B 
inhalation may not alter surfactant but may be cytotoxic by other means [20,21].
To further elucidate the significance of Candida spp. in respiratory 
secretions and the safety and efficacy of ABDC inhalation therapy, we retrospec-
tively compared clinical courses of mechanically ventilated patients colonized 
with Candida spp. in the respiratory tract which received ABDC inhalation with 
those of a comparable group of patients in which ABDC was not initiated. The 
hypothesis was that ABDC is a safe and effective treatment for Candida spp. 
colonization of the respiratory tract and thereby prevents VAP and prolonged 
need for mechanical ventilation during SDD in the ICU.
Patients and methods
Patients
Data were retrospectively collected from our patient data management system, 
according to a predefined checklist. All patients >18 years of age requiring 
mechanical ventilation >48 h in the ICU of the Erasmus Medical Center Rot-
terdam, with at least 2 consecutive daily positive Candida spp. cultures of the 
respiratory tract (throat, tracheal aspirates or bronchoalveolar lavage), defining 
respiratory colonization, were included when admitted between December 2010 
and December 2011. The ICU is a tertiary care mixed medical-surgical ICU with 
2000 admissions per year. Patients with neutropenia (leukocyte count <0.5 
x109/L), positive blood cultures for Candida spp., immunodeficiency (HIV, solid 
cancer, hematologic malignancy, solid- organ or bone marrow transplantation, 
or long term or high dose steroid treatment) or who did not meet respiratory 
colonization criteria were excluded (Figure 1). Informed consent was not needed 
according to the Dutch law because of the retrospective analysis in which data 
collected during routine clinical care were used and anonymously treated.
Clinical protocol
Patients requiring mechanical ventilation for more than 48 h receive SDD in 
our unit. This involves administration of an oral paste, a suspension via the 
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nasogastric tube and a suppository, containing the non- absorbable antibiotics 
tobramycin, amphotericin B and colistin. For the first three days, patients also 
receive cefotaxim intravenously at 4 times 1 gram a day. At the start of SDD, 
cultures are taken (inventory cultures) from throat, tracheal aspirates, urine, 
rectum and drains or wounds. To monitor the effect of the SDD, surveillance 
cultures (from throat, tracheal aspirates, urine, and rectum) are done routinely 
three times per week. SDD and surveillance cultures are continued until ICU 
death or discharge. On indication, additional cultures of the respiratory tract 
are taken at the discretion of the attending intensivist. Standard microbiological 
methods were used to culture the specimens. For the purpose of fungal detection 
in respiratory samples a Sabouraud agar (SB), incubated at 26ºC was used. A 
Gram strain was performed to identify epithelial cells and bacteria. If the Gram 
strain contained 10 times more leukocytes than epithelial cells and if there were 
more than 6 species of one type of microorganism the streaked agar plates were 
incubated. Candida colonies are visually identified on the Sabouraud agar and 
identified to the species level using CHROMagar™. ABDC inhalation therapy is 
not part of the standard of care SDD regimen but can be added at the discretion 
of the attending intensivist when tracheal aspirates or throat cultures are repeat-
edly positive for Candida spp. and the patient is considered to be at risk for deep 
infection. For this purpose ABDC, dissolved in dextrose 5% with a final concen-
tration of 10 mg/ mL is nebulized in a Maquet nebulizing system (Maquet Servo 
Figure 1. Patient inclusion. ABDC = amphotericin-B deoxycholate.
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Ultra Nebulizer, Maquet, Sweden), 4 times daily (daily dose 4x 4 mL = 40 mg). 
ABDC inhalation therapy is discontinued after two consecutive daily respiratory 
tract cultures or after detubation of the patient. Other antifungal therapy was 
instituted at the discretion of the attending intensivist based on cultures taken 
from other body sites. Pneumonia was diagnosed and treated by the attending 
intensivist on the basis of clinical, imaging and microbiological data in close 
collaboration with the infectious disease specialists. VAP was defined as the 
presence of a new or progressive pulmonary infiltrate on the chest radiograph 
along with infectious signs such as fever ≥38.5 °C or ≤36.5 °C, leukocyte count 
≥10 x109/L or ≤4 x109/L and purulent tracheobronchial secretions [22].
Study protocol and data collection
At admission/baseline, demographic data and clinical variables, including 
age, sex, pre-morbidity, prior use of antibiotics including SDD and other risk 
factors for Candida spp. colonization, antifungal treatment, steroids, immune 
status (active malignancy or other causes of an immunocompromised state), 
reasons for admission, invasive procedures (arterial or venous central catheter, 
pulmonary artery catheter, endotracheal intubation) and treatment of organ 
failure (inotropic support, hemodialysis and mechanical ventilation settings) 
were recorded (but not all data are shown when considered not contribute). The 
simplified acute physiology score (SAPS II) was computed at admission. Day 1 
of the study was defined as the first day of respiratory colonization with Candida 
spp. The acute physiology and chronic health evaluation II (APACHE II) and the 
sequential organ failure assessment (SOFA) were recorded at day 1. All cultures 
from the respiratory tract were recorded from day 1 until day of decolonization, 
i.e. the duration of respiratory colonization. Airway Candida decolonization was 
defined as the first day of 2 consecutive daily respiratory cultures negative for 
Candida spp. in the ICU. Candida spp. load was calculated as the number of 
positive respiratory cultures and the sum of the load (in thousands of colonies) 
of the cultures divided by the total cultures taken, using cultures from day 1 until 
decolonization, ICU death or discharge, whatever came first. Candida spp. load 
was classified as mild, <104, moderate, 104-105, and severe, >105. For the ABDC-
treated group, the duration of respiratory colonization and load were calculated 
from day 1 until start of ABDC and from the start of ABDC until decolonization, 
ICU death or discharge, whatever came first. In order to calculate the clinical 
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pulmonary infection score (CPIS) [23] at day 1 and 7, routinely obtained temper-
ature (°C), white blood cell count (WBC, 109/L), amount of tracheal secretions, 
chest radiography imaging results and PaO2/FIO2 ratio (kPa) were recorded 
using the worse data recorded during the 24 hours of that day. At day 1 and 
7, we also recorded positive end-expiratory pressure (PEEP, cm H2O), ratio of 
arterial PO2 to inspiratory O2 fraction (PaO2/FIO2, kPa), total respiratory dynamic 
compliance (mL/cm H2O) and chest radiography imaging results to calculate 
the lung injury score (LIS) [24]. The compliance is calculated from tidal volume 
and difference between in- and expiratory pressures on the ventilator. The LIS 
is calculated by using the worst physical data recorded during the 24 hours of 
that day and the number of quadrants (0-4) on the chest radiograph showing 
alveolar consolidations. Patients were followed until day 28 and 90 after day 1 
and duration of ICU stay, duration of colonization and mechanical ventilation 
(from day 1 until start of inhalational ABDC and thereafter until detubation not 
requiring reintubation within 48 h) and vital outcomes were recorded.
Statistical analysis
Continuous variables were expressed as the mean with standard deviation (SD) 
or when the assumption of normality (Kolmogorov-Smirnov test P<0.05) was 
violated as median values and interquartile ranges. Since ABDC treatment was 
started at median 5 days of colonization, patients colonized for 5 days or more 
were selected from the non-treated group for comparisons of durations. Kaplan-
Meier curves were constructed and log rank testing was performed to evaluate 
group differences in colonization and ventilation durations, censored for death 
or discharge from the ICU. Multiple Cox proportional hazard modeling was 
done to evaluate the effect of ABDC treatment, irrespective of other variables 
associated with mechanical ventilation. Hazard ratios (HR) and 95% confidence 
intervals (CI) were calculated. All tests were two-sided and P<0.05 was consid-
ered statistically significant. Exact P values >0.001 are given.
Results
Characteristics of patients who received ABDC (n=51) and those who did not 
(n=62) are summarized in Table 1. There tended to be more males in the treated 
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group, but groups were otherwise comparable at baseline up to day 1, suggest-
ing similar general risks for respiratory Candida spp. colonization. However, 
Table 1. Patient characteristics at admission, day 1 of colonization and clinical course.
ABDC no ABDC yes P
n=62 n=51
Age, years 57 (17) 58 (20) 0.62
Gender, male 34 (55) 37 (73) 0.05
Premorbidity
Cardiac 31 (50) 18 (35) 0.12
Gastointestinal 21 (34) 24 (47) 0.16
Cancer 17 (27) 16 (31) 0.65
Pulmonary 16 (26) 13 (25) 0.97
Neurological 11 (18) 12 (24) 0.45
DM 12 (19) 8 (16) 0.61
Renal 5 (8) 9 (18) 0.14
Immune 2 (3) 0 (0) 0.16
Other 20 (32) 14 (27) 0.58
Reasons of ICU admission 0.28
Suspected infection 18 (29) 18 (35)
Respiratory failure 9 (15) 13 (25)
Shock 9 (15) 6 (12)
Neurological 11 (18) 4 (8)
Medical 3 (5) 3 (6)
Postoperative 6 (9) 4 (8)
CPR 4 (6) 1 (2)
Trauma 2 (3) 2 (4)
SAPS II 43 (18) 48 (16) 0.12
At day 1 of colonization
APACHE II 21 (12) 20 (9) 0.21
SOFA 9 (6) 9 (5) 0.18
Days from admission ICU 1 (3) 1 (2) 0.64 
Ventilation from admission, days 1 (2) 1 (3) 0.18 
Course
Duration of stay ICU, days 10 (12) 24 (18) <0.001
28-day mortality 19 (32) 10 (20) 0.13
90-day mortality 27 (45) 19 (37) 0.40
Numbers (percentage) or median (interquartile range), where appropriate. Abbreviations: ABDC = amphoter-
icin-B deoxycholate; DM = diabetes mellitus; ICU = intensive care unit; CPR = cardiac pulmonary resuscita-
tion; SAPS II = simplified acute physiology score; APACHE II = acute physiology and chronic health evalua-
tion II; SOFA = sequential organ failure assessment score.
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ABDC-treated patients had a longer duration of stay in the ICU but mortality did 
not differ from that in untreated patients.
Respiratory Candida spp. colonization, risk factors, bacterial 
infection and treatment characteristics according to ABDC 
inhalation treatment
Table 2 gives the data from day 1 of respiratory colonization until ICU death or 
discharge for the untreated and treated groups. Colonization lasted 5 (9) days 
in the untreated group and ABDC was started 5 (5) days after the day of first 
positive respiratory Candida spp. culture, so that we also compared groups for 
these comparable time frames. The data suggest similar risk and load of respira-
tory colonization with Candida spp. until treatment is started for both groups. 
However, the ABDC-treated group seemed to have an overall higher load and 
prolonged colonization than the untreated group, because of start of early and 
spontaneous decolonization in the latter. The CPIS score was higher 1 week 
after day 1 in the absence of more VAP in treated patients. Conversely, there 
was no decrease in the occurrence of VAP in the treated group. Even though 
Figure 2. Duration of respiratory colonization from day 5 (now day 0 in graph) of colonization in untreated 
(continuous line) and from start of amphotericin B (ABDC) on day 0 in graph in treated patients (dotted line) 
until negative cultures, censored for death or discharge from the intensive care unit, to day 28; P = 0.45 (log-
rank test).
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total Candida spp. cultures in the respiratory tract after start of ABDC (1 (2)) 
was lower than before start (3 (1)) (P<0.001), respiratory colonization durations 
were similar, from day 5 (untreated group) or start of treatment (ABDC-treated 
group) to 28 days later (Fig. 2).
Patient courses
Table 3 gives the ventilation characteristics for both groups. The LIS and PaO2/
FIO2 ratio at day 1 were similar between the groups, but at day 7 the LIS was 
higher and the PaO2/FIO2 ratio was lower in the ABDC-treated than untreated 
group. The PEEP was higher in the ABDC-treated group at day 7. Patients receiv-
Table 2. Respiratory Candida spp. colonization, risk factors, bacterial infection and treatment characteristics 
starting day 1 of colonization in untreated group and from day 1 of colonization to start of treatment in treated 
group and thereafter, until ICU death or discharge.
ABDC no
Day 1 until
ICU death or
discharge, n=62
ABDC yes
Day 1 to start
treatment, 
n=51
P vs 
no
ABDC yes
Day 1 until ICU
death or 
discharge, n=51
P vs no
Total Candida spp. cultures respiratory tract 2 (1) 3 (1) 0.67 4 (3) <0.001
Candida spp. load 0.46 0.36
Mild, <104 38 (61) 32 (58) 30 (60)
Moderate, 104-105 13 (21) 18 (33) 16 (32)
Heavy, >105 11 (18) 5 (9) 4 (8)
Candida albicans 41 (66) 34 (61) 0.45 32 (63) 0.74
Candida non-albicans 3 (4) 1 (2) 3 (6)
Both Candida spp. 18 (30) 20 (37) 16 (31)
Duration of respiratory colonization, days 5 (9) 5 (5) 0.66 12 (18) <0.001
Corticosteroids 23 (37) 18 (35) 0.85 22 (43) 0.52
TPN 21 (34) 16 (31) 0.78 18 (35) 0.88
Ventilator-associated pneumonia, 23 (37) 11 (22) 0.16 18 (35) 0.96 
Days after first Candida spp. culture 4 (6) 3 (4) 0.43 5 (4) 0.91
Gram positive 6 (10) 0 (0) 2 (4)
Gram negative 17 (27) 11 (22) 16 (31)
CPIS, day 1 7 (3) 8 (2) 0.10 NA NA
day 7 5 (4) NA NA 8 (3) <0.001
Systemic antifungal treatment 17 (27) 13 (26) 0.39 18 (35) 0.93
Echinocandins 11 (17) 9 (18) 11 (21)
Azoles 6 (10) 4 (8) 7 (14)
Numbers (percentage) or median (interquartile range), where appropriate. Abbreviations: ABDC = ampho-
tericin-B deoxycholate; TPN = total parenteral nutrition; CPIS = clinical pulmonary infection score; day 1 and 
7 refer to day of first isolation of Candida spp. in respiratory secretions and 1 week later, respectively; NA = 
not applicable.
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Table 3. Ventilation characteristics at day 1 and 7 of colonization.
ABDC no ABDC yes P
n=62 n=51
Tidal volume, ml/kg, day 1 7 (2) 7 (2) 0.77
Tidal volume, ml/kg, day 7 7 (3) 8 (3) 0.50
PEEP, cm H2O, day 1 9 (4) 9 (4) 0.10
PEEP, cm H2O, day 7 6 (5) 10 (6) 0.004
Compliance, mL/cm H2O, day 1 37 (28) 44 (39) 0.05
Compliance, mL/cm H2O, day 7 40 (27) 41 (36) 0.09
PaO2/ FIO2 ratio, day 1 213 (122) 197 (137) 0.40
PaO2/ FIO2 ratio, day 7 282 (123) 217 (147) 0.005 
Chest X-ray, no. of quadrants, day 1 2 (2) 2 (1) 0.27
Chest X-ray, no. of quadrants, day 7 2 (3) 2 (2) 0.41
LIS, day 1 2.0 (1.0) 1.8 (1.3) 0.47
LIS, day 7 1.0 (1.3) 1.8 (1.5) 0.002
Ventilation after day 1, days 7 (9) 20 (16) <0.001
Numbers (percentage) or median (interquartile range), where appropriate. Abbreviations: ABDC = ampho-
tericin B deoxycholate; PEEP = positive end-expiratory pressure; PaO2 = partial pressure of oxygen in the 
blood (kPa); FIO2 = the percentage of oxygen administered; LIS = lung injury score; day 1 and 7 refer to day of 
first isolation of Candida spp. in respiratory secretions and 1 week later, respectively.
Figure 3. Duration of mechanical ventilation from day 5 (now day 0 in graph) of colonization in untreated 
(continuous line) and from start of amphotericin B (ABDC) on day 0 in graph in treated patients (dotted line), 
censored for death or discharge from the intensive care unit, to day 28; P = 0.003 (log-rank test).
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ing ABDC were mechanically ventilated longer than patients without treatment 
(Figure 3), from day 5 or start of treatment onwards, in untreated and treated 
groups, respectively. The effect of ABDC on mechanical ventilation duration was 
independent from other factors such as duration of colonization after day 5 and 
LIS on day 7 (Table 4).
Discussion
This non-randomized observational study suggests that ABDC inhalation by 
critically ill, mechanically ventilated patients with respiratory Candida spp. 
colonization is not effective and potentially harmful. Patients on ABDC inha-
lation did not decolonize more rapidly, remained mechanically ventilated for 
an additional 13 days and had a longer ICU stay but no increased mortality, as 
compared to untreated patients.
Our study suffers from a non-randomised design, so that conclusions 
should be drawn carefully. Nevertheless, the data suggest that prior to start 
of treatment, disease severity, colonization risk and load were similar among 
the groups. Treatment was started approximately 5 days after the first positive 
respiratory Candida spp. culture, when in the untreated group spontaneous 
decolonization had already started. We are therefore uncertain, in disagreement 
with previous studies [16], whether decolonization would have also occurred 
in the treated group if treatment had been disadvised or postponed. However, 
when groups were matched for the same duration of respiratory colonization 
prior to treatment, no difference could be observed in rate of decolonization 
Table 4. Multiple Cox proportional hazard modeling for duration of mechanical ventilation.
HR (95% CI) P
ABDC treatment 3.63 (1.57-8.34) 0.003
Candida spp. load until day 5 1.19 (0.70-2.02) 0.51
Candida spp. load after day 5 0.67 (0.31-1.47) 0.32
Duration of colonization until day 5 0.96 (0.90-1.02) 0.13
Duration of colonization after day 5 0.92 (0.88-0.96) <0.001
CPIS day 7 0.91 (0.76-1.10) 0.32
LIS day 7 0.60 (0.40-0.91) 0.02
Hazard ratios (HR; 95% confidence interval, CI) are given for each variable. Abbreviations: ABDC = ampho-
tericin B deoxycholate; CPIS = clinical pulmonary infection score; LIS = lung injury score.
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(Figure 2), in contrast to the increase in decolonization with treatment from 62 
to 86% observed in a previous, but larger, non-randomized study [16].
A previous study showed an incidence of VAP in patients with respiratory 
Candida spp. colonization of 24% which is comparable to the 29% incidence in 
this study [9]. However, our data do not suggest that Candida spp. colonization 
in the respiratory tract predisposed to VAP, in contrast to studies suggesting that 
this could promote VAP development, especially when caused by Pseudomonas 
aeruginosa and multidrug resistant bacteria [9,10]. Conversely, there is no sug-
gestion that respiratory decolonization was associated with less VAP, in contrast 
to suggestions that systemic antifungal treatment decreases the incidence of VAP 
[11]. The differences in ventilation durations cannot be attributed to differences 
in the occurrence of VAP, even though the relatively non-specific CPIS (as well 
as the LIS) was higher on day 7 in the ABDC-treated group, since the CPIS was 
not a determinant of mechanical ventilation duration in multivariate analysis.
Safety issues of ABDC inhalation therapy remain a concern [19,20]. 
We therefore looked at pulmonary injury and ventilation durations, which ap-
peared independent of respiratory colonization duration in our patients. The 
lung scores suggest greater injury in treated patients at day 7 already than in 
untreated patients, independent of VAP. Two studies showed surfactant dys-
function by ABDC, thereby deteriorating gas exchange [17,18], possibly via direct 
inhibition or damage of the alveolar capillary membrane resulting in an influx of 
surfactant-inactivating plasma proteins. Loss of surfactant could lead to longer 
requirement of mechanical ventilation in patients receiving inhalational ABDC. 
Indeed, the longer duration of mechanical ventilation and thus ICU stay in our 
study in ABDC-treated patients can be explained by pulmonary adverse effects of 
the drug. Our data do not exclude that ABDC inhalation prevents pulmonary in-
fections with Aspergillus spp. but suggests that it may carry pulmonary toxicity.
In conclusion, treatment of pulmonary Candida spp. colonization in 
non-neutropenic critically ill patients by inhaled ABDC may not facilitate re-
spiratory decolonization but may increase duration of mechanical ventilation, 
because of direct pulmonary toxicity of the drug. Therefore, inhalation of ABDC 
for respiratory colonization with Candida spp. in non-neutropenic critically ill 
patients cannot be recommended outside prospective randomized trials. For the 
latter, the use of less toxic liposomal dissolved formulation may be preferred 
[21,25].
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Abstract
Background
Invasive Candida spp. infections are increasingly diagnosed in critically ill 
patients. For initial treatment, an echinocandin is recommended with a pos-
sible step-down to fluconazole when the patients’ condition is improving and 
the isolate appears susceptible, but there are no data to support such policy. We 
studied the safety and efficacy of step-down therapy in critically ill patients with 
culture proven deep seated or bloodstream infections by C. albicans susceptible 
to fluconazole.
Methods 
All patients admitted into the intensive care unit from January 2010 to Decem-
ber 2014, who had a culture proven invasive C. albicans infection and received 
initial treatment with an echinocandin for at least 4 days were included. Data on 
patient characteristics, treatment and vital outcomes where assessed.
Results 
Of the 56 patients, 32 received step-down fluconazole therapy, at median day 5, 
whereas the echinocandin was continued in the other 24. No differences were 
seen in baseline characteristics or risk factors for invasive C. albicans infection 
between the two groups. Response rates were similar and no difference where 
seen in 28-day or 90-day mortality between the groups.
Conclusion 
Step-down therapy to fluconazole may be safe and effective in critically ill pa-
tients with invasive infections by C. albicans, susceptible to fluconazole, who 
have clinically improved as early as 4 days after start of treatment with an echi-
nocandin.
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Introduction
Invasive fungal infections caused by Candida spp. are increasingly common in 
critically ill patients even when non-neutropenic [1-7]. These infections are as-
sociated with a prolonged hospital stay and increased mortality [1,4,8,9]. Early 
treatment with an appropriate antifungal drug is mandatory since mortality of 
candidaemia is directly correlated with delayed antifungal therapy [10,11].
Guidelines recommend to start with an echinocandin for treatment of 
critically ill patients with proven invasive infection caused by Candida spp. 
[12,13]. Step-down therapy to fluconazole is advised for patients who have 
improved clinically after initial therapy with an echinocandin and in whom 
fluconazole susceptible Candida spp. (e.g. C. albicans, C. parapsilosis, and C. 
tropicalis) have been documented [12,13], although some studies suggest an im-
proved outcome with continued echinocandin treatment [7,14-17]. Three other 
studies support step-down to (oral) fluconazole therapy after initial treatment 
of variable duration with an echinocandin in patients with candidaemia or in-
vasive candidiasis caused by susceptible C. albicans isolates [18-20]. However, 
their conclusion is based on expert opinion [18] or on results that were mostly 
obtained in non-ICU patients [19,20].
We therefore aimed to study the step-down strategy to intravenous and 
oral fluconazole after initial treatment with an echinocandin for invasive and 
susceptible C. albicans in the critically ill. We hypothesized that such strategy 
is safe and effective, even if done relatively early after start of treatment. We 
therefore studied response rates and disease severity-adjusted mortality among 
patients with and without such step-down treatment.
Patients and methods
Patients
Data were retrospectively collected from our patient data management system, 
according to a predefined checklist. All patients above 18 years of age diagnosed 
with deep seated or bloodstream infection by C. albicans and who received an-
tifungal treatment starting with an echinocandin (caspofungin, anidulafungin 
or micafungin) in the Intensive Care Unit (ICU) of the Erasmus Medical Center 
Rotterdam, were included when admitted between January 2010 and December 
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2014. The ICU is a tertiary care mixed medical-surgical ICU with 2000 admis-
sions per year. Candidaemia was defined as at least one blood culture drawn from 
a peripheral vein positive for C. albicans and invasive candidiasis was defined as 
C. albicans positive culture obtained from a normally sterile site, such as pleural 
or peritoneal fluid, in the context of pleural exudate/empyema, and secondary 
or tertiary peritonitis following a ruptured viscus and surgery, respectively [18]. 
In addition, the presence of one or more of the following signs and symptoms of 
infection was also required: fever or hypothermia; hypotension; localized signs 
and symptoms of inflammation; or radiological findings of invasive candidiasis. 
There were 124 patients diagnosed with invasive candidiasis from January 
2010 until December 2014 and 49 patients had invasive candidiasis with C. 
non-albicans species. All patients were initially treated with an echinocandin. 
Hence. there were 75 patients with invasive C. albicans infection who received 
initial treatment with an echinocandin, but we selected patients (n=56) who 
received echinocandin treatment for 4 days or more, since the average time to 
obtain culture results with susceptibility pattern takes approximately 96 hours. 
Hereby we eliminated patients with early death during echinocandin treatment, 
so that the remaining population had a proper chance for step-down therapy to 
fluconazole. Informed consent was not needed for this retrospective patient data 
analysis, according to Dutch law, because data had been collected during routine 
clinical care and were treated anonymously, and the purpose of this study is to 
evaluate a standard clinical care policy of unknown value.
Clinical protocol
Patients were taken care of by attending intensivists according to national 
and local guidelines. Selective decontamination of the digestive tract (SDD) is 
routinely used in our center for patients expected to remain on mechanical ven-
tilation for >48 hours. This involves the administration of the non-absorbable 
antimicrobial agents tobramycin, amphotericin-B and colistin. Patients also 
received cefotaxim 1 gram intravenously q.i.d. for a three-day period. As part 
of this protocol, inventory cultures are taken of the throat, tracheal aspirates, 
and rectum on admission. To monitor the effect of SDD treatment, surveillance 
cultures (from throat, tracheal aspirates, and rectum) were routinely done thrice 
weekly. The SDD cultures were screened for the presence of Gram-negative 
rods, and yeast that were identified to the species level (see below). At the discre-
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tion of the attending intensivist, additional cultures were taken from a possible 
source of infection, including blood cultures. For fungal detection, all materials 
obtained from a normally sterile site were cultured onto relevant agar plates for 
the detection of both bacteria and yeast. Blood culture bottles, specific for the 
recovery of yeast (BACTEC Mycosis IC/F), that became positive were subcul-
tured onto chocolate agar, Sabouraud agar, and CHROMagarTM to ensure purity 
or mixed infection and differentiation of yeast, and incubated at 35 °C. As soon 
as visible growth of a Candida colony form a normally sterile site was observed 
it was identified to the species level using auxacolor (Sanofi Diagnostics Pasteur) 
or MALDI-TOF. Susceptibility testing of isolates obtained from normally sterile 
sites was performed using a CLSI broth microdilution method (Sensititre®, 
Thermoscientific, USA) and results for azoles, amphotericin B and caspofungin, 
were reported according to revised species-specific CLSI clinical breakpoints. 
For fluconazole, C. albicans was considered susceptible if the minimum inhibi-
tory concentration (MIC) was ≤2 mg/L, and reduced susceptibility was defined 
as a MIC of ≥4 mg/L [21], after 24-48 hours of growth. The start and step-down 
to antifungal treatment was at the discretion of the attending intensivist in close 
collaboration with infectious disease specialists. The first echinocandin we used 
in the department was caspofungin, followed by anidulafungin and micafungin, 
exclusively used in 2013 and thereafter. For caspofungin patients received an 
intravenous daily dose of 50 mg after an initial single loading dose of 70 mg, 
adjusted for body weight and liver function. Patients receiving intravenous 
anidulafungin obtained a single loading dose of 200 mg followed by 100 mg 
daily dose. Micafungin was administered 100 mg intravenous once daily with-
out a loading dose. The step-down from an echinocandin to fluconazole was 
done when patients were considered to no longer need echinocandin treatment 
(i.e. clinical improvement, as defined below) and the cultured Candida spp. 
appeared susceptible to fluconazole. Fluconazole was given orally in patients 
with a normal gastrointestinal transit. Patients receiving intravenous (n=22) or 
oral fluconazole (n=10) obtained a single loading dose of 800 mg followed by a 
daily dose of 400 mg. Fluconazole therapy was adjusted for renal function, and 
patients with a creatinine clearance of 50 ml per minute or less received 200 
mg per day. Patients receiving renal replacement therapy obtained a daily dose 
of 400 mg after 800 mg loading dose. Removal of IV catheters suspected to be 
the origin of infection was routinely done as well as drainage of suspected pus 
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collections. The duration of the antifungal therapy was decided in close collabo-
ration with the infectious diseases physician, based on the Dutch invasive fungal 
infection guidelines which take several factors into account, such as the duration 
of positive cultures, the certainty of good drainage and clinical improvement, 
including absence of fever for >24 hours and haemodynamic stability, and neu-
tropenia [12,13,22].
Study protocol and data collection
On admission, baseline demographic data and clinical variables, including age, 
sex, pre-morbidity, reasons of admission, use of antibiotics including SDD, 
antifungal treatment, steroids, immunosuppressive medication, immune status 
(active malignancy or other causes of an immunocompromised state), and risk 
factors for invasive Candida spp. infection (neutropenia, recent surgery, dia-
betes mellitus, cancer, mechanical ventilation, renal replacement therapy, total 
parenteral nutrition, transplant and central venous catheters) were recorded. 
The acute physiology and chronic health evaluation II (APACHE II) and the se-
quential organ failure assessment (SOFA) score were recorded on admission. To 
monitor clinical improvement the SOFA score was also calculated at day 1 and 
4 after start of an echinocandin, since culture results with susceptibility pattern 
became available at day 4 and step-down therapy was initiated at median day 
5. For each patient a Candida score was calculated at the start of echinocandin 
treatment to help, when >3, establishing the risk for invasive candidiasis vs 
colonization [23]. The primary site of infection and the obtained culture results 
from admission until ICU death or discharge were recorded. A global response 
at the end of treatment was defined as both clinical success (cure – resolution 
of signs and symptoms of C. albicans infection, or improvement – incomplete 
resolution of signs and symptoms of C. albicans infection) and microbiological 
success (2 negative follow-up cultures for C. albicans, or presumed eradication 
when the follow-up culture was not available and clinical response was defined 
as cure or improvement at the end of treatment). The duration of C. albicans 
infection was defined as the period between the first positive culture and the first 
negative culture or ICU death or discharge. Duration of treatment was defined 
as the period between initiation and stop of antifungal therapy or ICU death or 
discharge. Patients were followed until day 28 and 90 after start of antifungal 
therapy and length of ICU stay and vital outcomes were recorded.
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Statistical analysis
There was no formal power calculation for this retrospective modified 
intention-to-treat analysis. Continuous variables were expressed as median 
and interquartile range since the assumption of normality was often violated 
(Kolmogorov-Smirnov test, P<0.05). The Mann-Whitney U test was used for 
continuous data and the Fisher exact test for categorical data. Kaplan-Meier 
curves were constructed and log rank testing was performed to evaluate group 
differences in survival. Multivariable Cox regression analysis was done to evalu-
ate determinants of mortality including step-down therapy. All tests were 2 
sided, and P<0.05 was considered statistically significant. Exact P values >0.001 
are shown.
Results
Fifty-six patients with invasive C. albicans infections received an echinocandin 
for 4 or more days. Of those patients, 32 received step-down fluconazole therapy 
(Group A) whereas the echinocandin was continued in the other 24 (Group B). 
No differences were seen in characteristics on admission and at the start of the 
echinocandin treatment between the groups (Table 1).
Infection and treatment characteristics
Of the 56 patients, 19 patients had candidaemia, 32 patients had abdominal and 
5 patients had pleural infection (Table 2). There were no patients with menin-
gitis, endophthalmitis or osteomyelitis. Both groups had a Candida score 3 on 
average. Fluconazole was started at median day 5 after start of echinocandin 
treatment in Group A, so that the echinocandin was administered for 5 days or 
more in 22 of 32 patients. The C. albicans isolates susceptible to fluconazole had 
a median MIC of 0.25 mg/L in Group A and 0.33 mg/L in Group B. In Group B 
2 isolates where fluconazole identified as less susceptible with an intermediary 
clinical breakpoint of 4 mg/L. There were no echinocandin-resistant strains. 
Durations of infection and treatment, and successful response rates where 
comparable between the groups. The difference in global response rate between 
Group A and B was -2% (95% confidence interval [95% CI] -25 to 22%). The 
difference in clinical response rates was -8% (95% CI -24 to 9%). The differ-
ence in microbial response rates between groups was 2% (95% CI -18 to 24%). 
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The length of ICU stay was comparable for both groups. No differences were 
observed in 28-day or 90-day mortality (Table 1 and Fig. 1). The difference in 
28-day mortality between Group A and B was -16% (95% CI -39 to 10%).
Table 1. Demographic and clinical characteristics at baseline and start of echinocandin for invasive Candida 
albicans infection.
Group A Group B P
(n=32) (n=24)
On admission
Age (years) 59 (20) 65 (21) 0.17
Gender (male)* 20 (63) 15 (63) 0.99
APACHE II score 25 (14) 28 (13) 0.24
SOFA score 10 (6) 10 (6) 0.87
Reasons of ICU admission* 0.46
Suspected sepsis 15 (47) 13 (54)
Respiratory failure 2 (6) 2 (8)
Renal failure 2 (6) 2 (8)
Liver failure 2 (6) 1 (4)
CPR 0 (0) 0 (0)
Shock 1 (3) 3 (13)
Postoperative 10 (31) 3 (13)
At start of echinocandin
Risk factors for invasive Candida spp. Infection*
Neutropenia 1 (3) 2 (8) 0.40
Broad-spectrum antibiotics 12 (38) 10 (42) 0.75
Immunosuppression 0 (0) 1 (3) 0.39
Steroids 12 (38) 9 (38) 0.99
TPN 6 (19) 4 (17) 0.84
Recent surgery 15 (47) 11 (46) 0.94
DM II 5 (16) 5 (21) 0.62
Malignancy 8 (25) 5 (21) 0.72
Transplant 4 (13) 3 (13) 0.99
Ventilation 31 (97) 22 (92) 0.40
CVVH 10 (31) 11 (45) 0.09
Central venous catheter 30 (94) 22 (92) 0.77
Duration between admission and start of echinocandin (days) 4 (6) 2 (4) 0.06
Duration between start of echinocandin and step-down (days) 5 (3) n.a.
*Numbers (percentage) or median (interquartile range), where appropriate. Group A: patient who stepped- 
down to fluconazole. Group B: patients only treated with an echinocandin. Abbreviations: APACHE II = Acute 
Physiology and Chronic Health Evaluation II; CPR = cardiopulmonary resuscitation; CVVH = continuous 
veno-venous haemofiltration; DM II = diabetes mellitus type II; ICU = intensive care unit; SOFA = sequential 
organ failure assessment score; TPN = total parenteral nutrition; n.a.= not applicable.
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Multivariable analysis
In multivariable Cox regression analysis, the SOFA score at day 4 was the best 
parameter (hazard ratio 1.18 95% confidence interval 1.06-1.31, P<0.002) to 
predict 90-day mortality, whereas age, APACHE II, SOFA score on admission, 
Candida score and step-down therapy did not contribute (P>0.05).
Table 2. Infection and treatment characteristics.
Group A Group B P
(n=32) (n=24)
Temperature at start, °C 37.7 (0.9) 37.7 (1.0) 0.60
Temperature day 4, °C 36.7 (0.9) 36.8 (0.8) 0.99
SOFA at start 12 (9) 13 (6) 0.11
SOFA day 4 7 (9) 9 (9) 0.12
Candida score at start 3 (3) 4 (1) 0.15
Source of isolates*
Blood 13 (41) 6 (25) 0.43
Intra-abdominal fluid 16 (50) 16 (67)
Pleural fluid 3 (9) 2 (8)
Antifungal therapy* 
Anidulafungin 18 (56) 14 (58) 0.54
Caspofungin 4 (13) 3 (13) 0.65
Micafungin 10 (31) 7 (29) 0.55
MIC fluconazole, mg/L 0.25 (0.25) 0.33 (0.25) 0.87
Global response* 22 (69) 17 (71) 1.0
Clinical response* 28 (87) 23 (96) 0.68
Microbial response* 26 (81) 19 (79) 0.85 
Gaining negative cultures* 22 (69) 15 (63) 0.78
Duration of infection (days) 4 (8) 3 (8) 0.97
Duration of treatment (days) 17 (12) 14 (13) 0.08
Length of ICU stay (days) 22 (26) 21 (16) 0.36
Mortality day 28 after start* 11 (34) 12 (50) 0.16
Mortality day 90 after start* 16 (50) 15 (63) 0.36
*Numbers (percentage) or median (interquartile range), where appropriate. Group A: patients who stepped- 
down to fluconazole. Group B: patients only treated with an echinocandin. Abbreviations: ICU = intensive care 
unit; MIC = minimal inhibitory concentration; SOFA = sequential organ failure assessment score.
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Discussion
This study suggests that step-down therapy to fluconazole can be safely and ef-
fectively applied in critically ill patients with invasive, fluconazole-susceptible 
C. albicans infections. No difference was seen in 28-day or 90-day mortality, 
with step-down to fluconazole versus continued echinocandin treatment after 
the first 4 days of echinocandin treatment.
The type and duration of treatment of invasive Candida spp. infections 
depends on the result of cultures and sensitivity testing, and the extent of organ 
involvement and patients’ clinical condition [12,13,18]. Three of 56 (5%) C. al-
bicans isolates in this study where non-susceptible to fluconazole, in line with 
the literature [4,24], whereas MIC’s of fluconazole to C. albicans were similar to 
Figure 1. Kaplan–Meier survival curve up to day 90 after initiation of antifungal therapy. Patient who 
stepped-down (>) to fluconazole(Group A) vs. those only treated with an echinocandin (Group B); P = 0.35 
(log-rank test).
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those in previous studies [14,16]. In patients with candidaemia or deep seated 
infection, continued therapy for 14 days after the first negative blood culture is 
recommended [12,13,18], which is in line with the observed length of treatment 
of 14-17 days in this study. Overall response rates in this study are comparable to 
those found in other studies [14-16,19,20]. Some experts and guidelines suggest to 
step-down to fluconazole therapy only after 5-10 days of echinocandin treatment 
[12-14,18,20]. Our results indeed suggest that this can already be done by day 5.
The results of this study are comparable to previous studies on the safety 
and efficacy of step-down therapy in mainly non-ICU patients [19,20]. In the 
largest (n=282) published study on step-down therapy that we are aware of [20], 
the APACHE II score in the step-down population was 12 and therefore lower 
than 25 in ours. Also, this study was mostly limited to non-ICU patients as only 
23 patients with early step-down treatment, a population comparable to ours, 
were in the ICU for >4 days. Finally, the study [20] also included patients with 
C. non-albicans spp. and step-down therapy to oral voriconazole. It separately 
studied early step-down therapy to (only oral) fluconazole in susceptible C. al-
bicans infections (n=41), but did not evaluate its mortality as we did. Therefore, 
our study adds relevant data on step-down therapy in critically ill patients and 
suggests that this strategy is safe as soon as susceptibility is documented and the 
patient has clinically improved during echinocandin therapy. Our retrospective 
data are in line with the most recently published post hoc data from the Ama-
rCAND2 study in France, suggesting that de-escalation of systemic antifungal 
therapy for suspected or documented invasive candidiasis is safe and not associ-
ated with increased mortality [25]. The overall 28-day mortality in our study 
was 41% and comparable to the mortality observed in other studies [3,4,7,16].
The step-down therapy we studied has several advantages. Depending 
on the local resale price of the echinocandins, there may be substantial cost sav-
ings as a result of the step-down therapy [19,26,27]. Furthermore, fluconazole 
has an excellent bioavailability and can be given orally in patients with a normal 
gastrointestinal transit [12,19,20]. Finally, as expected, acquired resistance 
during prolonged treatment of ICU patients with echinocandins has been 
observed [24]. Studies suggest that already after seven days of echinocandin 
exposure resistance associated FKS mutations can be observed [28]. Applying 
a step-down strategy to fluconazole decreases the echinocandin exposure time 
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and may partially prevent the occurrence of these mutations and the risk for 
breakthrough infections with echinocandin resistant Candida spp. [29].
Our study has several limitations and results should be interpreted cau-
tiously. The number of patients included in this study was relatively small, so 
that results should be regarded as preliminary. This study enrolled 75 patients 
with invasive candidiasis by C. albicans in a four-year period in a tertiary care 
ICU with 2,000 admissions per year. Hence, the reported incidence of invasive 
candidiasis was 10 per 1,000 ICU admissions and comparable to the incidence 
of 5 to 10 cases per 1,000 ICU admissions in a large review [5]. C. albicans is the 
most cultured Candida spp. responsible for invasive fungal infection, however 
a shift to azole non-susceptible isolates and the emergence of resistant C. non-
albicans spp. has been noted [2-5,7,8,15,24,30]. Therefore, a step-down therapy 
may become less applicable in centers with a high incidence of resistant C. 
(non-)albicans spp. infections. Obviously, there is patient selection in this study 
of step-down therapy, but SOFA day 4 was a major determinant of outcome, 
irrespective of Candida score or step-down therapy, thereby suggesting that the 
latter was not only done in patients with relatively high overall survival chances. 
Otherwise, the objective clinical course did not differ between groups until day 
4, when clinicians decided on step-down therapy in many (Group A), but not all 
(Group B), patients, on the basis of clinical improvement with absence of fever 
>24 h and hemodynamic stability. We could not retrospectively further capture 
the arguments on which this decision was taken. It is unlikely that a sufficiently 
powered randomized study to confirm our retrospective findings will ever be 
performed.
In conclusion, step-down therapy to fluconazole may be a safe and effec-
tive approach in critically ill patients with candidaemia or invasive candidiasis 
caused by fluconazole susceptible C. albicans, who have clinically improved as 
early as 4 days after start of treatment with an echinocandin.
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Summary
Background 
In critically ill patients the incidence of invasive fungal infections caused by Candida 
spp. has increased remarkably. Echinocandins are recommended as initial treat-
ment for invasive fungal infections. The safety and efficacy of micafungin compared 
to caspofungin is similar, but no comparison is made between anidulafungin and 
micafungin concerning safety and efficacy. We therefore performed a retrospective 
study to assess these aspects in critically ill patients with invasive candidiasis.
Methods
All patients in the intensive care unit (ICU) with invasive candidiasis, who were 
only treated with anidulafungin or micafungin, between January 2012 and 
December 2014 were retrospectively included. Baseline demographic character-
istics, infection characteristics and patient courses were assessed.
Results
A total of 63 patients received either anidulafungin (n=30) or micafungin (n=33) at 
the discretion of the attending intensivist. Baseline characteristics were comparable 
between the two groups, suggesting similar risk for developing invasive candidiasis. 
Patients with invasive candidiasis and liver failure were more often treated with an-
idulafungin than micafungin. Response rates were similar for both groups. No differ-
ence was observed in 28-day mortality, but 90-day mortality was higher in patients 
on anidulafungin. Multivariable cox regression analysis showed that age and serum 
bilirubin were the best parameters for the prediction of 90-day mortality, whereas 
APACHE II, Candida score and antifungal therapy did not contribute (P>0.05). 
None of the patients developed impaired liver function related to antifungal use and 
no differences were seen in prothrombin time, serum transaminases and bilirubin 
levels between the groups, after exclusion of patients with liver injury or failure.
Conclusion
Micafungin can be safely and effectively used in critically ill patients with inva-
sive candidiasis. The observed increased 90-day mortality with anidulafungin 
can be explained by intensivists unnecessarily avoiding micafungin in patients 
with liver injury and failure.
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Background
The incidence of invasive fungal infections caused by Candida spp. is increas-
ing in critically ill patients [1,2]. The latter is associated with prolonged duration 
of hospitalization and higher mortality rates [3-5]. The mortality of invasive 
candidiasis is directly correlated with a delay in starting antifungal therapy and 
therefore early treatment with an appropriate antifungal drug is mandatory [6,7].
A relatively novel class of antifungal agents are echinocandins which have 
activity against a broad spectrum of Candida spp., including C. glabrata and C. 
krusei, against which fluconazole has less activity [8]. Echinocandins are recom-
mended as initial treatment for invasive candidiasis in patients with moderate 
to severe illness, keeping fluconazole reserved for less critically ill patients[9]. 
The recommendation are based on prospective randomized clinical trials which 
demonstrated that all three echinocandins are at least as effective as flucon-
azole for the treatment of invasive candidiasis [10-15]. The antifungal activity, 
pharmacokinetics and toxicity profile of each echinocandin is slightly different, 
but the relevance of this finding remains unclear [16]. Both caspofungin and 
micafungin undergo hepatic metabolism, in contrast to anidulafungin, which 
undergoes spontaneous degradation [17]. Concerns about possible hepatotoxic-
ity of micafungin have been raised which may affect its use in daily practice [2]. 
Two randomized controlled trials [16,18] and one retrospective observational 
trial [19], compared the safety and efficacy of micafungin versus caspofungin 
in the treatment of invasive candidiasis, showing similar results in the safety 
and efficacy of micafungin compared with caspofungin. One systematic review 
including 8,000 patients [20] and one observational cohort study with 8,696 
patients [21], evaluated the safety of micafungin versus other echinocandins, 
showing no increased risk of hepatic injury by micafungin. Both studies only 
evaluated the safety concerning hepatotoxicity of antifungal medication in 
mostly non-ICU patients, but did not evaluate mortality or efficacy.
As far as we are aware there are no studies comparing the efficacy and 
safety of micafungin versus anidulafungin in critically ill patients with invasive 
candidiasis. We performed a retrospective study to compare the safety and ef-
ficacy of micafungin versus anidulafungin in critically ill patients with invasive 
candidiasis.
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Methods
Patients
We retrospectively gathered data from the patients’ medical records using a 
predefined checklist. Between January 1, 2012, and January 1, 2015, all patients 
over the age of 18 with invasive candidiasis and who only received anidulafun-
gin or micafungin as systemic antifungal treatment in the Intensive Care Unit 
(ICU) of the Erasmus University Medical Center Rotterdam, were considered 
for participation. Candidemia was defined as at least one positive blood culture 
for Candida spp. drawn from a peripheral vein. Invasive candidiasis was defined 
as a positive culture with Candida spp. obtained from a normally sterile site, 
such as pleural or peritoneal fluid, in the context of pleural exsudate/empyema, 
and secondary or tertiary peritonitis following a ruptured viscus and surgery, 
respectively [22]. In addition, patients needed to have one or more of the fol-
lowing signs and symptoms of infection: fever or hypothermia; hypotension; 
localized signs and symptoms of inflammation; or radiological findings of in-
vasive candidiasis. Between January 2012 and December 2014 there were 124 
patients diagnosed with invasive candidiasis of whom 20 received caspofungin, 
38 stepped-down to fluconazole and 3 received both antifungals. In total there 
were 63 patients with invasive Candida spp. infection who only received an-
idulafungin or micafungin. The Dutch law states that informed consent is not 
required in case of retrospective analysis in which data collected during routine 
clinical care were used and anonymously analyzed.
Clinical protocol
Patients were taken care of by attending intensivists according to national and 
local guidelines. In our center selective decontamination of the digestive tract 
(SDD) is routinely used for patients with an expected duration of mechanical 
ventilation for more than 48 hours. This involves administration of an oral paste 
and of a suspension via the nasogastric tube, containing the non-absorbable 
antibiotics tobramycin, amphotericin-B and colistin. Patients also received ce-
fotaxime intravenously at 4 times 1 gram a day for a three-day period. Inventory 
cultures are taken of the throat, tracheal aspirates, and rectum as part of this 
protocol on admission. To monitor the effect of SDD treatment, surveillance 
cultures (from throat, tracheal aspirates, and rectum) were routinely performed 
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three times per week. All SDD cultures were screened for the presence of Gram-
negative rods, and yeast that were identified to the species level (see below). In 
case a patient is suspected for having an infection, additional cultures (besides 
the routinely SDD cultures) can be taken from the possible source of infec-
tion, which includes the use of blood cultures. All materials obtained from a 
normally sterile site were cultured onto relevant agar plates for the detection 
of both bacteria and yeast. Blood culture bottles, specific for the recovery of 
yeast (BACTEC Mycosis IC/F), that became positive were subcultured onto 
chocolate agar, Sabouraud agar, and CHROMagarTM to ensure purity or mixed 
infection and differentiation of yeast, and incubated at 35 °C. Auxacolor (Sanofi 
Diagnostics Pasteur) or MALDI-TOF was used to identify the species level of 
a Candida colony as soon as visible growth from a normally sterile site was 
observed. Susceptibility testing of isolates obtained from normally sterile sites 
was performed using a CLSI broth microdilution method (Sensititre® , Ther-
moscientific, USA) and results for azoles, amphotericin B and caspofungin, 
were reported according to revised species-specific CLSI clinical breakpoints. 
For fluconazole, C. albicans was considered susceptible if the minimum inhibi-
tory concentration (MIC) was ≤2 mg/L, and reduced susceptibility was defined 
as a MIC of ≥4 mg/L [23], after 24-48 hours of growth. The decision to start 
an echinocandin was taken by the attending intensivist in collaboration with 
infectious disease specialist. The initiation of antifungal therapy was based on 
clinical signs (i.e. fever, hypothermia, hypotension, leukocytosis or leukopenia), 
risk factors for invasive candidiasis, culture results, radiological findings of 
invasive candidiasis, and according to published criteria [9]. Caspofungin was 
introduced in 2001, followed by anidulafungin and micafungin respectively. In 
case of severe liver injury and liver failure, which was defined as the presence 
of clinical signs and symptoms of an abnormal liver function (increased liver 
enzymes, hyperbilirubinemia, coagulopathy and encephalopathy), intensivists 
prefer anidulafungin over micafungin. In all other instances, the choice between 
anidulafungin or micafungin was at the discretion of the attending intensivist. 
For anidulafungin patients received an intravenous daily dose of 100 mg after 
an initial single loading dose of 200 mg. Micafungin was administered at a dose 
of 100 mg intravenous once daily without a loading dose. No dose adjustment 
was needed for body weight or impaired renal or hepatic function. Drainage of 
suspected pus collections as well as removal of IV catheters suspected to be the 
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origin of infection was routinely done . The duration of the antifungal therapy 
was decided in close collaboration with the infectious diseases physician, based 
on Dutch invasive fungal infection guidelines which take several factors into ac-
count, such as duration of positive cultures, the certainty of good drainage and 
clinical improvement (absence of fever for >24 hours, haemodynamic stability, 
and neutropenia) [9,24,25].
Study protocol and data collection
Demographic data and clinical date were recorded on admission, including 
severity of illness scores, risk factors for invasive Candida spp. infection (neu-
tropenia, recent surgery, diabetes mellitus, cancer, mechanical ventilation, renal 
replacement therapy, total parenteral nutrition, transplant and central venous 
catheters), the duration of ICU stay, and mortality at day 28 and 90 after start 
of antifungal therapy. Patients were checked for abnormal liver function dur-
ing antifungal therapy, serum aspartate transaminase (AST) and serum alanine 
transferase (ALT) were recorded at start and stop of echinocandin treatment. Se-
rum bilirubin, prothrombin time (PT), AST, and ALT peak values were recorded 
daily during echinocandin treatment. At the start of echinocandin treatment a 
Candida score was calculated for each patient to help, when >3, establishing the 
risk for invasive candidiasis vs colonization [26]. The primary site of infection 
and the obtained culture results were recorded. A global response at the end of 
treatment was defined as both clinical success (cure – resolution of signs and 
symptoms of Candida spp. infection, or improvement – incomplete resolution 
of signs and symptoms of Candida spp. infection) and microbiological success 
(2 negative follow-up cultures for Candida spp., or presumed eradication when 
the follow-up culture was not available and clinical response was defined as cure 
or improvement at the end of treatment). The duration of Candida spp. infection 
was defined as the period between the first positive culture and the first negative 
culture or ICU death or discharge. Duration of treatment was defined as the pe-
riod between initiation and stop of antifungal therapy or ICU death or discharge.
Statistical analysis
Continuous variables were presented with median and interquartile range 
because of the not normal distribution (Kolmogorov-Smirnov test, P<0.05). 
Continuous data were examined with The Mann-Whitney U test and categorical 
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data with the Fisher exact test. The Kaplan-Meier estimation of survival curves 
(compared by log rank tests) and multivariable cox regression were used for 
survival analysis. All reported P values are two-tailored. Statistical significance 
was set at P<0.05.
Results
Sixty-three patients with invasive candidiasis received either anidulafungin 
(n=30) or micafungin (n=33). Patients using anidulafungin were more often on 
renal replacement therapy (Table 1).
Infection and treatment characteristics
Of the 63 patients, 22 patients had candidemia, 37 patients had abdominal and 4 
patients had pleural infection (Table 2). The average Candida score was 3 for both 
groups. Anidulafungin was initiated at median day 3 and micafungin was initi-
ated at median day 2 after ICU admission. There were no echinocandin-resistant 
strains. Four C. albicans isolates were considered less sensible to fluconazole 
with an average clinical breakpoint of 100 mg/L. There was no difference in the 
duration of treatment and infection, and response rates, even when corrected 
for liver failure. Both groups had a similar duration of ICU stay. No difference 
was observed in 28-day mortality, but 90-day mortality was higher in patients on 
anidulafungin (Table 2 and Fig 1). Multivariable Cox regression analysis showed 
that age (hazard ratio 1.13, 95% confidence interval 1.02-1.23, P=0.02) and serum 
bilirubin (hazard ratio 1.06, 95% confidence interval 1.01-1.12, P=0.03) were the 
best parameters for the prediction of 90-day mortality, whereas APACHE II, 
Candida score and antifungal therapy did not contribute (P>0.05).
Liver enzymes and function
Patients with invasive candidiasis and liver failure were more often treated with 
anidulafungin than micafungin. None of the patients in this study developed 
liver failure or elevated liver enzymes requiring cessation of treatment related 
to the use of an echinocandin. PT, AST, ALT and bilirubin levels tended to be 
higher in patients treated with anidulafungin. When excluding liver failure, no 
differences were seen in PT, AST, ALT and bilirubin levels between the groups 
(Table 3).
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Costs
Table 4 describes the involved costs for both treatment strategies. The total 
treatment costs per patient seemed to be higher for micafungin, because of the 
longer treatment period. However, the treatment costs per patient per day were 
lower for micafungin.
Table 1. Baseline demographic and clinical characteristics.
Anidulafungin Micafungin P
(n=30) (n=33)
On admission
Age (years) 59 (20) 62 (20) 0.36
Gender (male)* 19 (63) 26 (79) 0.18
APACHE II score 26 (10) 23 (8) 0.13
SOFA score 10 (9) 9 (3) 0.63
Reasons of ICU admission* 0.14
Suspected sepsis 9 (30) 11 (33)
Respiratory failure 2 (7) 6 (19)
Renal failure 1 (3) 0 (0)
Liver failure 4 (13) 0 (0)
CPR 2 (7) 2 (6)
Shock 5 (17) 3 (10)
Postoperative 7 (23) 11 (34)
At start of echinocandin
Risk factors for invasive candidiasis*
Neutropenia 3 (10) 2 (6) 0.57
Broad spectrum antibiotics 18 (60) 15 (45) 0.25
Immunosuppression 4 (13) 3 (9) 0.60
Steroids 16 (53) 12 (36) 0.18
TPN 4 (13) 11 (33) 0.07
Recent Surgery 8 (27) 15 (45) 0.13
DM II 11 (37) 7 (21) 0.18
Malignancy 5 (17) 11 (33) 0.13
Transplant 5 (17) 4 (12) 0.61
CVVH 19 (63) 7 (21) 0.001
CVC 29 (97) 29 (88) 0.20
Mechanical ventilation 27 (90) 32 (97) 0.26
Duration between admission and start 
echinocandin (days)
3 (4) 2 (2) 0.17
Numbers (percentage)* or median (interquartile range), where appropriate. List of abbreviations: APACHE II 
= Acute Physiology and Chronic Health Evaluation II; CPR = cardiac pulmonary resuscitation; CVVH = con-
tinuous venovenous haemofiltration; CVC = central venous catheter; DM II = diabetes mellitus type II; ICU = 
intensive care unit; TPN = total parenteral nutrition
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Discussion
This study suggests that in critically ill patients with candidemia or invasive 
candidiasis, the safety and efficacy of the treatment with micafungin was similar 
to that of anidulafungin. No differences were seen in response rates, liver func-
tion and enzymes, and mortality. Treatment with micafungin seems to be less 
expensive then that with anidulafungin.
Echinocandins inhibit synthesis of the β-(1-3)-D-glucan compound of 
the fungal cell wall and are considered as safe drugs [2,17]. The overall efficacy 
between the three echinocandins is comparable, showing only little difference 
[27]. Nevertheless, the EMA still recommend to only use micafungin in case 
other antifungals are not appropriate, as rat experiments suggested a poten-
Table 2. Infection and treatment characteristics
Anidulafungin Micafungin P
(n=30) (n=33)
Candida score at start 3 (2) 3 (3) 0.71
Source of isolates* 0.25
Blood 10 (33) 12 (36)
Intra-abdominal fluid 17 (57) 20 (63)
Pleural fluid 3 (10) 1 (3)
Candida spp.* 0.46
Candida albicans 8 (27) 3 (9)
Candida dublienis 0 (0) 2 (6)
Candida glabrata 17 (57) 21 (66)
Candida krusei 3 (10) 3 (10)
Candida parapsilosis 1 (3) 2 (6)
Candida tropicalis 1 (3) 2 (6)
Global response* 21 (67) 23 (70) 0.80
Clinical response* 24 (80) 28 (85) 0.62
Microbial response* 21 (70) 24 (73) 0.81
Gaining negative cultures* 18 (60) 20 (60) 0.96
Duration of infection (days) 3 (5) 3 (5) 0.80
Duration of treatment (days) 12 (8) 14 (9) 0.40
Length of ICU stay (days) 13 (15) 14 (21) 0.64
Mortality day 28 after start* 20 (67) 18 (55) 0.33
Mortality day 90 after start* 26 (87) 21 (64) 0.04 
Numbers (percentage)* or median (interquartile range), where appropriate. Abbreviations: ICU = intensive 
care unit.
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tial risk for the development of liver tumors [27]. However, these results were 
obtained from studies using high dosages for prolonged time in male animals, 
similar eff ects were not reported by other studies on humans or animals [17]. 
Both caspofungin and micafungin undergo hepatic metabolization, in contrast to 
anidulafungin, which undergoes spontaneous degradation [17]. Transient eleva-
tion of liver enzymes occurs in 2 to 15% of patients treated with an echinocandin 
[28]. In this study we found an elevation in serum AST of 38% and 35%, and an 
elevation in serum ALT of 33% and 29%, in patients treated with anidulafungin 
or micafungin, respectively. The observed incidence of elevated liver enzymes in 
this study is much higher, but equal between both groups of echinocandins, but 
we only looked at elevated liver enzymes in general and not specifi cally caused 
by the echinocandins. Abnormal liver function tests can be found in up to 61% 
of critically ill patients, as caused by sepsis, drugs or ischemia [29]. Our results 
suggest that micafungin is as safe as anidulafungin concerning hepatotoxicity. 
The results are in line with two previous studies, which both concluded that 
anidulafungin and micafungin had a low risk of elevated liver enzyme levels not 
requiring the cessation of treatment [20,21]. Both studies only evaluated the 
safety concerning hepatotoxicity of antifungal medication in mostly non-ICU 
Figure 1. Kaplan-Meier survival curve up to day 90 after initiation of an echinocandin, P=0.04 (log rank test).
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Table 3. Liver enzymes and function
A Anidulafungin Micafungin P
(n=30) (n=33)
Liver failure* 9 (30) 2 (6) 0.01
Increased serum AST (U/L) after start* 13 (43) 12 (36) 0.58
Increased serum ALT (U/L) after start* 13 (43) 10 (30) 0.29
Serum AST (U/L) at start 95 (282) 55 (76) 0.09
Serum ALT (U/L) at start 56 (125) 39 (59) 0.13
Serum AST (U/L) at stop 115 (1011) 52 (108) 0.17
Serum ALT (U/L) at stop 75 (312) 45 (68) 0.14
Serum AST (U/L) peak 285 (228) 116 (181) 0.11
Serum ALT (U/L) peak 150 (404) 70 (126) 0.15
Serum bilirubin (µmol/L) peak 71 (192) 15 (29) 0.05
Prothrombin Time (sec) peak 18.3 (15.4) 17.8 (8.0) 0.27
B Anidulafungin Micafungin P
(n=21) (n=31)
Increased serum AST (U/L) after start* 8 (38) 11 (35) 0.85
Increased serum ALT (U/L) after start* 7 (33) 9 (29) 0.74
Serum AST (U/L) at start 61 (98) 55 (73) 0.82
Serum ALT (U/L) at start 43 (75) 39 (54) 0.89
Serum AST (U/L) at stop 44 (141) 49 (79) 0.98
Serum ALT (U/L) at stop 41 (83) 45 (54) 0.99
Serum AST (U/L) peak 129 (267) 113 (158) 0.88
Serum ALT (U/L) peak 69 (209) 61 (119) 0.95
Serum bilirubin (µmol/L) peak 20 (105) 14 (27) 0.74
Prothrombin Time (sec) peak 16.6 (7.5) 17.8 (5.3) 0.68
Numbers (percentage)* or median (interquartile range). Liver enzymes and function in all patients who were 
treated with anidulafungin and micafungin (A) and in patients without liver failure (B). Abbreviations: ALT = 
alanine transaminase; AST = aspartate transaminase.
Table 4. Treatment costs
Anidulafungin Micafungin
(n=30) (n=33)
Total treatment days 354 429
Total drug dose(mg) 41.600 42.900
Total drug costs (€) 183,805.44 209,553.63
Drug costs per patient (€) 6,126.84 6,350.11
Drug costs p.p.p.d. (€) 519.22 488.47
Micafungin costs € 460.82 (excluding VAT) per 100 mg ampoule, € 488.47 (including 6% VAT). Anidulafun-
gin costs € 416.83 (excluding VAT) per 100 mg ampoule, € 441.84 (including 6% VAT). Abbreviations: p.p.p.d. 
= per patient per day.
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patients, but did not evaluate mortality or efficacy, as we did. Therefore, this 
study adds important information about the safety and efficacy of micafungin 
compared with anidulafungin in critically ill patients. At day 28 the overall mor-
tality was 60% which is comparable to the mortality described in other studies 
[30,31]. The data suggest that higher 90-day mortality with anidulafungin than 
micafungin reflects more severe underlying liver disease rather than effect of 
treatment itself.
The type and duration of treatment of invasive candidiasis depends 
on culture results and sensitivity testing, the extent of organ involvement and 
patients’ clinical condition [9,24]. In patients with invasive fungal infections the 
recommended length of therapy is 14 days after the first negative blood culture 
[9,24], which is in line with the observed median length of treatment of 12-14 
days in this study. The overall response rates in this study are comparable to those 
found in other performed studies [11,32]. The overall response rate of micafun-
gin is comparable to that of anidulafungin. Our retrospective data, concerning 
the safety and efficacy of micafungin are in line with a recent performed study, 
which evaluated the safety and efficacy of micafungin monotherapy in critically 
ill patients with cancer and invasive candidiasis [32]. However, the study did 
not make a comparison with anidulafungin, as we did. The pharmacokinetics 
of micafungin are very well defined in non-critically ill patients and seems to be 
similar in critically ill patients [33]. In critically ill patients micafungin reaches 
a steady state by day 3, without the need for a loading dose, in contrast to ca-
spofungin and anidulafungin [9,24, 25,33]. Dose adaptations are not required 
for body weight and in patients with renal or hepatic impairment and renal 
replacement therapy [33]. The involved costs per patient per day of treatment 
with micafungin seems to be a bit lower compared with anidulafungin.
One of the limitations of this study is the relatively small number of 
patients included, so that results should be regarded as preliminary. This study 
enrolled 63 patients with invasive candidiasis caused by Candida spp. in a four 
year period in a tertiary care ICU with 2,000 admissions per year. Hence, the 
reported incidence of invasive candidiasis in a large review was 5 to 10 cases 
per 1,000 ICU admission, which is comparable with our reported incidence of 6 
per 1,000 ICU admissions [34]. Second, because of the retrospective design we 
cannot exclude that the use of either agent may have been subject to bias.
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In conclusion, our results suggest that micafungin can be safely and ef-
fectively used in critically ill patients with candidemia and invasive candidiasis.
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General discussion
The research questions we posed in the general introduction of this thesis have 
been answered. However, to come to a well-balanced conclusion the results of 
the different articles in chapter 2 till 5 needs to be combined.
Like the introduction of this thesis, we will also divide this discussion 
into two sections. Section I of this discussion will discuss the results of the four 
articles on different biomarkers for the prediction of infection and it’s sequelae. 
Section II of this discussion will discuss the results of the three articles on the 
safety and efficacy of different antifungals.
Section I - Prediction of infection in the critically ill
In most clinics the white blood cell count (WBC) and C-reactive protein (CRP) 
are used as markers for the prediction of infection in critically ill patients [1]. 
Less frequently procalcitonin (PCT) is used as well. These biomarkers have been 
in use for decades and seem to be useful in daily clinical practice, though, sensi-
tivity and specificity of these markers are suboptimal, which results in moderate 
operational characteristics at best [1].
To impact the attributable morbidity and mortality levels it is necessary 
to diagnose infections in an early stage [2-7]. Despite many years of research and 
development of new biomarkers for infection, diagnosing infection continuous 
to be a challenge and the quest for new and better biomarkers continuous [1]. 
More than 170 biomarkers, as possible new markers for detection of infection, 
have been studied over the last decades. One of those markers is the immature 
granulocyte, as discussed in Chapter 2 of this thesis. The host response to a 
microbial infection invariably starts with the activation of the innate immune 
system [8]. Consequently, it is reasonable to focus on cell specific haematologi-
cal information and methods aimed at detecting this early response to systemic 
infection [8]. Plasma cells or lymphoplasmocytoid cells are involved in the first 
line defence against pathogens [9]. In addition to the activation of circulating 
immune cells, the bone marrow responds to systemic infection as well by releas-
ing immature granulocytes into the peripheral blood [10]. Two previous studies 
showed that the presence of immature granulocytes in critically ill patients 
predict the presence of infections better than CRP does [11,12]. However the 
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additive predictive value of immature granulocytes for serious infections (i.e. 
bacteraemia) remained unclear [12-14]. In Chapter 2 of this thesis we showed 
that the predictive value for infection of immature granulocytes is better than 
the WBC, but equal to CRP. For bacteraemia, the predictive value of immature 
granulocytes was better than that of WBC or CRP. Although this new marker 
looks promising, its AUROC for the prediction of infection was 0.73 with cor-
responding sensitivity of 58% and specificity of 80% at a cut-off value of 0.4%. 
Although an AUROC >0.70 is often considered as clinical relevant [15], the 
AUROC value of the immature granulocytes is just an fraction above this cut-off 
value, and as a result of the low sensitivity a large number of infections will still 
be missed. Thus, immature granulocytes cannot be used as a single parameter to 
rule out infection. As mentioned in the introduction section of this thesis, it will 
be unlikely that a single parameter will have sufficiently power for the prediction 
of infection, since sepsis is the result of a very complex host immune response 
to infection [1].
Combining several parameters into a scoring system for the prediction 
of infection could be a possible option to improve the operational characteristics 
for the prediction of infection [1]. Indeed, combining different markers of infec-
tion led to better predictive values, as shown in Chapter 2 and 5 of this thesis. 
In Chapter 2 we combined the immature granulocytes with WBC and CRP and 
described the predictive value for infection for this combination of markers. The 
addition of immature granulocytes to WBC and CRP resulted in a better predic-
tive value as compared to using WBC or CRP as single parameter, even when 
CRP and WBC were used together. The question arises which combination of 
markers should be used to optimize the diagnostic accuracy for the prediction of 
infection. Another question is whether we should use markers of infection only 
or that we should implement clinical variables (e.g. heart rate, respiratory rate) 
or clinical scores (e.g. SOFA, APACHE) as well. Peres Bota et al. devised the 
Infection Probability Score which combines clinical parameters (temperature, 
heart rate, respiratory rate, SOFA score) as well as biomarkers (WBC, CRP) to 
predict infection [16]. Another scoring system by Lukaszewski et al. only used 
biomarkers (IL-1β, -6, -8, -10, TNF-α, FasL and CCL2 mRNA) [17]. Although 
both scoring systems look promising, there is a substantial difference in the 
predictive values for both scoring systems. Peres et al. described a positive 
predictive value of 53.6% and Lukaszewski et al. described a predictive value of 
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83% [16,17]. In Chapter 3 of this thesis we also describe a novel scoring system 
for the prediction of infection. The scoring system called, The Intensive Care 
Infection Score (ICIS), uses 5 blood cell derived parameters for the prediction 
of infection. All these five blood cell derived parameters of the ICIS score char-
acterize the early innate immune respons, so this infection score focuses at the 
early response to systemic infection [8]. The predictive value of ICIS was indeed 
better than that of WBC, CRP or PCT. Though the predictive value of ICIS was 
not superior compared to CRP and PCT. In fact, the predictive value of ICIS was 
comparable to that of the immature granulocytes, as described in Chapter 2 of 
this thesis. Although positive predictive values of the different infection scoring 
systems vary substantially, using these scoring systems for the prediction of 
infection seem to be promising and useful. Further research and development 
of the different scoring systems is recommended, with particular attention to 
which combination of clinical and non-clinical parameters should be used to 
optimize the diagnostic accuracy for the prediction of infection.
So far, the positive predictive values of the different biomarkers remain 
insufficient to accurately predict the presence of infection. However, some of the 
described biomarkers seem to have a high negative predictive value. Instead of 
using biomarkers to predict the presence of infection, it would be more realistic 
to use a biomarker to rule out infection, by using its high negative predictive 
value. One of the biomarkers that could be used to rule out infection is procalci-
tonin. Previous studies demonstrated that PCT can accurately predict bacterae-
mia in patients with pneumoniae and fever and that bacteraemia becomes very 
unlikely when PCT levels are below a certain treshold [18-20]. In Chapter 4 and 
5 of this thesis we focus on the diagnostic accuracy of procalcitonin for serious 
infections i.e. bacteraemia. In Chapter 4 we demonstrated that procalcitonin has 
a positive predictive value of 88% to predict bacteraemia in critically ill patients, 
with corresponding sensitivity of 89% and specificity of 78% at a cut-off of 0.25 
ng/mL The negative predictive value of procalcitonin varied from 95-98% which 
makes PCT a good biomarker to rule out bacteraemia in critically ill patients. 
Indeed, in chapter 5 of this thesis we demonstrated in a prospective randomized 
controlled trial that PCT is useful to rule out bacteraemia. Ruling out infection 
at an early stage, in a patient suspected of having infection, is very useful. In 
case of a low procalcitonin (<0.25), bacteraemia is very unlikely and antibiotics 
can be withheld, while further exams focus on other causes of systemic inflam-
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mation that may need to be addressed. In case of an elevated procalcitonin level 
(>0.25), bacteraemia could be possible and could guide the physician to start 
empiric antibiotics and strive for improved source control, in anticipation of 
further exams such as blood cultures or results of other biomarkers.
Future perspectives
Critical care medicine is a fairly new field of patient care. It all started with Flor-
ence Nightingale who suggested in the 1850s that critically ill patients needed 
special, separate care. However, it was not until some 100 years later that the first 
ICUs began to be built. Since those early days, intensive care medicine has grown 
exponentially in terms of number of patients admitted, our understanding of the 
complex pathophysiological processes affecting ICU patients, and technological 
developments [21-23]. In Europe over five million adults are admitted to an ICU 
every year. As the population ages, more patients are treated with immunosup-
pressive therapies, and the boundaries of medical treatment continue to expand, 
this number will continue to rise [21-23]. Moreover, as emergency care transport 
and management improves, more patients will survive acute illness and severe 
trauma to reach the ICU [21-23]. As a results of all those factors it will be likely 
that the incidence of sepsis will continue to increase as well [21-23]. For the 
clinician the future challenge would be to correctly discriminate infectious from 
non- infectious causes of systemic inflammation. Therefore it’s crucial that the 
search for better biomarkers for the prediction of infection continuous, where 
the focus should be on further improving the above described infection scores. 
Other more recent techniques (proteomics, genomics and PCR techniques) are 
very complex and it remains to be seen if they will become part of our diagnostic 
armamentarium [1]. Special attention should be paid to the combination of 
parameters to be used in a new scoring system. Maybe the clinicians clinical 
judgement should be added to a scoring system, which is, according to my view, 
still a fast and reliable decision tool to decide whether a patient is suffering from 
an infection or not. Further research should also focus on the use of the nega-
tive predictive value of biomarkers to rule out infection and the consequences 
of excluding an infection. In case an infection is very unlikely blood cultures 
can be withheld and antibiotics are unnecessary. In addition, further research 
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is needed to better define the role of biomarkers when deciding to continue or 
stop antibiotic treatment in a patient with an infection. A recently performed 
study showed promising results in the reduction and consumption of antibiotics 
in critically ill patients by using a procalcitonin guided algorithm [24]. This will 
result in lower costs for the intensive care unit, but more important is that the 
patient will not be unduly exposed to antibiotics. These efficient strategies which 
could lead to a reduction of antibiotic prescription are urgently needed, because 
of the ever increasing bacterial resistance to multiple antimicrobial agents [25].
Section II – Candida infections in the critically ill
Over the last decades substantial progress has been made on the diagnostic 
and therapeutic arsenal to conquer infection, but still infectious complications 
continue to be a major challenge in critical care medicine [26]. In critically ill 
patients the incidence of invasive fungal infections has increased remarkably as 
a result of the widespread use of broad spectrum antibiotics, advanced care in 
the intensive care unit, the ever increasing patient population on immunosup-
pressive therapy and improved knowledge on fungal infections [26-28].
For the management of invasive candidiasis there is no single strategy 
that can be considered the most appropriate [29]. In particular, four manage-
ment options are available: prophylaxis, empirical therapy, pre-emptive therapy, 
and treatment of a culture proven infection [29]. In this thesis we focus on the 
treatment of culture proven invasive candidiasis in critically ill patients, as 
well as on prophylaxis in patients colonized with Candida spp.. During the last 
decades several new antifungal drugs haven been developed. The choice of a 
particular antifungal drug is based on local and international guidelines, the 
aim of therapy, the properties of the drug and local epidemiology [30-32]. Local 
and international guidelines give recommendations on the optimal length of 
treatment and the possibility to step down to smaller spectrum drugs [30-32]. 
The evidence in favor of or against a particular antifungal treatment strategy is 
often scarce.
In Chapter 6 of this thesis we evaluated the safety and efficacy of 
amphotericin-B deoxycholate inhalation therapy for the treatment of Candida 
spp. colonization of the respiratory tract. Amphotericin-B is part of selective 
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decontamination of the digestive tract (SDD) protocols, which were introduced 
in 1983 in the Netherlands. Even though amphotericin-B is used for many years 
in critically ill patients to eradicate Candida spp. from the respiratory tract, little 
is known about its safety and efficacy [33]. The use of inhaled amphotericin-B 
deoxycholate has been associated with a decreased activity of pulmonary sur-
factant in rats [34-36]. In humans, liposomal amphotericin-B inhalation may 
not alter surfactant but may be cytotoxic by other means [37-38]. In Chapter 
6 we showed that the use of conventional amphotericin-B deoxycholate was 
associated with a longer length of mechanical ventilation, independent of the 
presence of ventilator associated pneumonia. Patients using amphotericin-B 
remained mechanically ventilated for an additional 13 days, with higher lung 
injury scores and low PaO2/FIO2 ratios in this group. The decreased activity of 
pulmonary surfactant caused by amphotericin- B deoxycholate results from 
the direct damage to the alveolar capillary membrane, resulting in an influx 
of surfactant-inactivating plasma proteins [34-35]. Surfactant is important to 
stabilize the alveoli at low lung volumes and to prevent alveolar collapse during 
physiological conditions and in acute lung injury [38]. Alveolar collapse results 
in more inhomogeneous ventilation which is correlated with increased risk of 
ventilator associated lung injury, as demonstrated by Blankman et al [39]. Loss of 
surfactant could therefore lead to longer requirement of mechanical ventilation 
in patients receiving inhalational amphotericin- B deoxycholate. Furthermore, 
phospholipids and proteins of pulmonary surfactant provided an important 
component for the innate immune defence mechanism of the lung [38]. We can 
speculate that an impaired innate immune defence results in a higher risk for 
pulmonary infections. However, an impaired surfactant activity has not been 
associated with the use of liposomal amphotericin- B and may therefore be a 
patient-friendlier alternative [34,35,40].
As said before, amphotericin-B is part of the SDD protocol which was 
introduced in 1983. Since then no studies have been performed to evaluate the 
safety of this strategy. In 2013 Ong et al. performed the first cohort trial to evalu-
ate the efficacy of amphotericin-B nebulization therapy in critically ill patient 
with Candida spp. colonization of the respiratory tract [33]. They concluded that 
amphotericin-B facilitated faster decolonization of the respiratory tract as com-
pared to patients who did not receive amphotericin-B. However, effective de-
colonization of the respiratory tract did not results in a decrease in the incidence 
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of ventilator associated pneumonia, ICU length of stay or mortality. Therefore 
they do not recommend to use amphotericin-B as part of the SDD protocol for 
decolonization of the respiratory tract [33]. In contrast to the faster decoloniza-
tion as seen by Ong et al, in Chapter 6 of this thesis we could not confirm that 
the use of amphotericin-B deoxycholate facilitates a faster decolonization of the 
respiratory tract. Furthermore we demonstrated that the use of amphotericin-B 
deoxycholate is associated with an increased length of mechanical ventilation. 
We therefore do not recommend to use amphotericin-B deoxycholate to achieve 
decolonization of the respiratory tract in critically ill patients, as its use is not 
effective and is associated with pulmonary toxicity.
The safety and efficacy of certain antifungals is not well established in 
critically ill patients, because only a small fraction of the patients included in 
phase III trials were admitted to the ICU. In addition, also the safety and efficacy 
of certain antifungal treatment strategies are not well described. In Chapter 7 of 
this thesis we evaluated the safety and efficacy of a echinocandin to fluconazole 
step-down therapy in patients with invasive infections caused by C. albicans 
who were initially treated with an echinocandin. In critically ill patients with a 
proven invasive fungal infection, guidelines recommend to start with an echi-
nocandin [31,41]. Step down to oral fluconazole is possible in patient who have 
improved clinically, and in whom fluconazole susceptible Candida spp. is the 
cause of the infection [31,41]. However, some experts recommend to continue 
antifungal treatment with an echinocandin [44,43]. At this moment experts and 
guidelines differ on the recommendations on the exact time to apply a step-
down approach. Some experts opt to step-down at day 5 of treatment in patients 
who have clinically improved after initial treatment with an echinocandin, while 
other guidelines prefer to step-down at day 10 of treatment [31,41,44,45]. In 
Chapter 7 of this thesis we showed that applying an early step-down strategy 
can be done at day 4 after start of echinocandin therapy, in critically ill patients 
with candidemia or invasive candidiasis caused by fluconazole susceptible C. 
albicans who have clinically improved. We showed that applying an early step-
down strategy can be safely applied without an increased mortality rate in the 
early step-down group. Our results are comparable to those in other studies 
and with the recent AmarCAND2 study in France [45-47]. Acquired resistance 
to echinocandins, caused by FKS mutations have been described recently and 
typically occur after very prolonged treatment of critically ill patients with echi-
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nocandins [48,49]. Applying a step-down strategy to fluconazole decreases the 
echinocandin exposure time and may partially prevent the occurrence of these 
mutations and the risk for breakthrough infections with echinocandin resistant 
Candida spp. [50]. Furthermore, substantial cost savings are another advan-
tage of step down-therapy [51]. In conclusion, we recommend to apply an early 
step-down to fluconazole in critically ill patients with invasive fungal infections 
susceptible for fluconazole, who have clinically improved after initial treatment 
with an echinocandin. This step-down can already be performed at day 4.
The last part of this discussion will focus on the safety and efficacy of 
micafungin for the treatment of invasive fungal infection in critically ill patients. 
Micafungin is one of the three echinocandins, which are part of a relatively novel 
class of antifungal agents. Caspofungin was introduced in 2001 for the treatment 
of invasive fungal infections, followed by anidulafungin and micafungin respec-
tively [52,53]. Echinocandins inhibit the beta-1,3-D-glucan synthase enzyme 
complex, which causes loss of resistance to osmotic forces and cell lysis among 
Candida spp. and are therefore fungicidal [53]. The intracellular beta-glucan 
synthase complex is not present in human cells. Therefore the echinocandins 
cause less toxicity than amphotericin-B or triazoles and few drug-drug interac-
tions are reported [53]. The major advantages of echinocandins relative to other 
antifungal agents are their fungicidal activity against Candida spp, including 
fluconazole-resistant C. glabrata and C. krusei, combined with their relatively 
low potential for renal or hepatic toxicity or serious drug-drug interactions 
[53-55]. Most experts consider all three echinocandins to be interchangeable 
for the treatment of invasive candidiasis, since these drugs have a rather similar 
in vitro spectrum of activity and mechanism of action [53-56]. Though, most 
intensivists prefer anidulafungin above micafungin for the treatment of invasive 
candidiasis in patients with severe liver injury or liver failure, as micafungin has 
been associated with hepatotoxicity in some studies [57]. However, these re-
sults were obtained from studies using high dosages for prolonged time in male 
animals and studies on humans or other animals data did not report similar 
effects [55,57] In chapter 8 of this thesis we evaluated the safety and efficacy of 
micafungin versus anidulafungin for the treatment of invasive fungal infections 
in critically ill patients. We demonstrated that the safety and efficacy of the 
treatment with micafungin was similar to that of anidulafungin. No differences 
were seen in response rates, liver function and enzymes, and mortality.
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We therefore suggest that micafungin, like anidulafungin and caspofun-
gin, can be safely and effectively used in critically ill patients with invasive fungal 
infections. There is no special preference for the use of a particular echinocandin 
for the treatment of an invasive fungal infection [54]. However, the three echi-
nocandins differ in terms of their dosing, pathways of metabolic elimination, 
and drug interaction profiles [54]. Therefore, it is important to appreciate these 
unique characteristics when selecting an echinocandin. For example, no loading 
dose is needed for micafungin and no dose adaptation needs to be made for 
body weight and for patients with renal or hepatic impairment, in contrast to 
anidulafungin or micafungin [58].
Future perspective
The incidence of invasive fungal infections in critically ill patients will continue 
to increase during the coming years [21-24]. This is the direct consequence of an 
aging population, the increased number of patients treated with immunosup-
pressive therapies and the expanding boundaries of medical treatment [21-24]. 
Invasive fungal infections are associated with increased morbidity and mortality 
[27-28]. To reduce these levels, the efficacy and safety of the different antifungal 
drugs and antifungal treatment strategies need to be well established. The safety 
and efficacy of the different antifungal drugs and antifungal treatment strate-
gies is not well established in critically ill patients [58]. This is the result of the 
very small number of patients included in most antifungal registration trials. 
Therefore further research is necessary to improve further understanding of the 
different antifungal drugs and treatment strategies, to improve survival in criti-
cally ill patients with invasive fungal infections.
With the increasing incidence of invasive fungal infections, the incidence 
in antifungal drug resistance in Candida spp. is also increasing [48]. This reflects 
the expanding use of newer broad spectrum antifungals [48]. Further research 
should therefore focus on the exact mechanisms of developing antifungal drug 
resistance, and methods for the rapid detection of resistance. It is also important 
to evaluate the usefulness of different antifungal treatment strategies, particu-
larly in patients for whom the potential benefit of treatment is unproven. For 
example, a recent study showed that pre-emptive therapy with micafungin was 
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not effective at reducing the development of invasive candidiasis compared with 
placebo in critically ill patients requiring emergency gastrointestinal surgery 
[59,60]. Avoiding unnecessary use of antifungal drugs will partially prevent the 
occurrence of antifungal resistance and the risk of break through infections [48]. 
Further research should also focus on the development of voriconazole resistant 
aspergillus species [61]. With the increasing incidence of voriconazole resistant 
aspergillus spp., liposomal amphotericin- B may reoccur as an important treat-
ment alternative in critically ill patients with invasive pulmonary aspergillosis.
Further research should also focus on the pharmacodynamics and 
pharmacokinetics of the different antifungal drugs when used in the critically 
ill. Over the last decade the boundaries of medical treatment in critically ill 
patients expanded significantly, for example with the broad implementation of 
extra corporeal membrane oxygenation. A better understanding of the pharma-
codynamics and pharmacokinetics of the different antifungal drugs in patients 
exposed to new medical techniques has the potential to improve their survival.
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Introduction
In the first part of this thesis we evaluated the diagnostic accuracy of biomarkers 
for the prediction of serious infections in critically ill patients. The main goal 
was to study the predictive properties of different biomarkers in critically ill 
patients, to evaluate the effectiveness of combining biomarkers into a diagnostic 
score, and to discuss the limitations for their applicability in clinical practice. 
In the second part of this thesis we evaluate the safety and efficacy of different 
antifungal treatment strategies and antifungal medication.
Section I - Prediction of infection in the critically ill
In Chapter 2 of this thesis we describe the predictive value of immature granu-
locytes percentage (IG%) in comparison with the white blood cell count (WBC) 
and C-reactive protein (CRP), for the prediction of infection, bloodstream infec-
tion, and septic shock in critically ill patients. Blood samples (IG%, WBC, CRP) 
were collected in 46 consecutive patients at the day (0) of a clinical suspicion of 
microbial infection and at day 1 and 3 thereafter. A clinical suspicion of infection 
could be raised by the presence of a body temperature >38 °C or <36 °C mea-
sured rectally while in the ICU, a WBC count >10,000/µL or <4,000/µL or CRP 
>9 mg/L. In patients suspected for infection microbial cultures were taken. We 
only considered infections confirmed by a positive microbial culture as primary 
endpoint (i.e. proven infection). Thirty-one patients had a proven infection, 
of which 13 patients developed septic shock. Bacteraemia was confirmed in 15 
patients. Our results suggest that IG% is a useful marker, as CRP, for the predic-
tion of infection, its invasiveness and severity in a critically ill patient suspected 
for having infection.
Although the results of the IG% seems to be promising, it will be unlikely 
that this single parameter will be used for the prediction of infection, since sepsis 
is the result of a complex host immune response to infection. An option would 
be to combine different biomarkers, whether or not with clinical data, into a 
scoring system. Indeed, the diagnostic accuracy for the prediction of infection 
increased when IG%, WBC and CRP were used together, as shown in Chapter 
2. In Chapter 3 we evaluate the diagnostic accuracy of a novel diagnostic score, 
the intensive care infection score (ICIS) for the prediction of infection, and 
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compared its performance with WBC, CRP and procalcitonin (PCT). The ICIS 
consists of five blood cell-derived parameters characterizing the early innate 
immune response and routinely obtainable in blood samples sent to the labora-
tory for cell counts.. We prospectively obtained 301 blood samples in patients 
suspected for having an infection. Patients were divided into groups of increas-
ing likelihood of infection and invasiveness, suggestive of increasing severity: 
Group 1 without infection or with possible infection irrespective of cultures, 
Group 2 with probable (irrespective of cultures) or proven local infection (with 
positive cultures of a causative microorganism) without BSI and Group 3 with 
BSI irrespective of local infection. The results suggest that this novel diagnostic 
score is potentially useful for the prediction of infection in critically ill patients 
suspected for having infection. However, the predictive properties of ICIS did 
not significantly differ from that of CRP or PCT. Further research and develop-
ment of the different scoring systems is recommended, with particular attention 
to which combination of clinical and non-clinical parameters should be used to 
optimize the diagnostic accuracy for the prediction of infection.
 One of the most studied biomarkers for the prediction of infection is 
PCT. Though, the results of the different studies on the diagnostic use of PCT 
have been contradicting. This could be explained by the fact that in the majority 
of the literature PCT is used to diagnose sepsis rather than proven microbial 
infection. In this thesis we have tried to study the use of biomarkers for the 
prediction of serious infections, i.e. bacteraemia, which is a more robustly de-
fined culture proven infection. In Chapter 4 we performed a systematic review 
and meta-analysis to study the diagnostic accuracy of PCT for bacteraemia. 
The study included 58 articles which described 16,514 patients of whom 3.420 
suffered from bacteraemia. The results showed that PCT had a fair diagnostic 
accuracy for the prediction of bacteraemia in adult patients suspected for sepsis 
or infection. At a cut-off value of 0.5 ng/mL the area under the hierarchical sum-
mary receiver operating characteristic (HSROC) was 0.79, with corresponding 
sensitivity of 76% and specificity of 69%. In particular low procalcitonin levels 
can be used to rule out the presence of bacteraemia, because of its high negative 
predictive value. This could lead to a cost reduction by saving blood cultures.
In Chapter 5 of this thesis we studied the safety and efficacy of PCT of 
guiding blood culture taking in critically ill patients with suspected infection. 
We performed a prospective multi-center, cluster randomized, cross-over trial 
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in 564 clinical patients suspected for having infection. Patients were divided in a 
control group (standard of care) and a PCT-guided group. In both groups blood 
was drawn at the same moment for a PCT measurement and blood culture.
In the PCT-guided group blood cultures were not sent if the PCT was 
below 0.25 ng/ml, unless otherwise indicated. The control and intervention 
group included 288 and 276 patient respectively. Eighteen sets of blood cultures 
were saved in 17 patients in the PCT- guided group. There was no difference in 
mortality at day 28 and day 90 between both groups. Using this strategy could 
save 1.14 euro per suspected infection episode. The results of this study suggest 
that PCT to guide blood cultures in critically ill patients with suspected infection 
can be used safely and (cost-)effectively.
Section II – Candida infection in the critically ill
In section II of this thesis we focus on the antifungal treatment of invasive 
Candida infections in te critically ill patient. Selective decontamination of the 
digestive tract (SDD) is a frequently used strategy in many Dutch intensive care 
units (ICU’s) and consists of oral administration of non-absorbable antibiot-
ics. Amphotericin-B deoxycholate (ABDC) inhalation therapy is started via a 
nebulizer is case of respiratory colonization with Candida spp. This treatment is 
started as part of many SDD protocols used in large trials.. However, its safety 
and efficacy are not well established, in the absence of randomized trials. In 
Chapter 6 of this thesis we performed a retrospective study to assess the safety 
and efficacy of ABDC inhalation for the treatment of respiratory Candida spp. 
colonization in critically ill patients. We included 113 patients who had positive 
Candida spp. cultures of the respiratory tract for more than 1 day and required 
mechanical ventilation >48 hours. Fifty-one of them received ABDC inhala-
tion therapy. The results showed that using ABDC inhalation therapy does not 
lead to faster decolonization of the respiratory tract as in untreated patients. 
Furthermore, ABDC inhalation therapy is associated with an increased length 
of mechanical ventilation, because of direct toxicity of the drug on the lung. 
Therefore we do not recommend to use ABDC inhalation therapy for respiratory 
colonization with Candida spp. in non-neutropenic critically ill patients.
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In critically ill patients with a proven invasive infection caused by Candida 
spp., the initial antifungal drug of choice is an echinocandin. Step-down therapy 
to fluconazole is advised for patients who have improved clinically after initial 
therapy with an echinocandin and in whom fluconazole susceptible Candida spp. 
have been documented can step- down to fluconazole. Though the exact timing to 
step-down is a subject of debate. We therefore performed a retrospective study in 
56 patients with invasive C. albicans infections who initially received an echino-
candin for 4 or more days (Chapter 7). Of those patients, 32 received step-down 
fluconazole therapy, at median day 5, whereas the echinocandin was continued 
in the other 24. Our results showed that the global response rates at the end of 
treatment, which was defined as resolution of signs and symptoms of C. albicans 
infection, were similar between the groups. No difference were seen in 28-day 
or 90-day mortality between the groups. Our results suggests that step-down 
therapy to fluconazole can be safely and effectively applied in critically ill patients 
with invasive, fluconazole-susceptible C. albicans infections, who have clinically 
improved after initial treatment with an echinocandin. This step-down approach 
can already be done at day 5 of treatment.
In the last chapter of this thesis, Chapter 8, we studied the safety and 
efficacy of micafungin in critically ill patients with invasive candidiasis. Mica-
fungin has been associated with hepatotoxicity, therefore intensivists prefer 
anidulafungin above micafungin for the treatment of invasive fungal infections 
in critically ill patients with severe liver injury or liver failure. We performed a 
retrospective study in 63 critically ill patients with invasive fungal infections 
to evaluate the safety and efficacy of micafungin compared to anidulafungin. 
Thirty patients received anidulafungin and 33 patients received micafungin. 
None of the patients developed impaired liver function related to antifungal 
use and no differences were seen in prothrombin time, serum transaminases 
and bilirubin levels between the groups. The global response rates at the end of 
treatment, which was defined as resolution of signs and symptoms of an invasive 
fungal infection, was similar for both groups. No difference was seen in 28-day 
mortality, but 90-day mortality was higher in patients on anidulafungin. The 
increased 90-day mortality was not correlated with the use of anidulafungin, as 
shown in the cox regression analysis. Our results suggest that micafungin can 
be effectively used in critically ill patient with invasive candidiasis and is not 
associated with hepatotoxicity.
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Introductie
In het eerste deel van dit proefschrift onderzochten we de diagnostische waarde 
van biomarkers voor de voorspelling van ernstige infecties bij ernstig zieke 
patiënten. Het belangrijkste doel was om de voorspellende eigenschappen 
van de verschillende biomarkers te bestuderen bij ernstig zieke patiënten , de 
effectiviteit van het combineren van biomarkers in een diagnostische score 
te evalueren, en om de beperkingen van hun toepasbaarheid in de klinische 
praktijk te bespreken. In het tweede deel van dit proefschrift evalueerden we de 
veiligheid en effectiviteit van verschillende antifungale behandelingsstrategieën 
en antifungale medicatie.
Deel I – Voorspellen van infectie in de ernstig zieke 
patiënt
In hoofdstuk 2 van dit proefschrift beschrijven we de voorspellende waarde van 
het percentage onrijpe granulocyten (IG%), vergeleken met witte bloedcellen 
(WBC) en C-reactief proteïne (CRP), voor het voorspellen van infectie, bloed-
vergiftiging en shock in de ernstig zieke patiënt. In 46 patiënten die verdacht 
werden van infectie werd bloed afgenomen voor het bepalen van IG%, WBC en 
CRP. Bloed werd afgenomen op dag 0 (dag van inclusie) infectie en op dag 1 
en 3 daarna. De klinische verdenking op een infectie kan worden ondersteund 
door de aanwezigheid van een lichaamstemperatuur > 38 ° C of <36 ° C rectaal 
gemeten, een WBC telling> 10.000 / ul of <4000 / ul of een CRP> 9 mg / l . Er 
werden kweken afgenomen van patiënten die verdacht werden van een infectie. 
Het primaire eindpunt in deze studie was een bewezen infectie middels een 
positieve kweek. In totaal hadden 31 patiënten een bewezen infectie, waarvan 13 
patiënten in shock waren. In 5 patiënten was er sprake van een bloedvergiftiging. 
De resultaten van onze studie suggereren dat IG%, net als CRP, een bruikbare 
marker is voor het voorspellen van infectie, de invasiviteit van de infectie en de 
ernst van een infectie in een ernstig zieke patiënt.
Ondanks de veelbelovende resultaten van IG%, is het onwaarschijnlijk 
dat een enkele biomarker gebruikt zal worden voor het voorspellen van infectie, 
omdat sepsis het resultaat is van een complexe reactie van het lichaam op een 
infectie. Het combineren van verschillende biomarkers in een scoresysteem 
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zou een oplossing kunne vormen voor dit probleem. In hoofdstuk 2 hebben we 
eveneens IG%, WBC en CRP samengevoegd tot een scoresysteem, waarmee we 
aantonen dat de voorspellende waarde voor infectie verbetert. In hoofdstuk 3 
hebben we een nieuw scoresysteem geëvalueerd, de intensive care infectie score 
(ICIS), voor het voorspellen van infectie, waarbij we de voorspellende waarde 
van ICIS hebben vergeleken met die van WBC, CRP en PCT. ICIS bestaat uit een 
vijftal cellijnen welke betrokken zijn bij de eerste respons van het lichaam op 
een infectie. De gegevens voor deze studie hebben we prospectief verzameld in 
301 patiënten die werden verdacht voor het hebben van een infectie. Patiënten 
werden ingedeeld in verschillenden groepen van toenemende invasiviteit 
en ernst van de infectie. Groep 1 bevatte patiënten zonder infectie of met een 
mogelijke infectie. Groep 2 bevatte patiënten met een bewezen infectie of een 
zeer waarschijnlijke infectie. Tot slot bevatte groep 3 patiënten met een bewezen 
infectie en daarbij een bloedvergiftiging. De resultaten van het onderzoek sug-
gereren dat ICIS een potentieel bruikbaar scoresysteem is voor het voorspellen 
van infecties in de ernstig zieke patiënt. Echter, de voorspellende waarde voor 
infectie van ICIS was niet significant beter dan die van CRP of PCT. Het wordt 
dan ook aanbevolen om verder onderzoek te verrichten naar de ontwikkelingen 
van verschillende scoresystemen. Hierbij moet vooral worden gelet op welke 
combinatie van klinische en niet- klinische parameters gebruikt moet worden 
om de diagnostische nauwkeurigheid voor de voorspelling van infectie te opti-
maliseren.
PCT is een van de meest onderzochte biomarkers voor de voorspelling van 
infectie. De resultaten van de verschillende onderzoeken naar het gebruik van 
PCT voor het voorspellen van infectie zijn echter tegenstrijdig. Dit kan worden 
verklaard door het feit dat in de meeste literatuur PCT wordt gebruikt voor het 
voorspellen van sepsis in plaats van een bewezen microbiële infectie. Daarom 
hebben wij ervoor gekozen in dit proefschrift om biomarkers te gebruiken voor 
het voorspellen van ernstige infecties, zoals bijvoorbeeld een bloedvergiftiging, 
welke een bewezen microbiële infectie is. Hoofdstuk 4 beschrijft de resultaten 
van een systematische review en meta-analyse naar de nauwkeurigheid va PCT 
voor het voorspellen van bloedvergiftiging. De studie omvatte 58 artikelen met 
16.514 patiënten, waarvan 3.420 patiënten een bloedvergiftiging hadden. De 
resultaten toonden aan dat PCT een goede voorspellende waarde had voor het 
voorspellen van bloedvergiftiging in ernstig zieke patiënten. Bij een afkapwaarde 
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van 0,5 ng/ml was de hiërarchische summary receiver operating characteristic 
(HSROC) 0,79, met overeenkomstige sensitiviteit van 76% en specificiteit van 
69%. Vanwege de hoge negatieve voorspellende waarde, kunnen lage PCT-
waarden gebruikt worden voor het uitsluiten van een bloedvergiftiging. Dit 
resulteert in een kostenbesparing door verminderde afname van bloedkweken.
In hoofdstuk 5 van dit proefschrift bestudeerden we de veiligheid en 
effectiviteit van PCT geleide bloedkweek afname bij ernstig zieke patiënten 
met een vermoedelijke infectie. Hiervoor hebben we een prospectief multi-
center, cluster gerandomiseerd, cross-over onderzoek verricht bij 564 klinische 
patiënten die werden verdacht van het hebben van een infectie. De patiënten 
werden verdeeld in een controlegroep (standaardbehandeling) en een PCT-
geleide groep. In beide groepen werd bloed afgenomen op hetzelfde moment 
voor een PCT bepaling en een bloedkweek. In de PCT-geleide groep werden 
bloedkweken niet verzonden indien de PCT waarde lager was dan 0,25 ng / 
ml, tenzij anders aangegeven. In totaal werden 288 patiënten geïncludeerd in 
de controlegroep en 276 patiënten in de interventiegroep. In de PCT-geleide 
groep werden 18 bloedkweken bespaard in 17 patiënten. Er was geen verschil 
in mortaliteit op dag 28 en dag 90 tussen beide groepen. Met behulp van deze 
strategie kan 1,14 euro bespaard worden per vermoedelijke infectie episode. De 
resultaten van deze studie suggereren dat een PCT -geleide bloedkweek afname, 
veilig en (kosten)effectief gebruikt kan worden in ernstige zieke patiënten, die 
worden verdacht van een infectie.
Deel II – Candida infecties in de ernstig zieke patiënt
In deel II van dit proefschrift richtten we ons op de behandeling van invasieve 
Candida-infecties in de ernstig zieke patiënt. Selectieve de contaminatie van het 
spijsverteringskanaal (SDD) is een veel gebruikte strategie in veel Nederlandse 
intensive care units (ICU) en bestaat uit orale toediening van niet-absorbeerbare 
antibiotica. Amfotericine-B deoxycholaat (ABDC) inhalatie therapie wordt 
gestart via een verstuiver indien er sprake is van kolonisatie van de luchtwegen 
met Candida spp. Deze behandeling wordt gestart als onderdeel van vele SDD 
protocollen, welke uitgebreid zijn onderzocht in diverse onderzoeken. Echter, de 
veiligheid en effectiviteit van ABDC inhalatietherapie is niet goed onderzocht. In 
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hoofdstuk 6 van dit proefschrift hebben we een retrospectieve studie verricht 
naar de veiligheid en werkzaamheid van ABDC inhalatietherapie voor de be-
handeling van respiratoire Candida spp. kolonisatie bij ernstig zieke patiënten. 
In totaal werden 113 patiënten geïncludeerd met positieve keelkweken voor 
Candida spp. en die langer dan 48 uur mechanisch werden beademd. Eenen-
vijftig patiënten werden behandeld met ABDC inhalatie therapie. De resultaten 
toonde aan dat het gebruik van ABDC inhalatietherapie niet leidt tot snellere 
dekolonisatie van de luchtwegen. Daarnaast werd ABDC inhalatietherapie geas-
socieerd met een toegenomen lengte van mechanische beademing, als gevolg 
van directe toxiciteit van het geneesmiddel op de long. Daarom raden we niet 
aan om ABDC inhalatietherapie te gebruiken voor dekolonisatie van Candida 
spp. in de luchtwegen.
Ernstig zieke patiënten met bewezen invasieve Candida spp. infectie 
worden bij voorkeur behandeld met een echinocandine. Therapieversmalling 
naar fluconazol wordt geadviseerd voor patiënten die klinisch zijn verbeterd 
na initiële behandeling met een echinocandine en bij wie er sprake is van een 
fluconazol-gevoelige Candida spp. De exacte timing om therapieversmalling 
toe te passen blijft een onderwerp van discussie. Daarom hebben wij een ret-
rospectieve studie verricht in 56 patiënten met invasieve C. albicans infecties, 
waarbij de initiële behandeling uit een echinocandine bestond, voor een periode 
van tenminste vier dagen (hoofdstuk 7). In totaal werd therapieversmalling 
naar fluconazol toegepast in 32 van de 56 patiënten. Dit gebeurde gemiddeld 
op dag 5 van behandeling. De overige 24 patiënten werden uitbehandeld met de 
echinocandine. Onze resultaten lieten zien dat beide behandelstrategieën even 
effectief waren. Er was geen verschil in sterfte tussen beide groepen op dag 28 
of 90.
Onze resultaten suggereren dat therapieversmalling naar fluconazol, 
na initiële behandeling met een echinocandine, veilig en effectief kan worden 
toegepast in ernstige zieke patiënten met een bewezen C. albicans infectie, 
welke gevoelig is voor fluconazol. Onze resultaten suggereren dat therapievers-
malling naar fluconazol veilig en effectief kan worden toegepast in ernstig zieke 
patiënten met invasieve fluconazol-gevoelige C. albicans infecties, die klinisch 
zijn verbeterd na initiële behandeling met een echinocandine. De therapievers-
malling kan al worden toegepast op dag 5 van de behandeling.
Samenvatting en conclusies | 191
In het laatste hoofdstuk van dit proefschrift, hoofdstuk 8, hebben we 
de veiligheid en effectiviteit van micafungin bij ernstig zieke patiënten met 
invasieve candida infecties onderzocht. Micafungin is geassocieerd met lever-
schade, waardoor intensivisten de voorkeur geven aan anidulafungin boven 
micafungin voor de behandeling van invasieve candida infecties bij ernstig zieke 
patiënten met ernstige leverbeschadiging of leverfalen. We hebben een retro-
spectieve studie verricht in 63 ernstig zieke patiënten met invasieve candida 
infecties om de veiligheid en effectiviteit van micafungin, vergeleken met anidu-
lafungin, te evalueren. Dertig patiënten kregen anidulafungin en 33 patiënten 
kregen micafungin. Geen van de patiënten ontwikkelde leverfunctiestoornissen 
of levertestafwijkingen ten gevolge van de antifungale medicijnen. Het succes 
van de behandeling was gelijk voor beide groepen. Er was geen verschil in 
sterfte tussen beide groepen op dag 28. Echter, de sterfte op dag 90 was hoger 
voor patiënten die werden behandeld met anidulafungin. Na het verrichten van 
een Cox-regressie analyse kwam naar voren dat de verhoogde sterfte op dag 
90 niet werd veroorzaakt door anidulafungin, maar werd veroorzaakt door de 
onderliggende ziekte bij de patiënt Onze resultaten suggereren dat micafungin 
effectief kan worden gebruikt in ernstig zieke patiënten met invasieve candida 
infecties en er geen associatie is met het optreden van leverschade.
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Dankwoord
Inmiddels bent u aanbeland bij het meest gelezen hoofdstuk van het proefschrift. 
In dit dankwoord probeer ik een ieder te bedanken voor zijn of haar bijdrage 
aan dit proefschrift. Het dankwoord is zorgvuldig samengesteld, maar mocht ik 
iemand vergeten zijn dan hoop ik dat dit niet persoonlijk word opgevat.
Promotoren
Prof. dr. A.B.J. Groeneveld, beste Johan, je hebt er alles aan gedaan om aan-
wezig te kunnen zijn op mijn verdediging, maar helaas mocht het niet zo zijn. 
Ruim vier jaar geleden zijn we begonnen aan dit proefschrift, welke wij samen 
hebben afgerond tot een mooi einde. Je kwam toen ter tijd vers over uit het 
VU Medisch Centrum te Amsterdam, voor de meeste geboren en getogen Rot-
terdammers zou dit al een probleem opleveren. De samenwerking tussen 010 en 
020 verliep echter zeer soepel. Ondanks het ziek worden wist je toch energie te 
vinden om mij te steunen met het afronden van dit proefschrift. Ik respecteer 
je doorzettingsvermogen, precisietijd en oplossingsvermogen. Op de momenten 
dat ik er klaar mee was kwam jij met een oplossing, gevolgd met succesvol re-
sultaat. Gedurende de jaren heb ik veel van je geleerd, zowel uit de kliniek als op 
onderzoeksgebied. Met als grootste leerdoel: precisietijd, want zoals jij altijd zei 
‘het moet buiten gewoon precies’. Mijn hartelijke dank voor je vertrouwen, hulp 
en tijd die je gegeven hebt om dit proefschrift met succes af te ronden. 
Prof. dr. D.A.M.P.J. Gommers, beste Diederik, gedurende mijn periode op de 
intensive care als onderzoeker en arts assistent stond jou deur altijd open voor 
raad en advies. Daar maakte ik dan ook regelmatig gebruik van. De afgelopen 
jaren waren leerzaam, verrijkend, leuk, maar ook vaak lastig. Maar voor die las-
tige momenten had jij vaak een ‘ to the point’ oplossing. Ik wil je bedanken voor 
je luisterend oor en adviezen. Daarnaast wil ik je bedanken voor het vertrouwen 
wat je mij hebt gegeven de afgelopen jaren, met als resultaat het succesvol afron-
den van dit proefschrift.
Co- promotor
dr. B.J.A. Rijnders, beste Bart, langzaam en geleidelijk ben jij betrokken ge-
raakt bij dit proefschrift. Ondanks alle bezigheden wist jij toch tijd te vinden 
om mij te begeleiden met het schrijven van de artikelen en vooral kritische en 
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goede verbeteringen aan te brengen in het geschreven werk. Het best kan je 
omschreven worden als een stille kracht, die veel belangrijk werk heeft verricht 
op de achtergrond. Ik wil je bedanken voor het vertrouwen dat je in mij stelde, 
zeker gezien het feit dat de meeste communicatie per e-mail of telefoon verliep. 
Bedankt dat je mijn co- promotor wilde zijn
Overige leden van de commissie
Beste prof. dr. Eric van Gorp, prof. dr. Jozef Kesecioglu, prof. dr. Jan Klein, prof. 
dr. Bart Jan Kullberg en prof. dr. Margreet Vos hartelijk dank voor jullie bereid-
heid om mijn proefschrift door te nemen en zitting te nemen in de commissie 
ingesteld voor mijn promotie.
De co- auteurs
Erik Dieters, beste Erik, allereerst wil ik je bedanken voor de prettige samenwer-
king en al het werk wat jij hebt gedaan. Het waren niet de leukste klusjes, maar 
mede dankzij jou inzet is mijn promotie succesvol afgerond. Waarschijnlijk heb 
ik je besmet met het Intensive Care en onderzoeks virus, want inmiddels zit je 
in dezelfde stoel als ik. Het wordt tijd om de Boudewijn weer eens af te sluiten, 
gouden tijden! Ik kies alleen zelf het bier weer uit, anders is the day after weer 
verloren.
Mostafa Mohseni, beste Moessie, bedankt voor alle hulp en de leuke samenwer-
king. We hebben samen een mooie onderzoekslijn opgezet met de ICIS studie. 
Het wordt tijd dat je de Ipad weer eens meeneemt want dan kunnen we weer 
World of War spelen.
Daan Nieboer, beste Daan, ik wil je bedanken voor alle statistische ondersteu-
ning die je hebt geleverd voor de artikelen. Het waren niet altijd de makkelijkste 
vragen en opdrachten die moesten worden opgelost, maar gelukkig is alles 
geslaagd. Hopelijk heb je mijn e-mail bombardement niet als storend ervaren, 
bij vlagen was ik soms wat ongeduldig.
Ook de overige co- auteurs, Rob Brouwer, Ben van den Hoven, Nicole Hunfeld, 
Sophie Ladage, Ewout Steyerberg en Alieke Vonk, wil ik bedanken voor hun 
inzet en goede adviezen wat heeft geresulteerd in een aantal mooie artikelen.
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De paranimfen
Paul Blankman, CHEEEEEEEEFFFFFFFF, waar zal ik dit ellendige stukje tekst 
weer beginnen. Allereerst wil ik je bedanken voor het feit dat je altijd voor mij 
klaar stond en daar waar nodig hulp kon geven. Hard werken, veel gezelligheid 
en doffe ellende, dat was de combinatie Paul en Patrick (alias Epi en lepsie) in 
het onderzoek hok. Het was maar goed dat ik halve wegen mijn promotie traject 
de luxe heb verworven over een eigen kamer met collega Hoeboer. Echter voor 
alles was een oplossing, dus het duurde niet lang voordat wij een nieuw geza-
menlijk onderzoek hok hadden gevonden, de Albron (onder leiding van Koekie). 
In Albron vond minimaal een keer per dag overleg plaats en indien nodig twee-
maal of meer. Dit onder genot van een KK’tje welke soms werd geüpgraded tot 
een KKF’je. Hier bespraken we de dagelijkse ellende, met als sport wiens artikel 
weer het snelst was afgewezen. Super tof dat je mijn paranimf wil zijn! Tot slot, 
ik kan het niet laten, de chef vocabulaire van de afgelopen vier jaar: Chef, doffe, 
ellende, terror, duif, hoe, ho, beun, goud, patat, pizza, pannenkoek, poffertjes, 
bier, jenever (alias de duikboot), koffie, bakkie, gevulde koek, flappelap, rue de 
bakkie, George V, Roosevelt, Argentine, Slopel, poes en last but not least Geile 
Gerard. Paul we did it! 
Vincent Rietdijk, ouwe bier bom! Mensen we gaan even terug in de tijd, naar 
het jaar 2003, inmiddels alweer dertien jaar geleden. En de ellende is allemaal 
begonnen in Barcelona, met onze bus chauffeur ‘kale Ronaldinho’ en de docente 
maatschappijleer die jou even een nachtzoen kwam brengen. We weten allemaal 
hoe dat is afgelopen. We kennen elkaar alweer dertien jaar, kort samengevat: 
zuipen, bier, feest, bomen, berm, takeldienst, Wageningen, VerVer, zonnige 
donderdag ochtenden en heel veel gezelligheid. Dit alles gerelativeerd met Rot-
terdamse nuchterheid. Vincent, je stond altijd voor mij klaar, dag en nacht. Het 
is niet meer dan logisch dat jij dan ook mijn paranimf zou zijn, anders komt er 
niks terecht van dat feestje.’ Oh Oh,’ zou jij zeggen, ‘het is weer goed met je’. 
Waarop mijn antwoord zou zijn: ‘zeker weten’ .
Collega onderzoekers Intensive Care en het onderzoekshok
Sandra Hoeboer, Engeltje, tsja waar zal ik beginnen. We hebben in hetzelfde 
schuitje gezeten. De afgelopen jaren hebben we gehuild, gevloekt, maar ook 
zeker veel gelachen. It was a hel of a job, but we did it. Soms hadden we een 
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pittig meningsverschil, maar meestal zaten we op een lijn en was het goed zaken 
doen. Tijd om weer eens een glaasje Chablis te drinken. Dank je wel poppedop.
Mo Egal, Yo Mo, waar moet ik beginnen bij jou. Als je een vraag of probleem 
hebt, vraag het aan Mo en hij komt met een oplossing. Vragen over Excel, Word, 
SPSS, R, instellen werk e-mail, codes voor bepaalde pakketten, Mo regelt het. 
Super bedankt voor alle ondersteuning en de gezellige momenten. Nog heel 
even doorbijten en ook jij bent bijna zover.
Ditty van Duijn, beste Ditty, hartstikke bedankt voor alle ondersteuning de afge-
lopen jaren. Promovoeren is niet alleen artikelen schrijven, maar ook heel veel 
administratie regelen. Gelukkig was jij overal van op de hoogte en kon jij goede 
ondersteuning en advies geven om het onderzoek uit te voeren.
Patricia Ormskerk, beste Gerard, allereerst: ik wacht samen met Paul Blankman 
nog steeds op een Bok biertje en een BBQ. Geduld wordt beloond zeggen ze. 
Patricia, ik wil je bedanken voor alle hulp en steun de afgelopen jaren bij mijn 
onderzoek. Daarnaast had jij altijd een luisterend oor en kon ik altijd bij je te-
recht om even te praten en alle stress en emoties te ventileren. Patricia super 
bedankt. En uh, hoe is het met geile Gerard?
Tot slot wil ik alle overige onderzoekers van de intensive care bedanken voor de 
prettige samenwerking en leuke momenten. Peter Somhorst, Matz Koeneman, 
Atsku Shono en Alex Lima, bedankt.
Stafleden Intensive Care Volwassenen
Joachim Weigel, Hond! Het is super fijn om jou als vriend te hebben. We heb-
ben samen goede gesprekken gehad over diverse onderwerpen. Je had altijd 
een luisterend oor met gepast advies. Zowel privé als voor het werk. Daarnaast 
heb je mij geïnspireerd en enthousiast gemaakt voor de interne geneeskunde. 
Dank je wel mijn vriend. Wanneer gaan we weer Jack Ass kijken? En de halve 
marathon van 020? FEYENOORD.
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Willy Thysse, Willy, ik wil je bedanken voor alle klinische ervaring die ik heb 
mogen opdoen onder jou supervisie. Daarnaast was het altijd fijn om de emoties 
van het intensive care werk te verwerken onder het genot van een cappuccino of 
een goed glas witte wijn. Thnx Willy.
Patricia Gerritsen, beste Patricia, bedankt voor alle gezellig diensten, etentjes 
en klinische lessen acute geneeskunde. Ik mis de presentaties met alle sappige 
plaatjes. Van infecties en bacteriën moet jij niet veel hebben, zoals jij het om-
schrijft: borring! Maar van zo’n kinky coccy kan je nog best veel last hebben. 
Groetjes aan Albert!
Ard Struijs, Struijs, bedankt voor je luisteren oor en adviezen. Jouw deur stond 
altijd open, daar heb ik dan ook regelmatig gebruik van gemaakt. Ik vond het su-
per tof om met jou samen te werken in de kliniek. Beiden eigenwijs, resulterend 
in goede discussies. Ik mis de zeven-tweetje momenten. Bedankt Ard.
Ik wil alle stafleden van de Intensive Care Volwassenen (Johan van den Akker, 
Jasper van Bommel, Jelle Epker, Hilde de Geus, Christine Groeninx, Jubi de 
Haan, Ben van den Hoven, Can Ince, Mathieu van der Jagt, Erwin Kompanje, 
Dinis dos Reis Miranda en Robert van Thiel) bedanken voor de ondersteuning 
tijdens het uitvoeren van mijn onderzoek op de intensive care. Daarnaast wil i k 
alle stafleden bedanken voor de klinische ervaring die heb ik mogen opdoen op 
de intensive care van het Erasmus MC.
Verpleegkundigen
Ik wil alle verpleegkundigen van de 3 zuid, 10 zuid en thorax intensive care 
bedanken voor alle ondersteuning en inzet die zij hebben geleverd voor mijn 
onderzoek. Het was een enorme klus, waarbij ongeveer 8000 bloedbuizen zijn 
gecollecteerd door jullie. Dankzij jullie inzet heb ik deze mooie artikelen kunnen 
maken.
Els Forman
Dag mevrouw! Els, ik wil je bedanken voor alles wat je voor mij hebt gedaan 
de afgelopen jaren. Daarnaast kon ik altijd bij je terecht om even heerlijk te 
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mopperen in de zwarte stoel in de hoek. Gelukkig mopperde je soms ook even 
lekker terug! Bedankt Els.
Afdeling Klinische Chemie
Robert de Jonge, beste Robert, ik wil je bedanken voor het beschikbaar stellen 
van de laboratorium machines van de afdeling klinisch chemie. In totaal hebben 
we 8000 bloedbuizen verwerkt tijdens mijn studie, voor mij een enorm aantal, 
voor het AKC maar een klein topje van de ijsberg. Daarnaast wil ik je bedanken 
voor het feit dat je mij in contact hebt gebracht met Sysmex Europe. Dit heeft 
geresulteerd in een enorme impuls voor de opzet van mijn thesis.
Ik wil alle medewerkers van de afdeling klinische chemie van het Erasmus MC 
Rotterdam bedanken voor hun inzet tijdens mijn onderzoeksperiode. Speciale 
dank gaat uit naar Rob Brouwer, Monique de Waart en alle dames van het Trial 
Lab.
Maasstad Ziekenhuis
Servet Duran, beste Servet, ik wil je bedanken voor alle inzet en steun voor mijn 
onderzoek de afgelopen jaren. Daarnaast wil ik je bedanken voor de gastvrijheid 
en de mogelijk tot het verrichten van mijn onderzoek in het Maasstad ziekenhuis.
Ik wil alle verpleegkundigen, arts assistenten en stafleden van de Intensive Care 
van het Maasstad ziekenhuis bedanken voor hun inzet tijdens de studie. Dankzij 
jullie inzet hebben we een mooi aantal patiënten kunnen includeren in deze 
multicenter studie.
Tot slot wil ik de mensen van de afdeling klinische chemie en de afdeling medi-
sche microbiologie bedanken voor hun inzet tijdens mijn studie. Speciale dank 
gaat hierbij uit naar Stan Nijkerken en Oscar Pontesili.
Sysmex Europe
Jo Linssen, beste Jo, ik wil je bedanken voor alle steun en inzet tijdens mijn 
onderzoek. Ongeveer vier jaar geleden zijn wij met elkaar in contact gekomen en 
heb ik de kans gekregen om met een zeer interessante en nieuwe biomarker te 
mogen werken. Onze gesprekken over biomarkers en infectieziekten waren altijd 
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erg interessant en leerzaam, waarbij we vanuit twee verschillende perspectieven 
de zaken evalueerden. Ik hoop dat we onze samenwerking zo voort kunnen zet-
ten en nog meer mooie onderzoeken kunnen leveren.
Alexandra Maroz, dear Alex, I would like to thank you for all your support du-
ring my research period. I really liked our meetings in Hamburrg were you have 
taken me to some of the best restaurants in Hamburg. I hope we can continue 
our cooperation and deliver some more interesting articles.
I would like to thank all other employees of Symex Europe who were involved 
with my research for their effort and advices.
Leon
Lieve Leon, tegen de tijd dat jij dit leest zijn we bijna twee jaartjes samen. De 
afgelopen twee jaar heb je mij enorm gesteund. Jij zorgde ervoor dat ik op tijd 
stopte met werken en vooral ook tijd bestede aan het doen van leuke dingen. Je 
gaf tegengas en steun op de juiste momenten. De afgelopen twee jaar hebben we 
vele leuke reisjes gemaakt (Barcelona, Valencia, Altea, Cannes, Monaca, Saint- 
Tropez, Istanbul en zo kunnen we wel even doorgaan) en vele heerlijke barretjes 
en restaurantjes ontdekt. Ik hoop dat wij samen nog vele reisjes kunnen maken 
en nog meer nieuwe restaurantjes kunnen ontdekken, dit alles onder het genot 
van heerlijke wijntjes. Dikke kus.
Ouders
Lieve Pa en Ma, inmiddels zijn we vijf jaar gemopper en getier verder, maar het 
boekje is dan eindelijk klaar. Jullie staan altijd voor mij klaar en hebben altijd 
een luisterend oor. Dit heb ik enorm gewaardeerd, want de afgelopen vijf jaar 
waren niet altijd makkelijk. Tot diep in de late uurtjes werd doorgewerkt, wat 
mijn humeur niet altijd ten goeden kwam. Ik ben heel erg blij en dankbaar dat ik 
altijd bij jullie terecht kon en dat jullie ten alle tijden mij steunden. Jullie inzet 
is dan ook onbeschrijfbaar. Lieve pa het is dan nu eindelijk tijd voor een bor-
rel, proost. Lieve ma, mijn dagelijks gemopper is nu eindelijk voorbij, voortaan 
kunnen we leuke dingen bespreken aan de telefoon in plaats van mijn gemopper 
over dat onderzoek aan te horen.

